var title_f27_34_28192="Lymphangitic cancer CT I";
var content_f27_34_28192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography appearance of lymphangitic carcinomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphangitic carcinomatosis from metastatic carcinoma of the cervix characterized by diffuse bilateral thickening of bronchovascular bundles. Peribronchial thickening results in visualization of more peripheral bronchi. The major fissures are slightly thickened. Several thickened interlobular septa are seen in the posterior aspect of the right lung. Small subpleural nodules represent thickened centrilobular bronchovascular structures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28192=[""].join("\n");
var outline_f27_34_28192=null;
var title_f27_34_28193="Ground glass pulmonary edema CT";
var content_f27_34_28193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary edema after cocaine freebasing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral patchy areas of ground glass opacity are seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28193=[""].join("\n");
var outline_f27_34_28193=null;
var title_f27_34_28194="Patient information: Viral meningitis (The Basics)";
var content_f27_34_28194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/35/16946\">",
"         Patient information: Aseptic meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/1/31762\">",
"         Patient information: Bacterial meningitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/48/1796\">",
"         Patient information: Meningitis in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Viral meningitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/viral-meningitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10925609\">",
"      <span class=\"h1\">",
"       What is meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Meningitis is a condition that can cause a fever, headache, and stiff neck. Meningitis happens when the lining that covers the brain and spinal cord (called the &ldquo;meninges&rdquo;) gets inflamed or infected. This can occur after a person has an infection in another part of the body. The germs can travel through the blood to the lining of the brain and spinal cord.",
"     </p>",
"     <p>",
"      There are 2 main types of meningitis, depending on which germs are causing the infection. Viruses cause viral meningitis, and bacteria cause bacterial meningitis.",
"     </p>",
"     <p>",
"      It is important that doctors figure out what kind of meningitis a person has. That&rsquo;s because bacterial meningitis is a medical emergency. It can lead to brain problems or even death.",
"     </p>",
"     <p>",
"      Viral meningitis is serious, but not usually as serious as bacterial meningitis. People usually recover from viral meningitis within 1 to 2 weeks without any long-term problems.",
"     </p>",
"     <p>",
"      Both viral and bacterial meningitis can have the same symptoms. So the only way a doctor can know for sure which type of meningitis someone has is to do tests in the hospital.",
"     </p>",
"     <p>",
"      This article discusses viral meningitis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10925624\">",
"      <span class=\"h1\">",
"       What are the symptoms of viral meningitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Stiff neck &ndash; This is most often seen in adults and children. Babies might not get a stiff neck.",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Having light bother a person&rsquo;s eyes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Babies can also have other symptoms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Not feeding well",
"       </li>",
"       <li>",
"        Being more sleepy or fussy than usual",
"       </li>",
"       <li>",
"        A bulging soft spot on the skull",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People can have other symptoms, too, depending on the virus that&rsquo;s causing the infection. These can include diarrhea, a runny nose, sore throat, muscle aches, cough, or a rash. A rash can also happen with bacterial meningitis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10925639\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have a fever, headache, and stiff neck, go to the emergency room right away. If you think that your child has meningitis, bring him or her to the emergency room right away.",
"     </p>",
"     <p>",
"      It&rsquo;s very important to go to the hospital if you think you or your child has meningitis. That&rsquo;s because the only way a doctor can make sure someone has viral meningitis &ndash; and not life-threatening bacterial meningitis &ndash; is to do tests in the hospital.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10925654\">",
"      <span class=\"h1\">",
"       Will I have tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will learn about your symptoms and do an exam. He or she will do tests to find out if you have meningitis and which virus is causing it. The tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A lumbar puncture (sometimes called a &ldquo;spinal tap&rdquo;) &ndash; During this procedure, a doctor puts a thin needle into your lower back and removes a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. He or she will do lab tests on the spinal fluid.",
"       </li>",
"       <li>",
"        A CT scan of the brain &ndash; This is an imaging test that creates pictures of the brain.",
"       </li>",
"       <li>",
"        Other tests &ndash; For example, the doctor can use a cotton swab to collect a sample from the back of the throat. Then he or she can do lab tests on the sample.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10925670\">",
"      <span class=\"h1\">",
"       How is viral meningitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for viral meningitis usually includes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Resting",
"       </li>",
"       <li>",
"        Drinking fluids or getting fluids into a vein through a tube called an &ldquo;IV&rdquo;",
"       </li>",
"       <li>",
"        Taking an over-the-counter medicine to treat a fever or headache",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Viral meningitis is NOT treated with antibiotics. This is because antibiotics treat bacterial infections, and not viral infections.",
"     </p>",
"     <p>",
"      Your doctor might recommend other treatment, depending on the virus that&rsquo;s causing the infection. Some viruses can be treated with &ldquo;antiviral&rdquo; medicines.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10925685\">",
"      <span class=\"h1\">",
"       Can meningitis be spread from one person to another?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The viruses that cause meningitis can be spread from 1 person to another. But even if you catch the virus, it doesn&rsquo;t usually lead to meningitis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10925702\">",
"      <span class=\"h1\">",
"       Can viral meningitis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help lower the chance of getting viral meningitis, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Make sure that you and your children get the vaccines your doctor recommends. Vaccines are treatments that can prevent certain serious infections.",
"       </li>",
"       <li>",
"        Wash your hands often, especially after you change a diaper or use the bathroom, and before you eat.",
"       </li>",
"       <li>",
"        Avoid sharing cups or silverware, especially with people who are sick.",
"       </li>",
"       <li>",
"        Avoid getting bitten by mosquitoes. Some mosquitoes carry viruses that can infect you and lead to meningitis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10925717\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1796?source=see_link\">",
"       Patient information: Meningitis in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/35/16946?source=see_link\">",
"       Patient information: Aseptic meningitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=see_link\">",
"       Patient information: Bacterial meningitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1796?source=see_link\">",
"       Patient information: Meningitis in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/34/28194?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16955 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28194=[""].join("\n");
var outline_f27_34_28194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10925609\">",
"      What is meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10925624\">",
"      What are the symptoms of viral meningitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10925639\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10925654\">",
"      Will I have tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10925670\">",
"      How is viral meningitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10925685\">",
"      Can meningitis be spread from one person to another?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10925702\">",
"      Can viral meningitis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10925717\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/35/16946?source=related_link\">",
"      Patient information: Aseptic meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/1/31762?source=related_link\">",
"      Patient information: Bacterial meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1796?source=related_link\">",
"      Patient information: Meningitis in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_34_28195="Chronic cough in adults";
var content_f27_34_28195=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Chronic cough in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/34/28195/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28195/contributors\" id=\"au4064\">",
"       Ronald C Silvestri, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28195/contributors\" id=\"au6191\">",
"       Steven E Weinberger, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/34/28195/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28195/contributors\" id=\"se5257\">",
"       Peter J Barnes, DM, DSc, FRCP, FRS",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28195/contributors\" id=\"se4823\">",
"       Talmadge E King, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?27/34/28195/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28195/contributors\" id=\"de1810\">",
"       Helen Hollingsworth, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?27/34/28195?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Coughing from time to time helps clear particles and secretions from the lungs and helps to prevent infection. However, sometimes a cough can become a chronic condition. A chronic cough is usually defined as a cough that lasts for eight weeks or longer.",
"    </p>",
"    <p>",
"     Although coughing is not usually a sign of a serious problem, it can be annoying. Coughing frequently is embarrassing, can make you physically tired, make it hard to sleep, and cause you to be dizzy, hoarse, strain muscles, sweat, and leak urine (especially in women).",
"    </p>",
"    <p>",
"     This article discusses the possible causes and treatments of chronic cough in adults. Coughing that began less than eight weeks ago is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/57/9106?source=see_link\">",
"      \"Patient information: Acute bronchitis in adults (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about chronic cough is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"      \"Evaluation of subacute and chronic cough in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27913?source=see_link\">",
"      \"Treatment of subacute and chronic cough in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CAUSES OF CHRONIC COUGH",
"     </span>",
"    </p>",
"    <p>",
"     The most common causes of chronic cough are postnasal drip, asthma, and acid reflux from the stomach. These three causes are responsible for up to 90 percent of all cases of chronic cough. Less common causes include infections, medications, and lung diseases.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Postnasal drip",
"     </span>",
"     &nbsp;&mdash;&nbsp;Postnasal drip occurs when secretions from the nose drip or flow into the back of the throat from the nose. These secretions can irritate the throat and trigger a cough. Postnasal drip can develop in people with allergies, colds, rhinitis, and sinusitis.",
"    </p>",
"    <p>",
"     Signs of postnasal drip include a stuffy or runny nose, a sensation of liquid in the back of the throat, and a feeling you need to clear your throat frequently. However, some people have so-called \"silent\" postnasal drip, which causes no symptoms other than a cough.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Asthma",
"     </span>",
"     &nbsp;&mdash;&nbsp;Asthma is the second most frequent cause of chronic cough in adults, and is the leading cause in children. In addition to coughing, you may also wheeze or feel short of breath. However, some people have a condition known as cough variant asthma, in which cough is the",
"     <strong>",
"      only",
"     </strong>",
"     symptom of asthma. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Asthma-related cough may be seasonal, may follow an upper respiratory infection, or may get worse with exposure to cold, dry air, or certain fumes or fragrances.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Acid reflux",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gastroesophageal reflux, also known as acid reflux, occurs when acid from the stomach flows back (refluxes) into the esophagus, the tube connecting the stomach and the throat. Gastroesophageal reflux disease (GERD) refers to symptoms caused by acid reflux. Many people with cough due to acid reflux have heartburn or a sour taste in the mouth. However, some patients with GERD have cough as their only symptom. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Other causes",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of other conditions can lead to chronic cough. These include:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Respiratory tract infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;An upper respiratory infection such as a cold can cause a cough that lasts more than eight weeks. This may be due to postnasal drip (as described above), or to irritability in the airways that developed as a result of the infection. Many people with a chronic cough after a respiratory infection respond to treatment for postnasal drip or cough variant asthma. (See",
"     <a class=\"local\" href=\"#H3\">",
"      'Postnasal drip'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     Sometimes bacterial tracheobronchitis or bacterial sinusitis can develop following a viral upper respiratory tract infection. In almost all cases of bacterial tracheobronchitis, patients will have a cough that produces sputum. The sputum is colored from light yellow to dark green or even brown. &nbsp;Likewise, in almost all cases of cough from bacterial sinusitis, patients will have sinus congestion and the nasal secretions that drip or flow into the back of the throat are similarly off-colored. If such colored sputum or postnasal drip continues unimproved for more than 10 to 14 days, antibiotics may be needed to treat the infection. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/57/9106?source=see_link\">",
"      \"Patient information: Acute bronchitis in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/13/37073?source=see_link\">",
"      \"Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Use of ACE inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medications known as angiotensin converting enzyme (ACE) inhibitors, which are commonly used to treat high blood pressure, cause a chronic cough in up to 20 percent of patients. The cough is usually dry and hacking. Switching to another medication often improves the cough over the course of one to two weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Chronic bronchitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chronic bronchitis is a condition in which the airways are irritated, causing you to cough, sometimes raising phlegm. Most people with chronic bronchitis are current or past smokers. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"      \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Lung cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although lung cancer can cause coughing,",
"     <strong>",
"      very few",
"     </strong>",
"     people with a chronic cough have lung cancer. Cancer is possible, however, especially if you are a smoker and your cough changes suddenly, you begin to cough up blood, or if you continue to cough more than one month after quitting smoking. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"      \"Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Eosinophilic bronchitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;A special type of inflammation in the airways called eosinophilic bronchitis can cause a chronic cough. This is diagnosed when your breathing tests show no evidence of asthma, but your phlegm or airway biopsy shows cells called eosinophils. Eosinophilic bronchitis is much less common than asthma.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      CHRONIC COUGH DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     To investigate the cause of a chronic cough, your healthcare provider will ask about your symptoms and perform a physical examination.",
"    </p>",
"    <p>",
"     Based upon your symptoms and examination, your clinician may recommend a trial of treatment before other testing is performed. If you improve with treatment, no further testing is generally needed. If you do",
"     <strong>",
"      NOT",
"     </strong>",
"     improve, or if your diagnosis is not clear, further testing may be recommended, such as:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18741066\">",
"     <span class=\"h2\">",
"      Lung imaging",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you are a current or former cigarette smoker, or if you have other medical conditions that can affect the lung, a chest X-ray or even a chest CT scan may be done.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Lung function tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;If asthma is suspected but cannot be confirmed, the clinician may perform lung function tests that measure the pattern of air flow into and out of the lungs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Acid reflux testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;To confirm a diagnosis of acid reflux, a test may be done to measure the acid level of fluid in the esophagus. This test is called a pH probe. In some people, a test called upper endoscopy will be done to look for irritation of the esophagus and to obtain a biopsy of the esophagus. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      CHRONIC COUGH TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of chronic cough aims to eliminate the underlying cause. Most of the time, each type of treatment is tried separately, one after another, instead of all at the same time. Seeing which one works best helps to figure out the underlying cause. Here are some examples of treatment choices for different causes of cough.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Postnasal drip",
"     </span>",
"     &nbsp;&mdash;&nbsp;A cough related to postnasal drip may improve with the use of a decongestant, nasal or oral antihistamine, nasal glucocorticoid, or a nasal spray that contains ipratropium. The best treatment (or combination of treatments) depends upon your symptoms and medical history. The following are some examples of how these medications may be used:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18741079\">",
"     <span class=\"h3\">",
"      If you have postnasal drip from a cold",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antihistamines that are taken as a pill, such as chlorpheniramine (brand name: Chlor-Trimeton",
"     <sup>",
"      &reg;",
"     </sup>",
"     ) or clemastine (Tavist",
"     <sup>",
"      &reg;",
"     </sup>",
"     , Dayhist",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), may help, but can cause side effects such as drowsiness and drying of the eyes, nose, and mouth. Most of these are available over the counter. Decongestants such as pseudoephedrine can improve nasal congestion, make it easier to blow one&rsquo;s nose, and thus lessen post nasal drip. Most drugstores in the United States carry pseudoephedrine behind the counter, so you must request it from the pharmacist (a prescription is not required). The nasal spray ipratropium bromide (Atrovent",
"     <sup>",
"      &reg;",
"     </sup>",
"     , available without a prescription) can also help relieve runny nose, postnasal drip, and sneezing associated with a cold.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18741086\">",
"     <span class=\"h3\">",
"      If you have postnasal drip from allergies (&ldquo;hay fever&rdquo;)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nasal glucocorticoids such as fluticasone (Flonase",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), triamcinolone (Nasacort",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), or mometasone (Nasonex",
"     <sup>",
"      &reg;",
"     </sup>",
"     ) can be prescribed to help reduce nasal inflammation, postnasal drip, and cough. The usual dose is one squirt in each nostril twice per day.",
"    </p>",
"    <p>",
"     Oral antihistamines such as loratadine (Claritin",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), fexofenadine (Allegra",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), or cetirizine (Zyrtec",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), are also effective for allergic postnasal drip and they are available without a prescription. They are less likely to cause sleepiness than older generation antihistamines such as chlorpheniramine or diphenhydramine. Nasal antihistamine sprays such as azelastine (Astelin",
"     <sup>",
"      &reg;",
"     </sup>",
"     ) can also relieve postnasal drip.",
"    </p>",
"    <p>",
"     All three of these forms of treatment (nasal glucocorticoids, oral antihistamines, and nasal antihistamines) can be tried alone, or they can be used in combination if needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Cough variant asthma",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your cough is due to asthma, you will be given the standard treatment for asthma, which includes an inhaled glucocorticoid such as fluticasone (Flovent",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), budesonide (Pulmicort",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), or beclomethasone (QVAR",
"     <sup>",
"      &reg;",
"     </sup>",
"     ). You may also be prescribed an inhaled bronchodilator such as albuterol (ProAir",
"     <sup>",
"      &reg;",
"     </sup>",
"     , Ventolin",
"     <sup>",
"      &reg;",
"     </sup>",
"     , or Proventil",
"     <sup>",
"      &reg;",
"     </sup>",
"     ) if you have wheezing or shortness of breath. The glucocorticoid decreases inflammation of the airways while the inhaled bronchodilator opens up the airways. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Acid reflux",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cough due to acid reflux may respond to the following lifestyle changes:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Avoid substances that increase reflux, such as high fat foods, chocolate, colas, red wine, acidic juices, and excessive alcohol",
"      </li>",
"      <li>",
"       Avoid eating for two to three hours before lying down",
"      </li>",
"      <li>",
"       Elevate the head of the bed six to eight inches",
"      </li>",
"      <li>",
"       Lose weight, if you are overweight",
"      </li>",
"      <li>",
"       Stop smoking",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In addition, you may be given a medication to slow the production of acid in your stomach, called a proton pump inhibitor. Examples of proton pump inhibitors include omeprazole (Prilosec",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), esomeprazole (Nexium",
"     <sup>",
"      &reg;",
"     </sup>",
"     ), and lansoprazole (Prevacid",
"     <sup>",
"      &reg;",
"     </sup>",
"     ). It may take eight or more weeks of treatment before your cough improves. If your cough does not improve during this time, further testing may be recommended.",
"    </p>",
"    <p>",
"     For more information about acid reflux, (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Eosinophilic bronchitis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Eosinophilic bronchitis is treated with inhaled glucocorticoids. These medications are also used for asthma and work to decrease inflammation in the airways. Examples include budesonide (Pulmicort",
"     <sup>",
"      &reg;",
"     </sup>",
"     ) and fluticasone (Flovent",
"     <sup>",
"      &reg;",
"     </sup>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Cough suppression",
"     </span>",
"     &nbsp;&mdash;&nbsp;If, after a thorough evaluation, the cause of your cough cannot be determined and the cough persists, a medication that suppresses your cough may be recommended.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Non-prescription cough medicines that contain dextromethorphan (Delsym",
"       <sup>",
"        &reg;",
"       </sup>",
"       ) may help suppress the cough reflex.",
"      </li>",
"      <li>",
"       Benzonatate (Tessalon",
"       <sup>",
"        &reg;",
"       </sup>",
"       ) is a prescription medication that may be recommended if dextromethorphan is not helpful.",
"      </li>",
"      <li>",
"       Codeine and hydrocodone are prescription narcotic medications that can be added to cough syrup; these may be tried if other treatments have not been effective. However, both medications can cause you to feel sleepy and should not be used while working or driving.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804403057\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5510633\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/28/24002?source=see_link\">",
"      Patient information: Acute bronchitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/43/22195?source=see_link\">",
"      Patient information: Coughing up blood (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/31/7666?source=see_link\">",
"      Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43186?source=see_link\">",
"      Patient information: Breathing tests (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/25/39314?source=see_link\">",
"      Patient information: Bronchiectasis in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/9/14483?source=see_link\">",
"      Patient information: Interstitial lung disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5510670\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/57/9106?source=see_link\">",
"      Patient information: Acute bronchitis in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/13/1236?source=see_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12458?source=see_link\">",
"      Clinical manifestations and diagnosis of bronchiectasis in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/48/36613?source=see_link\">",
"      Diagnosis of wheezing illnesses other than asthma in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/18/5418?source=see_link\">",
"      Evaluation of subacute and chronic cough in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16009?source=see_link\">",
"      Hoarseness in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30537?source=see_link\">",
"      The common cold in adults: Treatment and prevention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27913?source=see_link\">",
"      Treatment of subacute and chronic cough in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American College of Chest Physicians",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.chestnet.org/accp/patient-guides/patient-education-guides-cough\">",
"      file://www.chestnet.org/accp/patient-guides/patient-education-guides-cough",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Canadian Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lung.ca/diseases-maladies/a-z/cough-toux/index_e.php\">",
"      www.lung.ca/diseases-maladies/a-z/cough-toux/index_e.php",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?27/34/28195/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?27/34/28195?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28195/abstract/1\">",
"      Pratter MR, Brightling CE, Boulet LP, Irwin RS. An empiric integrative approach to the management of cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:222S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28195/abstract/2\">",
"      Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest 2006; 129:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28195/abstract/3\">",
"      Pratter MR. Chronic upper airway cough syndrome secondary to rhinosinus diseases (previously referred to as postnasal drip syndrome): ACCP evidence-based clinical practice guidelines. Chest 2006; 129:63S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f27_34_28195=[""].join("\n");
var outline_f27_34_28195=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CAUSES OF CHRONIC COUGH",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           CHRONIC COUGH DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           CHRONIC COUGH TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f27_34_28196="Acetaminophen and phenyltoloxamine: Patient drug information";
var content_f27_34_28196=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetaminophen and phenyltoloxamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/57/38806?source=see_link\">",
"     see \"Acetaminophen and phenyltoloxamine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      RhinoFlex&trade; [DSC];",
"     </li>",
"     <li>",
"      RhinoFlex&trade;-650 [DSC];",
"     </li>",
"     <li>",
"      Zgesic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701426",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetaminophen, phenyltoloxamine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever for more than 3 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698992",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain for more than 10 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12004 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28196=[""].join("\n");
var outline_f27_34_28196=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129619\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026508\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026507\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026512\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026513\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026515\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026510\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026511\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026516\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026517\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/57/38806?source=related_link\">",
"      Acetaminophen and phenyltoloxamine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_34_28197="Lap hernia still A";
var content_f27_34_28197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Lap hernia still A",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 272px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEQAg4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5f1b/AJCt7/12f/0I1Uq3q3/IVvf+uz/+hGqlABRRRQAUUUUAFFFFABRRRQAUV7h4e/Zq8Ya9oGmavZ6l4fS21C1iu4llnmDqkiBgGAiIzgjOCa6B/wBl7xQQoSTw4ABgk6hcEn3P7j+VBUIqT1dvv/RM+b6K+jP+GXPFn/Pfw3/4HXH/AMZqxa/sw+Jo2zOPDUw9P7RuV/lDQaqlB/bX/k3+R810V9PN+zRrhUBbPw2D6/2rdf8Aximn9mbXe1r4c/8ABrdf/GKBqhD/AJ+L/wAm/wDkT5jor6Vb9mLxGSdq+GwD2/tK5/8AjFI37MPiUgYHhsf9xG5/+M0x+wp/8/Y/+Tf/ACJ810V7t41+A2s+D/Dd1rmqrokllbPEsi217O8n7yRYxgNEoPLjuOM156uj6bnH2fP/AANv8aR00MtniE3SnF29f8ji6K7yPRNL2DNoS2QOJG/xrTtvDGiecyzWo4k27WlcZXHUYNK5v/YeI7r8f8jzCivZR4L0Fn2rp/U8fvpM/wDoVS/8IR4f+YfYDuXqfOkx/wChVl7eJnLKKy6r8f8AI8Vor2VvBOgne/2EpGOn72T/AOKrD1DwvpgjSK1tQJmwN5kfseTjP4VSqqWxm8sqrqvx/wAjzaivVh4T0M3CL9kIDQrKAZH5z+PelvPBujjaLeymLqoaRS7DH6nj3q7q9jP6hU7o8oor0aTwzpMUql4G2/xASNgfrUEnh/SvMmeGEvAjDGWYMV65IzV8rYfUandHAUV3N1oGnrEJI7chfOIPzt93t3qpJo1ksIPkZbkE72/DvRysX1Kp3RyNFdB/ZIllVbW2kmbDFkjyxAAyW47CrUekWbwBxD97OPnPb05pJXJWEm3a6OVorrBo1q7hFgIc5AG44Pv1q7a+HrNkP+i+ZgffaRlBbuBjtjvT5WX9Rqd0cNRXoq6BorRhlt0MZIw4kcEjvgbuaqroWlyzMiQhFXqWL/8AxVHKw+o1O6/r5HCUV36+GrBoGYQjI4zvYfnz6c1X/sHTBJh0cDcAQHJ6/wD1qOVj+oVO6/r5HEUV3kug6Z5cTJauhJIO6Q8+nGfSm/2Bp+8A2zZAxs3Nkkde9KwfUKndf18jhaK9Hbwnp6naYVOAH3pMWXaRnrmq8/hqwUgpADnPHmMQB+dFmL6jU7o4Ciu7uPD2nQcvENucffbn9aoz6PZxuR5IGD/fb/GiwvqNTujkqK6YaZZn/lj+O5v8aQ6bZjP7nj/eP+NIf1Cp3X9fI5qiuiOnWo5EWfbcf8aX+zrXOBATz/eP+NAfUandHOUVpanp/kDzoMmE9QeqH0NZtByTg4PlkFFLRxQSJRS0GgBKKKKACiiigAooooAKKKKACvQPgp/yNV1/15P/AOhx15/XoHwU/wCRquv+vJ//AEOOgDitW/5Ct7/12f8A9CNVKt6t/wAhW9/67P8A+hGux8D/AA01Hxl4evdS0q9s1nt5/JFrKxVn+UNnPbrgZ9+RVRi5u0RSkoq7ODora8ReGNZ8OXBh1rTri1OcB2XKN/usOD+BrFpNOLswTTV0FFFFIYUUUUAFT2ds91cLFHgE9WPRR6mo4o3llSOJSzuQqqOpJ7V2M+nxaBbW8bSI9xLkzArkHGOAfTPH1FBtRpe0lbofe3wn/wCSWeDf+wLZf+iErqq5X4T/APJLPBv/AGBbL/0QldVQYnhXgLxpr+r694fgXXL++vbq+vhf2F3YRQ2sdnFLKgkhlESF2BEQwrycsd2MVt6P8bNI1C/t9w07+zrr7QYGttTSe7RYo3k3TWwUGMMsbY+ZucA4zXURfDzSodB0zTbe5v4X029kv7S9jkQXEUkkryOA23aVPmMpUqQVODk81LY+B7ezZIF1fVpNFjWVE0hniFsqSKylDtjEjKAxwGcgcegwAcn4j8a+Mj4Kg1ix0Cz0yK6ksJLeaTUhI+ya5iTy5E8k7WZXAONwUMxB3KAejm8aXdknimPUdKgS70HSY9TkSC8MiSlxOfLDGNSMeR94r/F045ij+G9sNCfRp/EHiC405Yo4rWGWaL/QxHIskZjIjBZlZEwZN/Ax0Jy3xF4As7621C41HxLrVst1p/2LU7lJLeL7VAm8hpD5W1NokflAnB5yKAIF+I7y+NF0GGw09CJLeNhdaosFzIssauZIIWT96i7sEhwcqwA459ErjZPBVnqdzaXcmuareaWk0F9DYmaJ7bzIgpjdW2bwMqGwrhSe2Ca7KgDzL9pP/kjOu4/562f/AKVw18cxqVOCetfY37SfPwY13/rrZ/8ApXDXx2VJI8sMB0y1Sz6TI/gl6lqzhkndQAQoON2MCtzRoEvL8zSJzvO0DoR0H8qzbK9hgsZba6MikNuRlxxkenXNaOnypL5UKsNkaBQcbePU+9J7HuXu7HSjfJI8UaGNY/lZmHOfSrwtPMUbAViHc/xVRs0PmqoYMrD5h6+laMs3kxCJWAwOc9uf51yzsjlquyKGpECIIh5bCj27lj7Cub08G8knuUBWI4EW4YIXp/8AXz71oazO8ztbRARiRSJJM8pH36c+2K2PD+jqLMrE8YWPl02kseP4s1tRjZczOWTuU7WyDRSTygjzNoUDkhB2H+NaEqRwK20kJgNJI5yAevJ7+lasWkyXDxmAmKOM7nSM7Nw7Dd6dq57WZbOO08mW83GKTLJJNlGQEnafU9BjrT3Y400zGvIfMXzXjI3khY/u8f3vxFZN0oRwzqWmC+Xn68YHriugkuDNbQ3EQke3UMNzkAJx1Htj+VcxMftHyxSOzSI7MEH/AHx+Bzn8K6KburGFSHK7FUCfylZiJI5nJZM4KgHA/lmq8m1rWMK3WTaex4PerMlwiuEhKsplKgsCBhcA4PvVeWRJxHNEGALfvBnv0zWhDVzLaKMv++8xYjneYx84XPO3PGadYSBlCwh/KDAqDgnp34wKmuPlic9CQeR7Voajpd3pa6N9qshbRXtmt5ABOJC8bEgMccKcg8YyKSWphJWkgt0ikUG4EoJH+rHAwffv071btVZpWeUvImBuTooXp2qPyg5+TIMig4P15FTwpK15GiAFT8hIHBxTZukXt3l28scmFLZ8sIuOuenoP8axrWVh8zEBhwxYZq5r0hWRYlkKqi4b/e+orCmu4UYB7iIPjBRnAwfp6EUFpJK7ZaM65kGwFHBCsO3p+tJG7tGZZG3MwUBsZ2n1IFUZLuyIbZcwBSm4DeOuOnWtFLvTEt4RFe28YfBkw43qcfWkLngupLNbuTGUIzK3yjbk5UZ55/OlmvQjrbSxjzE/ung55zmmXOoabOYPJuoImTdtPmKFAPOcZznjvWZJqENxM07XFruY7XBcDOBjOPwodgU4PqjftLqVEdEjLhvnwcFsdMCrH2mN0mwdsm4gpgqdvuTx1x2rCgv7eJV8y8t2Gc4WVc4qy2r2TH97PbOOOVmXPvweMGosK8O5Nc2se793KZdwB2tjgnt1NULgknayBWHGMdRUn9pWEjPuuYFYAEYkAHHbr1qtJeWspG27twqr0aRRj6Y/lQw5o9yJlJX5BjPHtUIxjI7evepQu4kxlXQ9Dnj8Kdszu7UgsQFQeDSd+35VLg44z781GwI9yePSgNgGM42hgRtKnkMPSuf1Wx+ySb48tA5+U+h9D71vlTn27UkiK8bxygtG4AYenuPcUjmxNBVY+ZyNFWb+1ezuDG+CMZVh3HY1WoPFaadmFFFFAgooooAKKKKACiiigAooooAK9A+Cn/I1XX/Xk/8A6HHXn9egfBT/AJGq6/68n/8AQ46AOK1b/kK3v/XZ/wD0I1oeFvEV74dvxcWUrKpI8xAcbh/j6Gs/Vv8AkK3v/XZ//QjVSk0mrM0pVZ0ZqpB2aPoey+IWp3mlLNBHba1ZMv76yuUG5h3AOPvfUEHtXPPZfDXxpJttppvCurNkGKQAQlvx+X8AV+leWaHrFzo90JrY5RsCSM/dceh/xrrdW0y08U2J1PRyqXg/1sR4LH0Pv6HvShi50HyVveh0b3XzPVqYChmkHWwa5Ky+KK2l5xW3qh3if4S+JNGQ3FrCmq2ONyzWR3kj1K9fyzXASI0bskilXU4KsMEV0Ph3xf4h8K3BXTL+4twpw9vJ8yZHYo3Fd2vxG8NeKYxD488OxeeRj7dZDDj3P8X6n6V2ctGp8Ls/Pb7z55yq09JK/pv9x5BS16xdfC2w1uB7vwF4gtdQjA3fZZ22yr7Zx/MCuOh8Hapa60lprdlPZxL88jyL8rKOyt0JPQYNZzoVIataGlOrGo7Repf8HaFmwnv5TJHdkAWw4G1TnLnnv0HHrVnV7J7jy2lZPtAU7sI3PPAPb8q2VingdpbQoT91Vbso6L7gVPBqVslwralaSSWbIUmhjk8t1J/iR8Fcj0Iwe9R7OS0Z9BQhThTstz7K+E//ACSzwb/2BbL/ANEJW3r9xLaaFqNxbtsmhtpJEbAOGCkg4PvWJ8J/+SWeDf8AsC2X/ohK6iWNJonjlRXjcFWRhkMD1BHcVB4Z49oEvi7UtU8OWEvjS+X+1dAbVpZUsbQNHKphULHmIgKfPydwY/JwVzR4d8farf6RcX9/ew2//FHWurKNiKq3TtcKzjI6EpH8pJA44559Zg02xglt5YLO2jlt4TbQukShoojtJjUgcL8q/KOPlHoKzrvwl4bvIbOK78P6RPFZJ5dqktlGywJ/dQFflHA4GKAPOtX8TeILe9t76fVLyHR44LDzJdPhs50jllxvF1G5Ew3Fl2+VjAOcGof7V1XxB4G1/WtQ8SiBJBqtmdEEMIQCJJkWMMVEvmgIJCdxGM/KBzXp0vhfQJdTt9Rl0PSn1C3CiG6a0jMsQX7u18ZGO2DxRJ4X0CXU5tRl0PSn1CdGjlumtIzLIrLtZWfGSCOCCeRxQB463ifxelhcRaDHfRwaJpVi0Aj+wLays1ukha5e4kWQIclMx4xtY5J4r3lCSill2sRyM5wax9Q8K+HtTktZNR0HSbuS0QR27T2cchhUdFQkfKB6CtmgDzX9owbvg/rK4LZnshgd/wDTIa+QZpIbUGXG5wcbAen1r68/aQ5+DeuD/prZ/wDpXDXyk6xXV5FcXEkayOuPnbGAO+aLXPfyiryU5LzM9Yi8on1IlFIyEQ4JHb6VtaJpYZXnkV4baRvljbk7e3NMa3hG0qscrk7lCtvOfoOKcv8AaSxnCQx7+m5izD32jj86Ti+h6iq9Tp0vILWJmzs4JLsefoPQVz2r65NJCRp4LFxyU6geuT/Sqg0+7WQSXssku3GUZfWrdxDZK2I5ApC5KkZKn0qYUVu2Q05FDw5qAbUIrSfcskjg+ZLJ1OOQw+nFehfaNRjsIrnSTFJMrbDE6k71z0GD6gfyrzO7sopwwSUSY/iKgflitvwNBPc3d7BPMLgRRbxBIxO4fxEc+n1rSSsxqNndnaXreKLtlt4NKtIlSJT5l2fKRfmzkLu5yeOc/SugghMWmJNqltZzTgfvRFCACzdkJzkDA596pw66ltp0ZmDgAgiHb5igA5Geen51h3nim6cObLTrggHAaQiNGPXAJ5PXoBWUojb7GL8QTb6XPdi1eL/S1GY4xgLgAEj0GO2K4GHVPst2kpiErDYCCxIO0cdPwrQ8TOWuJZtRuBJqB+VIYh8kf+fXvWXLpN9chJ47eRopAdpQE8Ack/1NNNrYxl72iKIv38xS/IG7A9N3WrOnSEq7eWG2AAAdyeMD370270qWzWFriMoHcLgjB/zio4ZNpJVwuw+Zn3zx+NVFvqYWadmaJj2qq4ONxUhjk5yAf5VUsFZ5mLEkKRsDHOF54HoKnjkdpZBIFBBLFQc9QCagsfm+0HOBlMH061smZyWtzft2EcZcZHJDZyeKsC4eB9yBQifMAw+9jtnNVLOZvuN/Fxipnj+TrlB+eKpmkUNmi85CGO/zQXXPv2r6R/ZOGPA2uj01l/8A0mt6+c4Qy/JyRztx098V9G/sond4J18g5/4ncn/pNb1E9jkzH+EvX/M9rriPEXxEtNE1TWbRtF1m8j0a2iu9QurVYDHbxSByGIaVXbAjcnapwBXb15H4t+HWoeI/FXjG93y2yXNpYCwZrlvs108XmmSK4hVsPGcop3qcBiV71meKei3HibQraawhutY0+2nv0V7WGe4SOSdT0KKxBPXsKTUPFPh/TdR+wajrulWl/t3/AGae8jjk24JztJzjAJz7V5Jr/hPxHq8uu3N5pOvRJ4gtLeOXT9PudMEdvsjCGKSWZWcKGBdWi3fezgMMV1Xh3SdV0LxFrNrdeGTqlvqOsjUI9W8+DZGhVQDIHbzN8e0hdqkHjBHNAHReD/Hfh3xbpdheaTqdoXvANlq9xH56OUL+WyKxw4VWJXnhSe1aGo+J9A0y2FxqWuaXZ25leDzbi7jjXzFJDJkkDcCCCOoxXmmg6L4k0zw54Cjl8OXkl14VnMc8KXNtm7Q200HmQEygYBdWxIUOO2aqSeGvEf2aC9Og6tbat9r1WVH0+8sZDClzNvCSpPmN0YBSSDuGMY5oA9qhljmhSWF1kikUMjochgeQQe4p9Znhi3u7Tw3pVvqaWyX0NrFHOtqu2FZAgDBB2XOcD0rToA/NqwIFjb56bF/lVtCpUkk5+lUrE/6Jb45Plr29q0IY9rA5G4Hj0qz6eK91EbLkDHQj8ahkU9sD2q3Ku1huzknJ+tQuo5PGe5pNEyIMc+lB4X5RT8c/X0pjE9hU2EVru2F7bmE/6xcmI+/p+NcywKsQQQRwRXV56EdvSsvXrX7t0oxuO2Qf7Xr+NB5uMo/8vEY1FFLQeaJS1t+GfCuteJrjytF0+a4wcNJjbGn+8x4Felw/D7wn4LjW5+IOspdXYG4abZMck+hP3j/46PetqdCdTVLTuZTrQho3r26njOOK3IfDN7JoEmrM0UcKgsqOSGdR1Ye3869C1PWdO8efZNO0vQLXSfD+mSeb5iKBK+RjYCOBu4z1PGc1x/jjxAt7J/Z9kAlrCdp28AkcAD2HSuWvJxqKlTd+77HsYPCQ+qyxmLTS1UV1k/8AJdfuOQopTSVoeYFFFFABXoHwU/5Gq6/68n/9Djrz+vQPgp/yNV1/15P/AOhx0AcVq3/IVvf+uz/+hGqlW9W/5Ct7/wBdn/8AQjVSgAq/pGqXOlXa3Fo+CPvKfusPQiqFFJpSVmXTqTpSU4OzXU9AvrKz8X2BvdO2xalGo8yMsBn2P9D+ftwk8MkEzxTIUkQlWVhgg1Np19caddJcWj7JF/Ij0I7iu2mhsfGWnma32W+rRL8ydM/X1Hoe3Q1ypvDOz1h+X/APelGGcx54WjXW66T81/e7rqcJbXE1rMs1tLJDKpyrxsVI+hFe1+HPGurWei20OuganG/MjTjlQei5xyQOeeea8l0vTX/tjyL6MoIctKre3b8TgV081wvKvN5h3buD0P0/rXp4etKDvF6HiQwkajaqR2+89IRfDeurm0nbTZ26I33CfbPH6is3VPDWo22TLAlxB1EsBz+a9a4Wa4Y8KT64zitHSvEeqaZIv2a5dUH/ACzf5lP511e2pz0mreaNPYVqS/dyuuz/AM9yvNpVpM7C3toVKnDMYhtH4VROjw+csb26hz90hBhvyFd5H4r0vVFCa9pypJ0+0W3+c/zqRvDlvqURm0G/tr6PvE7Ycexx/gKh4bm1g7/mOOLhD3a0eV/h9551JpUSMDFGhP8AEjxgke/uKlWK2yBNaWqL03rCCDW7qFhc2T+VcwvG6n5RIu0/g3QioHt5JFBONvqvHH07VhyJaM9CE1a8bNGdNb6TEqB0sn3dwjKf0yKsxt4dRRvijYj0tgc/icUk2mSbQTFkdR7is2S2VCVAKnPKk1Lpl+18l9xburzTkOLTRrUg9GmjX+QqFJVmPFhp8an+7aocfmKrIhj3KeV6qGHB/HtU1rKUkCoxRj/C3Q/Q1DjYqMk91+CJn01g0bxrbq4YENHEq/kQODWvZrd2u4zNkjBXzU3g8+vWrGlykxgNEhA6gLzXR6db+ep+dUAHTaTkewzWdzphyx1sZ+nXMu4ENGhXqVABP4VaN6qROfMdivGMYJrR/s5fOULcIYyOqrjHsQOhqK60y5gJfaJYfUYz/wDXqXqzaPKzGhme4lKyOdvUIvJPvV1NOjeJikFzKz4+dzsA+p71cguDb7o4i0GeC0bhOPT/APVUdxb3Ii3xSRTE9RIAwH0Ycfnii1jW9tiCXTYHkkjiZYwijckMe9sD/aPArJk0/Fzm38yGSM5ErSYdfy/lWjcXdzDCYjGElU7mXG0t+HcfQ0+3EctuS8qCU5dgrgDGOuf8aEmJ3sVzNrSjbFqrsMZLOoI44weOtZ+tz6uIxLcalO5YYxH8uP8AAVvWcs6BE8uMMwy0YBxH7H/aPTNUPEe23t0a4kgLMeYyeemPrVJdzPrqit4G0829zDq1xEZFMmyKQkEK3fcOpOK7lpbK2tWnlcRSvuz5zBVAPIRVHJzXnng+SY3eLK3kvJY1LmNnCAAeme/t3rX1i9020DTXUd99vYMBExUYzjj5e1NWQNRSuYnjnVJL+O3kk3BN2I/7w2jHJ9eRx2rn7W1kn+VIi0zj5VHpjr/9ekub9r26Luvz/dRF6RjPRff3rYhP9nafOiqDez4VcvuZF/u49e9Jas5HJN3RmOnkFolDbyoTI5BHektnZJJ/LP3SMA9CR2qxMjny3K8oNpU9Pcn61Wt/3Pmyyf6oNjcOjNjOPyq1a5MmXUuGMQlGMAhc+h9a3EilcK8Z+dkwcDHOK522GXaNcGEqWB9fb860pH3SQzRlg+3gK3BA6/iKtXN4pNIsNOQm0Ha+Mnjkc9MV9I/snEt4G14sQT/bT8/9u1vXzZJCbtEbcFlIA5H3vx9a+lf2UoHtvBOvQy/fXWnz/wCA1vSlscWZq1Fev6M9rrgtT+JtlYXl7EdC16e3tL9dMkuoYYmjNw23YigyB23FlUELgFhnFd7XF3Hgbzre7i/tHb5+vwa5nyPu+XJE/lfe5z5WN3bd0OOczwySx8fWFxPb2s9hqNlfyap/ZElrOsZeCYwNOC5R2UoY1yCpbqPfC33jyxgkjgttP1G+vpb6fT4rWARK8jwrudgZJFQKAO7AnsKpat4CnudXvtVsNWjtr+TV4NXtzLaGWOJo7QWxR1DqXBXcchlIJHXHNSf4d38+jfYrvVdH1Jpb6e9uV1PQ1uIJmkxjEfmKUK84IfvyDQBpT/EG3E4trPQNfvr2O1S8u7WC2QS2cbkhRIruuWO1sIm5iASARWbonjmeFtSt76C91bUZNcvLKws7OOISGGLB6syIFUEZZmzyOpNJpPw61Pw9sbwx4mNrNLp8NjdveWX2rf5RbZLGPMXYwDsADvXG3IOOWan8KrW9d7iSXS7y7GpXd/ENT0wXduq3G3fG0RdSSNikOGXp0wSKAO38Na3a+ItHh1GxWVInZ42jmXbJFIjlHRh2ZWVgfpxmtSsbwfog8PeHrbTQbMmIuxNlZpaQ5Z2bCxKSFAzjqScZJJJNbNAH5tWDAWVuFIRti8856VaL8clWpthcumn248uMjykH3RkjFTC7GCPJT27ZrQ+nh8K9BySpJweH6YxUbjGV49RSNLhvlUqfanF/MYDJ3EZzjGPakJkTg7cccGoHOMn8KnaNmUv83HHSmGMj6e9JkMr4HBxQQkiNFJ/q5BtY+nofwrqPD3gnWdd2yRWwt7Xqbm5yi49QOp/Cuj8nwX4PbNxIfEOqJ1jXHlIfcfd/PJ9q1hhpyXM9F3ZwV8ZSg/Z/FLstX/wDzLw14D8Q+I7lo9NsW8lW2tcy/JEPfcev4ZNd0vhnwJ4FxJ4q1H+3dVTn7Da/cVvQ8/8AoRH0rI8d/ELxBqtqiW0406wyYzBa/Lx2y3XGOwwK8zJJOSck1fNSpfCuZ93t9x406VVytP3V26/f/kemeJvi9rF9AbHw/DDoWmKNqRWoAfb/ALwAx/wECuD02yu9c1VII2aSeUlnkck4HUsxqjGjSOqIpZmOAAMkn0r0OKOHwZoJeUK+qXP3hnof7v0Hf3rjxWKnbXVvZHp5VlsK83KXu046yfl/m+hD4n1KDQtKj0XSSVbbl3789Sfc/oK4AmpbieS4neaZi0jnLMe5qGopUvZrXd7lZjjnjKl4rlhHSK7L/PuFFFFannhRRRQAV6B8FP8Akarr/ryf/wBDjrz+vQPgp/yNV1/15P8A+hx0AcVq3/IVvf8Ars//AKEaqVb1b/kK3v8A12f/ANCNVKACiiigAqxZXc9lcpPayGOVDwRVepIY2mmSJBlnYKB7mhq+jKjKUJKUXZo9PszB4i0uO4kiSC9dcHPUgHH/AHz/ACrJnsIYp2ieHa47A4z+NW9nksi2cgVoAEQHjgcD+taCSR6tF5Nyvk3iD5ff3Ht7Vz2lhHfeH5f8A+ypKOZwSlZVvwl/9sYJsUbB3SIT0GaTypIWKhyyjs1WboS2zmGYMGHbt9ahSUA5fHPHPeuxSurxZ5U6ThJxkrND0l+UlIhn604TJFOJB5kE38Lxkgj34quJQkgVgdp4zVg5MKSRbW5KuGzx6U4zZLgrWZ0+leK7+JPJv2t9TtiORMMNj69z9RWnDDoWrN/o0sum3JPEUoyhPtn+hrhf3iqMpGWPoelTRlzgbmIH97k10LEt6TV0cjwME+ai+R+W3zWx1N/oGqWaq4SO5gXp5eTx9OtY00VrcvtaPypScbSeh+tWtN129sVTyZCqj+DHDfXNbJ1zStS+TWrOFGx/rY2yR/X+dUlSn8Ls/MnnxFH+LHmXdb/d/kcfcaYy5LJ8nQMDmqr2TohCorxn+E13a+H47iMyaFqUd1D18h2B/wD1fpWNeWU8TGO4tpYJOxI+Vh7GonSlH4kbUq9Kq/clr22f3HP23mW7jywyL7ncP/rVs2moyxqRKwQY4kVQfz/xFRtp0ow7wzAEjOFyv/fQpkivENskYaM98YIrnnFHUm1ozciuZv8AWKA5PzBkbg1Dd+fdgP5l15Q5KLLwPXNZNrGUUkTbEBzvA/RgO/vVuC5uDEQ6QTDnY8fcep9KxOiNSxdgexk3g22oxOq5j2RrKd/c5LDr9Ku/2Jb3Fgt7FewsDlmjWN0KD/b4AH1zWfZ3LskikoysCpSOQg8/1rVj1q/tvK+wPFp5iXyYzbFUJX/a6gnHB4AqotdS3Vl0MQXCRma2vreXbg7N44jPZl5yfrmqfl3hcNDJbTSMSMRH5o8H+MEYGevFdFd35umRr5dOkkTgPIAZMfVcVjSy2kN080MsJkKgPFGSFIH8Wexpt9g9o92RPHeRSBrzzSfvARyDJx6Y61m6mZZHDfZlt4zjAICn3JJOa1xqUEkL+SNuTkszZwPU4zTbS+hieaaa5t3dgEVXh3jHbkjgUaCdS5zsawxln3F3HO4HAAqGaEsM7yPQkf1ropbTTZptwlD3BGWjTIT68CkXTHwWjbIB2/KuBj6ntQkjF3bOT8goFfAX+78361qaM8IhlWY/M3b29c1ceAXVzIiKyon3pG5yfTHoPSo0treKMIcicnLrnJH4U3oEUQX0xeERqcyudgPTP+1UT27rGWXITcUKkcZHIJ/DipBGpkEj5EakhAByff6Z/lW94ZdFtZp3IxM0ilH6MmMYJ+uKIrmdhTRzlq7RsGcEo/BYDGDnuK17FUlZlLBWzuXGOuKzrm2azA8tsIJCG3fMAD/nrSFpVILRh4v4wh/r61Tui4ysbE4BOFwj55YL/nFdT4M+KHiLwDYXtlpMWlva3N19qdry2klcP5aR8MsqjGIwenc1w6XjeRxIlyn3QucPjuP/AK9V4ryzYlCZIeciUNuB4/iU5/Sk33CpCFVWmro9kX9oTxtIR5MPhhwfW0mB/Lz6tWPx68Z3adPDEcuceW1jPuz/AN/68Pk2ybN4t3LZw0bjn86o3BEXJcwyDlflIIPrmp0MHhMPb4fxf+Z9D6n8b/HGnRyGWPw27J12WMxH0z9o6+1UJ/j54+hVi1p4YGBuUNZ3ALD1H76vH7LVJbqyZZJFmmZSgy67lHIPyntg+xqxG52/6gwsqbBIyA9sZ6n0pXQvquH/AJfxf+Z6cn7RHjxsY07w7KD3gs5pPzAuMj8asJ+0D44eVYzZ6BGx6iTT5xj8rg15FHbsZ5JmFvuB3YTtgADJpTLFCVVLdSQfkO0yKMjnjpn60JdxfVcOvs/iz1a5/aJ8aQghbfw27g4wtnNgfj9oquP2kfG3H+ieGge+bO44/wDI1eXR3EcoRSpRl4UtCVUevbH50wb9y+VHG8kgIDFtuR689apIj6vh/wCX8X/mZ1rGYoUQHeqKF3g4Bx9anwT8wSZkP9wZxUzx2pkDyuzuB82IgAD+JqSL7K8Kr5gaU52QiNi7enCjHNUb+1srEUbKMAQTkn+/gZqWPcGDFAo6BRzXVaT4Ru54xdals0u2UZZ7jbvYf7vb8anm8Q6JoTbfDdgdRvsH/TJwdo+hx/LFbRw8rc03yrzOOpmEE+SmueXl+r2Kuk+DtT1KLzpQlhankzXIwcey9fzxV77b4V8LHbY2z65qSf8ALWTBjVvbt+QJ964zW/Euq6zITqF4Hj/55INqD/gP+OaxWlbA6YIzjpmn7SlT/hq77v8AyMnSrV/487LtH9X/AJHU+I/Futa5lLy4MVsf+XeDKJ+Pc/jXNhdvbn0qqbh93XH0FOaRmUEn8+9YTqTqO8nc6KVOlRXLTjYdPEJ4pYG6uDtyO45FcrXVQxsWV1zjOasaL4cW912ae6XGmxESH0ckZ2j+vtWM5qCcpbETwtTFVYwpK8noT+D9Mh0qwbXtUGAFJt0PUD+9j1PQfnXL69qsur6g9xLkL0RM/dFanjLXTqd39ntyFtIflUKMBj6/T0rmaxowbftZ7v8ABGmY4mFKCwOGfuR3f80u/otkFFFFdB4wUUUUAFFFFABXoHwU/wCRquv+vJ//AEOOvP69A+Cn/I1XX/Xk/wD6HHQBxWrf8hW9/wCuz/8AoRqpVvVv+Qre/wDXZ/8A0I1UoAKKKKACtnwmg/tmOVhlYFaXHuBx+pFY1b/hSe3tzdvcjJZVRT+OT/Kmty6SvNHStI0w+ZEX3Y5qAl1lRFmU4ywbpjHTFKdQtmjJilVSOgYVEtyWZsqj4GOvc81u1oeqqnK9Dat5l1W3FvfAR3S/ckXo3+fSse8gktpDFKmCOh659xUsV5IPkCKAPXt9K2EeLUrfyLo7ZR91wec+tcUqcsK+aOsOq7ea8j2qdenmcVTqO1VbS6S8n5+ZzvJiIYc98UtvKyZDD5WGasXlvLZylZVHsQOG9xSpCJgNy4Bz0NdUWpLmi9GeXUjOlJ06is0WEKPEH35IGDn1o8vJwuB+tVmCwyYkPyAjDjoatRjeQASR/dA5phFC20jCRY5xuQg4JolizE0bdT0Y1PCilRHJuRj0Y9BVuOTygVnhZj0DY6ntTVmU12Me3R7WFJw7QyD5BIjEN19RXVad4ru44gt00N/F0AkAV/z6H8a5+9icMSUzu5Hpn0FZhaNGYylkIBIx3NUqk6fwM56uHpVv4i/z+89PsbvT7xWFvLJZOxw0Uo+Rvp2/I1W1CxuoVkM1mLmDqph5/SvPo7maFo3jlypHIz29xWinibU7CUPaSHy9uSjHKk9uO1ac9Kfxq3mjBUsRR/hS5l2l/n/wCea909HCRxMwfOVx80RH978+tXTY3FtCmy0uEib5y5U/Me5B9Km07VLDxMBF4j0yO3uGTdFdQZAlx1UHqD7HNTjRdRhkW50DWPt8KHcbeaTkjoQQflOenaolhXJc1N3RrDH017tZOD89vvMg3W0FLmEuV5zIBuX61lvKWZnifnOeCV7+lddGy363a65pUIaBPM85k8hoeemc4fPbrWPqVlZySs2nxBoSAUWAMGHruJyMmuScORnpU0pK6ehnO02Cps/NPUkckfjms29uLholSSMwqDhcwnJ/Guj0/RJI52jaRmk4YBXwig+rdSfal1DTIrTULf7dMWilJAlY4wwHQ/hUc2tip09DmLDfbwyxuyxLMApEmVJHrT3uEyVUBxwFHbNauq2VtFOGa/tmjCEqwm35PpjJI+lZ7I6GIyFTHIoYEdT+GeKpWMVDXcmFxulEtukcjwgZC5BOfQegrUtNWkc+RMRlm6RoQAfc96yreHE4X91ErKTngsamgeRpNkChtrHoMk+/tTuaJG0rFYmVUwC3Lk5Yn0HpWUkgnnfzB8q5IVBndj/a9qW4e58yGFHxLKSm7H3RjLGus0bSraGxikuYw7tghT0UA9PxPJqXOxaSOe+xs9u4kXEjqCcD7i9cVatWkSCHyUjxESQhHyk9efxOav3TgG4lARZJCQefQdBWVb3ltJEzFyZVPlrGqjGeecn/AArem0lcU0mVddW2unaSBTElxGD5bH/VSr95foeCPrWJb288QRrdiFnXafmHHYhh25rV1/jTy+M5YEtyOcf/AF/0qjazrHAlwytLCzAywnjf2JH0NFR6XRirXsyGLR7hnXKSDvuUj8alm0GbaofeSWwNx5/Kt428sLCQ2kzRvklmxlffA4IqqbuaGdjEyiSTKqSNzj6AfyrmlJnT7BNXMS68MXiIHjy4z83QY/WpYfDbiMGWVmfkny2yMV2OmaqskEkc6xpMp2NGykEDp8wPI+tJPLFFMILeMBymc580k4OMBenPHOKjnZzOirnJPo0kYXcW3HAG6NGJ9+eaWaz/ALPBeV4o2TAEjQkDn/dOK6ey06e8eJ0tm3rJuddw3nIJAx2HHODWhp0UojGYYWOSHkkYlVHp0OfoKfM0Zyik9Dh0+zXSYjVLpuh2s3H5VoLYCFQioUZzhVQksT+PI+tbgs74tIbu1sBbrzHFExTnHf1/GrUEY+5aWEazsu1mXJbHp/8AXrVOb0SJslq2Yi6XEiESgyqRkoCX/XpQttZELbvYzNI3CRL94jvjHSuqOmhQJdUnjiiXny15b/6361jar4mayRIPDNrBCJSym5lXJYjrj/E10wwslrVlb8/uOOWOhJ8uHjzv7l95NF4bgt4Bda19k0u1XoC26Vvx9fzNQz+MNP0oGPwxpm+UjBu505PuB1P6Vyl5cvqQN3dTSTSA4dnfO0+w7U92a2ddqbP4QWrVVFT/AIS+b3MfYTr615XXZaL/AIIajf6rqkxmv5JJ5P4QzYVfYL0FU5LOR4wxRem7ABNaLSiMM7R7yw3Ak55qqf7SvCUtIWAxkkAis23J80tTrjCNNcsFZFVbPFuJJHKg5wCoHFVJzBHIULbj7c4raXQLlkaS+utgJ+4Dkk1Z8mwso4zawI7cFnf5jmpsPV7GLaaddXaj7Pb7I/778ZrRh0mK2P74l3HpVtr24aInepC/wocYHrTGnY7UEe4tgAA5JJ6UWSV2TqJDaG5nWGFQo6kn+EdzVfxvfmx0qKxsfkjJ8tyDyO+Pqa1riRdKs8LzdS8nPOP/AKwrjdbuIJdPuIzMjSqyuF3AnOcEfrXnJvEVOb7K282exibZbhXST/ezWv8AdXb1fU5eiiius+RCiiigAooooAKKKKACvQPgp/yNV1/15P8A+hx15/XoHwU/5Gq6/wCvJ/8A0OOgDitW/wCQre/9dn/9CNewfBT4F/8ACzfCt1rP/CRf2Z5F69n5P2Hzt21I33bvMXH38Yx2614/q3/IVvf+uz/+hGvsr9in/klmq/8AYal/9EQUAcp/wyN/1O3/AJSf/t1H/DI3/U7f+Un/AO3V6J4Ra61LxN4jlvNN8Yal9n8QzwRXNrrhitYI1ZcIYTdJlVySQIyCDjnpWno/jXxJINH1PUBo76TqOtz6OLaCCVJ0CzTRpJvMhU8xcrtHGTkdAAeUf8Mjf9Tt/wCUn/7dVq3/AGU3hgMS+M4yC27J0g56Y/5716D4S8W61qmi6dZeHLTQdJaDSn1KcGzdoADNLGkUUaSJtz5TktuOOPlOab4i+JepWPhSx1eyvtLe/GiQ6tdaUukXVy3zJvYmaKQiBCOAZFIGMkkdGnYabTujgW/ZVdk2t4xi+v8AZBz/AOj6Rf2VZ1csvjjk9f8AiVf/AG+vVNQ8a65D4wjs5BZ6XpE1zaw2sl7ptzIt2sqKSVuUbyo3DsUEbDkr1GRjH8Ma94wsvBOhTPqWlahc6pqzWET3NpNmIGSfczt5zF/uLtA24Axz1D5mV7SXc46P9mK6RAp8axOB/e0g/wDx+pE/ZovEII8aQ/8AgnP/AMfrtbrxZq+keIdV0uK10N9cutSsNOW/js3hSR5bdpDJMvmMzhUjKqu8HoM16Zoa6qlkV12Wxmu1dgJbKN4kdP4TsZmKn1G5vrRzMaqzXU+BdJ1e21W2jtr4qJWQEMePmx2pLmyms3bGTHjhwK5uzCC1hwVbKAkYww47Gur0K/F5ataXLMW+6GPBH4+tc8oTwz54K8Xuv1R9bRrQzGmqNd2qL4Zd/KX+ZnEhuHIb2q1bt5aljuMajO4dV+tLqtg1l+837ieASPvH/GqUV9KmGFurEEZHb8a6YVI1IqUdUcNSnUoTdOorNG/auWIEoDR+3ce1XGIwEkO+Nh8h9PrXN293dRmRpCpRyWAU4AyantdVa2u4pxDBIyHlZXJBq1KxMm1FuKu+x09rpM+pQlJofLQHMcx4NbVl4X063ZXuIhPIoByw+X646VQ0HVdT169Z1+zwadEcOsWSzHsMn9cVsWOqR373wtjujtj5e/1YDJ/CvPr16jfLsfm+dZrmblKlpBJXai7tJ7Xfd9keUXED27uJI8hmJBPB6+lMYfumCuTuHCgdakmvZrgbpZoSW5OFH+NRQwM0pYSqmeCeK7rqyP0WkrQj6IlhlkjjiMZMcisGUhT+7YHrjpXQeJwo1gnSLiRwY0mkkjj8oRzsoMiJgnK55BOO/FZltpcknMF0B9JBgn6Vs2kDpBKjKrfKCHGNxYHocVpTlrZMmdpLlY6w8RXklt5OpxRahbn5SsygN+fQn61dgj02c40jUp9MnfkQTANGT7Bv6GszyAl5JDNb7N3zjnAz3yelV9ZlQwsYY4SzEBVD7sAenHWtfbXVqiucVPCuEr0W4Py2+7Y1LuLxFpu50hguHc/8fEaFiR/T8q5d7kzzh9TjlmnBOWlGUXt90f1rZ03V7y0B+zXLiJThlkG7Z7EHt71oDVdO1CdG1KwMVz937VbH9Djn881KoUamtN28n/mdTr4ql/FhzLvHf7v8jmL2yRoyzRxShOB5S7SPbHrUcKRTLGyQwJtCAqSBuJz0AGevUmuwbw/BcQt9luIbpVB2/wAMgPuQao3eiXtpbwyW6bXjZQWD9APbGe9TWpOnujooV6OI/hyV+3X7jlpAba3UOltLgtl4x8w49/rWif7IsNOtpYbyW+vZEVjBGCqRyHop9cfrU14o1FmNxAINpO9/4n+gPc9B+dXQLMlE0vSZLeUsdzuQwHBGR/ia52b+zk9jN8MRXV7cfap34gOAhTAYHlh7Z4rt5XkmMiqm1QvLEYUewp3g+xEFtGlzboGfhSHGWI+8DjnPQ1q3NtFbEtdSjypG+6ecn0ArJWbNVFx0Zy1/E4TAUeY2FUY43GqFjai1ybSHzJ0+dd4yHIznd04P9K6C4gurjVoXMLQ2aq+wE5LN0HHbAptys9n5jlVAZ/mAHXAOR9K6oxInJI4++njOlXBB3JKu5Wxkbsg4FUdQXDNLbnbHcjLIFyDkfpWrex2xuLqKCOWKznZngRm4DAfdB/P61maqW0ueHyJHW2xhAxDbTgcHHX/69OxlLa7LXh+aa/sltJpCksDBFYt95TwOe4/+tUuoafLb3Khlb5T/AKxW5JPYnr+NZGmagtrd5cBoDGQYg3G09VB7c8j0roY7q1u4RJLMikgKwkBPGMAH0+tc8oNHTh5+6ky7pkXm7pDnJX5kYDJHY5P+TW1a2jXXmRWoUOq4LOpC57LkDms/S5ozcIpG5tucB/lBB4PvXTLdExBLWQR8MN3JAzwSPesJQbaSV2Ku4wTlJ2Rk6adP2kSRrNcruATquQMnH/66vpcIT/o1rHA/lohEOdrMq4ZiD03HsMCq1j4eSG6+0qsrzFAN7MfmA4zz6+3ep7q2umS5icTxKUBgktSvyuCSVcNyVYYGRjHNd1KhCnpWdn26/wDAPFniZVnbDR5l3ei/4PyKV1LbWId9RnUHqIk5Y1QGuz3A8nToUtY8E7yQSR6+grfsItITVklCw232mUXSXcrsskDBDvgWPowJJ4+mM1hxQadHoUraXPuvLeW4gkElr8853r5SsuTk7cgBcY5rsTUf4Wn5k/UXN82IfN5bL7v8yxo2lyXlrJdENMkjECUtndj3rN8a+HUsvCmlaikY8xLxo5iOyEYH5EV2EFxfaVb29jrel/2KrlTHt/eQv5gyvzrkKc8c9Ksanp8eoaFe6YyM8cXzzSNwF3DoffoRXO6bcrs3ceRJR0R4dcWnlpNLA7IU+eV88P3xj1rUmM2oCPbPtVcvjOMnH05qnqVteaddXNjqMYeRMBZv4WU/xH14xTs3MU4JlUgp8qoRwPapQlzbl6xmNrsWZEluM7VwM4q8PECrPFaxx5eRtgC8EHtn8axJblkiRTGoUZG8A5Ix/OrXw70mXUvGEc0+TBbfvyT3I4UH3zz+FRVqezVzLFYhYehKtU2irnfaz4XW5soJLYlbuGPDBeBLx39DnvXnVxcrbN9nkUiQDaUI+YY7GvWIdWS7g1J7QF5bKR4tp4Dsqg//AFq5PX7Wx8T6I2v6RMkF9BETKGwMgDJR/Rh2NefSrzWkj4vJM8r0pOnjb8je/wDK5aq/k+hx0cpluvLdSiY5JGM8ZrZs4RZRtd3BzIRhF6f5NZvh2KS8H2m4ZfsqDnIxuPXH4UmrapO0xxbBoF+4c9R60Vpyqy9lF+v+R+rYSjDCU/rlRXf2V3ff0X5lPUbmaWdmk53Hj2HpX2T+zHz8EPDv+9d/+lU1fFsl4hYGSORPpzX2j+zGQfgh4dI7td/+lU1dEUoqyPnswnKfvzd22zofCvjg+Jbe2vLLw3rUOkzl8ahcPaLEoUsCxUTmQDKkfc/TmtKDxdoWoW182ia5ol/cWtubhkTUI9qLtyGkZdxRDx82Dgc4NeafD3w5faB4et7TVvDvim3vYEuTJc/22r2K7jIQfIW7IIwRx5XXnHes3wzoWseJPAvhNrPQG0+Cw8KzW8c8ssGb6S4tUVVQI5IQn5yX2nOOOpqzzD1+88WaDpkVl/bWuaNYTXUIljSW+jUSAjkoWKl1/wBrHNSyeJ9Ai1saNLrmlprBIUWLXcYnyRuA8vO7JBB6dDmvDPFskvhzS/EPh67tLe81nXtMsYLaKO+tvOiKwLCYjEziRsOrMpjVwS55GCa6rx3pXjjXNZntvst7Jp0GrWVxY/ZmsktRBHLE7O7OftHmjD8LtHHVs7SAeg6l4z8N6fJfw3GuaZ9ssYXnntBdx+ciou5soWyOPXFVtM+IPhPUNDttVTxDpMNpMm7M17EpjbarMj/NgModcjPGR61w9r4W8Qf2/dQ2Om3dlpk1xqE8y6hLaXFuGnSQCS2dB9oRmdgWDcBSw9M6fhvRtXubvwFJqmgzWX9hWc1rcG4lgkAk8mJVePY7EqSrAHAbjkDjIB10XivSotLuNS1TVtEtbBLloEul1FGiP90M7BQrkdU5x6ms/wCJl1b3vwi8W3NlPFcW0uiXjxyxOHR1MD4II4IrjYfC2v6X4nttd/sZ9Rhtdb1O4+xRTwiVo7gII503uqZXYwwzKcOa6jxyHHwU8UebpqaXIdEvS1mjKwhJhkOMr8pPc44ye/WgD85a9A+Cn/I1XX/Xk/8A6HHXn9egfBT/AJGq6/68n/8AQ46AOK1b/kK3v/XZ/wD0I19lfsU/8ks1X/sNS/8AoiCvjXVv+Qre/wDXZ/8A0I19lfsU/wDJLNV/7DUv/oiCgD1iHwLolvqdxf2v9q209xcm8mWDV7uKKSUkEsYllCHOBkbcHpjFUPCfw50nQporudpr/UIru6u4pZZpfKiaaV3ykJcxowV9u5QCcE9yK7avGNN1HxJL4ivPC0E9/Lc+GDd3rTSStm9SRCbGN3/jH7xwwPUwDNAHReJvhjbX9nYWegz22k29tby2pJW5eUxO24pvjuY9y5ydsgkXPbqDo3Hwy8L3VhFaXdpdSRLYxadKEvp4RcQxqVQSrG6q5AJwWBIzxivJ/D+s6o1hO0fjKztrl9Ena+b+2rjU5opzs2yvAYVFqysWUqMYyRtJTNSrrqvo8scPiFLO2i1K2EtxL4pup7C8UwuWii1DZ5sJztZgeMqB/FyAexf8IN4f/tUagbScziWOfyzeTGAyIAEcw7/LLDaMMVzkA9ao6X4f8Jw6/daZYxzi+spotVa0NzcGK3eRpdsiIW8tdxMuVQAeo6V5Rc6/qM9lohu9Qk0zQzp0zQTar4omsTLci4kUsLlIibgBBGyBsblYEhuakuL6/E+rXF74htbO+m0PQTcagZJbaGcl5y4MqqHgVxkb9oK56CgD2bVPB2g6o2oNfWHmSX8kM08gmkR/MiGI3RlYGNlHQpg1oaHo9lodkbXTkmWJnaVmmnknd3bqzPIzMx9yTXM/CS/XUPDVzJG108SXssaSS6k2oxyAY+aG4YBpIvQtznI7V21AH5p6TArRRu8JIVV6H1HWtGwlEE0sOw792Q2OlZcN3G1tp8UIljkKCOdpJBsdt3ykf3QFx+tdnY6bFcyrpazRyalNIIbco4PnMTjqT0yOtdUWp6I9SE1FDbCYyH+z9Qw+6IOrHuPr60280kxQmVJd5DYKgHO31rGlWe3vFt7ggNEzLv3ZI7Hn0rtLdXbS4ZbldrlASccMD0NefXpSw0/aUlo90fQUK9PG040cS7NfDLt5Py/IwrTTRLwA+0jqGrRXw5HNdiCG4nIKj5iB+J/Clh32V0dufJkIHAzg11sITT7UzzKRNJjaD19hV+3g4c0Op89nmJqZRDkkv3j0iu7/AMilewwWGlR6TaySRRsuJHjGXCnqf941nadGmjSHT7GCYrdAFjICwTjA5+lbEDLJP5k2wyynO4nvWxNDDNEWh2u4AJCg1zzhKK9TLLcjpQwrp4pc8p6y83v+BzNtoVjBGqrp8SKvVlXnFZ7+H3mLlbiPDudoCfMi9gfSutS0vCu4bUU9AWOT/hXPa9Y3UTkWkgSW4YbipJyBW0JcsdT3o0G5JI09P8Oxw26KZI2xwxZM5+lJHp8cc72yL+7c/fz90/WtmwsHliUyTpEFAHl55ouLO2kZ47cyRTqTll6Y9a5nNp7hKlrqclcQzXsCIhdJ4sqwB6AnrVm4022kzOjSjjCxooA4GKt3Dz212blStwx4kI+UsmOfYsPQdaia5Ziywt8zgbCa1qVG7SXUmVC70MCw0YSNeeQZAyXA2qRu42clj6ZpkGlS3EnkW0CEiQ+enTylx94+mCOteh+GbGG1dI9SllisZm3TyRqCykKTv/76wDnjFc94n2WWsQz6fDftHfWZAadDEt1g53xnABQ8Dqc8VpRm5LQ6eRK0WcdZzyWWpQmQlTEwYnP3kzyCfp3rr31yJXSKNTKXPy4PUZGOfxFY97pN5LbwveRKk05IVOjJ7e1XfCCiCSawvrcHZHiKZm+QMB1J6dM11wxEo/C/VdDkxGDpV3+8jd99n961Lt7pUF3DFfw3KkSsd2G3YkA5Rx1BAHb8KTTNKZ777MiorTxiHzt+Mc5rsbbR9FtZb1Gika3uZvtQSOXapJQgLgcADPH1pdI0zSHkeHUZFmtZflimQFHhf0JHBHuabxWHqe7UjZ91/kc31fF4fWhPnXaW/wB/+aOat7X+x/Eknl20cjKpjuZpuJd2PvKPT1rqxpZlMUiMZJAMhMgjkdR+FWI/DM+n6iixXL3lg37yaAxbpHjHXb6np6Vsa7cWulsryW13AqkGOZ5FD8jIBGNuO2Cazm6FNpKabf3/AHHRRxU66tODjI43VJhboWuon+VN6/wlSSAP14rD1jU45LFILd08lPkZFX5s9zk9+TTvE2sfbHikPn3KSv8APIyjK7TxkfU9Kyry3jWaAMzK0hyqSdSO+ferVWKWht9XvqyK2hh1B9UijnZYreNXkSeP5VjYYLJ64Yj9a5HxLAoEVqzB2WRo/MTIVsYGcfrXYX1pHb/YzJLcxIGYs0R2qB2DH0PT8awNctvPu8wt5sSRhmkHGHk6L7nC4/CtL6GU6TfociszBmEfyrGNqgjqvfP161veH9IvNR8wQIgiB/eNJ9wHqMd/wqpPYRW2qaaNQmNtZSzqJZipJijJGSQOThc17enw18EeJ4nfwn4kuoYHwGgiuRKmOwKHDfma83GZphsvlH61ez6pNr5vocdWc6acYOz7s88sm0XTplge9W9v0Usqr93I6qCOAcc8ntXRQ6isUkUjiAJGW6E/vBkYOOnGCOOuc1V1z4F+JLdJF0u403UISchdxgf64Py5/wCBVz7+G/EekX0Y17RNRltogxJELSKSB13KCDj1zVU85w2KXLhKkUvJ6/jqZUcNTqT5sRLnfnt8lsdzY6ks2ZZXbY6YRCfujNaEnzwhhLlG6beSa4a31S3lto3tJ43aJl81ANrhe/B5rooNUEypIpRS/IUd8cVhOGup69ou3KaU53RBnjVuRtJGSCOlZszBbiYsscS3Eey4i2rtkG4NnOOGyByKWXWkELKiB3XjAOOT61kXmpWjXMEbz21vI5UNJITshU8FmxkgD6VUJTi/dZlOGl2bGuazaPoq6ebGMxnzC6kbllDENzjHIIGD2AxXEa54j1jVIbcG8Fvp9uvlwW0RIVFODhj1fpwTn2p+teIILLS7RbWFrk3ckkf9oyqY4JCpwwjzztG5ckgHmsybWLq38VaBrPiR72+0eOSKJZ4o3jSe3jbDRxMQucKSOPXrXdCvUlpI43KEBt9eXGr24jvj580ZwkigptXsDmofsVykCkta7c4+f5jXrOpeIPBeveIfCGp6DotlLYR3Muly6ZfuoPkqAyy+UG4CjfgvnJc8HFcB4v1DRm1rWFh0jTrcwyTx28mls0Q8w42MwYlSn3jtGDyK0lF/FczhUVT4Uc9MswKCWWJYx8uAME5q3omv3Ghvcix8qUyoN29CQpXPIP0rMubpEYNKVuJhggAEKnHQ+tVJ767m/dg/KEIKoowB/k1zyaa97UVfDQxFN0q0bxe52/wknkE+owysW89RLye+Tu/9Crn73w2f7Xu7RJFEayEEDPypnIyOmcVq+EIrm017TpWQLAiGIhT1LcEn1ro/ENqkGqTPENj3IDk+pAx/SuKrNwl7qu2ebgMPRo59yVnanUhf1cei8zlNXTFktjZApAnB2jr7f571jWthdSSGPeQBwAetddp1lLqGoJp1nCJb2QSOAXCqAiF2JJ6cKetZMjxSNG7yND5gDq4PIXHQ10UI+zjY+nxlf61Uc3olsuy6D7bw5fSvEHBnTBYpHHlioBZvyAJr6y/ZrVE+DGgrE26NZLwKfUfa5sV8ta3f2lxoVkYLe5g1uK7m8y4hkKobZlGFPPJGccdsg19RfsyAL8EfDoHQNdj/AMmpq6JM8HGbI9Kv7g2ljcXIhlnMMbSeVCAXkwM7VBIBJxgcjmuUuPiNoUNnZ3Ya5ltbnS21fzYowwjgGwLuGc7mZ9qqASSrdMV2VebWHwn0+DSfFOnXF9JcW+ssVgDRKfsMAdpUhUNkMqySO3I5BAI4qTgL83xKsLSK6XU9I1jT7+H7OUsLmOITTidykRQrIU5YEHc67SPmxUt14/S2eztn8N+IDq10Zymm+XAJikIUu4JlEbL8642uSc8Dg4yrT4azW1jqMMD+ErU3gjRorPwxHFbyIrElZozIzSA5H8a4xxzk1Vf4USf2ImmrfaHLbNNPPJbXehia2iaTA/0aMyhoAoHADkZJOOmADe1T4jafpxuGfS9Zlt7O3iutRmSBAunpIu4CZWcNuCncVRWKjrWXYePZrPW/ENpfR3WqTHXP7O0u0tFiVyv2SKYgM7IuBl2yzZ5wM8Cqd78HrRpN1pLotxJJa29vPc6zoseo3BMUaxCSN2dQpKquQyuMjOOoOpqXw7muH1gw32lTQalqX9oPaanpC3lvxBHEEKF1JI8vcGBXrjBoA7XRr86npkF4bS7sjKCTb3cYSWMgkYYAkduxIPUGsL4sf8ks8Zf9gW9/9EPWj4N0JfDPhmw0dLmS6FqhXzXGM5YnAGThRnAGTgADJxWd8WP+SWeMv+wLe/8Aoh6APzVr0D4Kf8jVdf8AXk//AKHHXn9egfBT/karr/ryf/0OOgDitW/5Ct7/ANdn/wDQjX1f+yJ4s8OaD8NtStdc1/SNNuX1aWRYry8jhcoYYQGAZgcZBGfY18oat/yFb3/rs/8A6EaqUAfpV/wsfwP/ANDl4b/8GkH/AMVR/wALH8D/APQ5eG//AAaQf/FV+atFAH6Vf8LH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFV+atdf4Sk36Rcx5/wBXMG/76GP/AGWlJ2VzSlT9pJRufff/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVfDsYQOiqSZHOAPWnFCiZwm0/3uDWftPI6/qP978D7g/4WP4H/wChy8N/+DSD/wCKo/4WP4H/AOhy8N/+DSD/AOKr4eVBtH7tWHfHOagl0W2u+VUovotP2gPAtLc5CB0MIWRSRgDIPIFaummJZjIUN4Tyd5IKfjWiNAhiDZV5sHpuwcVQXTrq3lneNXjWEZO706/jQpHRCDTVzUk+ySWwJiMRH8PUqPY1sWZnisB57sYWwE3t/D7CqFtYG/C/dyvLMB39BW7YaXJfXcVpITsUb3IP3R6fjQ6rS1NqlSnh4OrUdktzY8MWzXUJvLn7i5Klh1I703U7wXrs7eZCEBEeDzn1Iq7qlwisNOsmx5WBJt/9BqlcxJ9n35ZmyR0547V58uaL9pBHDkVNZtiP7QzG6VuWlf7K7tef9dDR8IaroyxJb62gFyhKlhn5z616Fo1lZX8e6ykPkg8KME9a8Xuo/Ik85LYSzDjZ0yfXPar+ha5f6ddl4JzG6n50ifv6ehr0qVZTjdbH0GJwtTDzcJ6Pp2fmj13VbKC0tpZlG2JOCZOAfp6muMncfbY7u7X92zFYYs8oMcEj35qlB4u/t52uNXmY26NshhPAAH8ZA6k1v6ZrOl3sZjSWNkXqXXbtH41nVmm9EFNOC11ZFG5llCxo8YHzbnGM1YWZHWXewIY9QM8Va1C70uaJwl1BJH1bfICMelctrOvafbOoRozGy7U8nO3I6KcCuaUG9kXD3tLF3UFTYBGqqegI4I45IrjrKKa01f7PEJ5pY2JEUYLGQH+IDtWhpmvRSRLFdXcXm4y58tmzn04qnqCB8vaG5lckqZBG2WjI5RicDafSunD0XZqezKSlGVkjpLa8t/MVpPLvbmPDeVKCbG17fP3ncZBAGEz1Jq2bzTZLG6i1W5Oo3l3EI5Ly8n3PFGDyAOij0VcAYFcCyl7lBfSLKCqiPzHaVtqjaF2L6YwAa6Pwp4O1PVby2kNlGttNJs8wwrujGCclB8qj/eyfarqyVPS9kbewg/fm/mZtzqc1yIikb6g2GjWYH5SVOM9M5IGau6ZY3l/qV+8kIgZoNsZJxHI5ddqsOwALdK9bsPhvp1gsTG6kUIhDHdlic5zu6Ae2Kz9R8V+DPB9y9raxyajqv3xHEplfJ6DeflH4V4lTPMPCfssMnVn2ir/e9jjni6b92knJnEaFofiDXZFl0zTilvG5j+0z5ijOOCVzyR+dd7aeBbHTLRLzxLqpKQsDiNvKiGcYUk8tz9K231jUbvQvtMsaadctHmSBny0OR3c4GQPaue8J6/pHhy18SWPiXU2nhvoPtSvdknznwVxG3U4wvT1yKccLm2NV6jVCPl70v8kYVq2IdNyStbotx198S/Dmjq1hpU9ihhUs32m4EO0cHgN87E5yBjmq9z4n0XxJBLa6p4j8MQ28ke1mOoxA4zn5QW4boRk8V2f7Ok0lxoHiSWeeGeZtY+d4XDJu+x2uVBHUDpn2rv8Axl4hh8K+G77W7qzu7u1s0MsyWuwuEHVsOyg4HbOfQGujDZFhcJU9prKa+03dnlSxjpTkorVPd7nyPe6jpFtrd1ZP4h069HnxH7SbmPYI1jzgMvyk5IBI6kVvzeJvCzWyrc6rpkjKMApNGSR75P619Iv4y0K0trR9a1Kx0W5uYkmW01G8himVXyFyA5ByVYcEjg88GreseJtB0SeGHWdb0vT5plLxx3d3HEzqO6hiMj6V6NSmpm39s1GknFHy3pHijwneyXVrcajaWyCLdHJK8RUkZ+Q5YZPAP9a4XWNZ0a7iNxHfQxtMsSNDGyKCRu3OVyccHAFfdMmq6fH9q8y/tE+yOsdxumUeSzBSqvz8pIZSAeoYeorOfxNp1l9ufWdT0axgt7r7MrtqC/e8sSbZNwUJJt3Nsy3ygNnnjojU5YqNhf2vO9+U+CtX1WwntrVGmt3JjWMiNhhCpYA/live/C3iLwjYfDjRp7rX9BK6dEZk0qK4jWWe8DkiVwfmBXBKjgEnnjFe93Pi/wANWumW2pXPiHR4dOuSVgupL2JYpSOoVy2Gxg9DUH/CUQyeLtK0a0jjuLfUNOm1CO8jmDLtjeJQAAMMG83Oc9u+aftfIwxGPddWcbHzB8OfHMSeJrzRrnxJEmjyu5t7q4vY7fylTlMM+5FBUY2Y6n1r17RfF1pJqWs29zqFld28EkX9ny6ZMLuS7RwSQEjySy45IGMfnXslfCnghNc0uPSb3w9ctZXk8UaJLCA0nllRuDDG3GRkA84xXn18pwOMv7Wir+Ss/vR0YdPGyairWR7Jf+I/BniXT9Xv/EelxGPSJY4Xnkty8mJCQuCFDryDlTjB45qnZ+DfBfiIS/8ACMarLbXESB2SNyxjU9CyPhgPxFeeeJtU1y4SS38R3VzcSahIPOlP7tpfIyIo2wu3CsxY4GSSM9q1vh2th9qnimtrm53SRNNMdxAZBuCsOQVB5w3J7dK4Fw9aXLhK86fk3zL7n/meisDUpwck7P7/API621+D8s1zIdU8RyLadktLUCWQe7OxCn8DXK658KZr+a1aXT20a18xYVYSm6dY1VyZrhh8rO7Ffu4CgY5r0Ky1e5n1O4MCTi2nc3BkilxsXG0AIwxyRnnFal94mktLzT4obiynhnY72kJVwAM8Y4JzVvD5zg/swrL/AMBf+RjONdy953PCf+Fe6NZarpi3WrDUdNcShljkChXABAIzkZ5z06Cqninwvb6oFh0nVb68+yLhIZpmlit4x2Un7oAA4FfTEMel63AblrO0vPkOSY1c+pAzzmsWbR/Ckxmto5IrORW3SxpLsOW5G5WrP+3fYq2Lw86fna6+9EOdN6Si7nzefA2p2NnaO6okjuZVkRMyAlRtVmHQHsPerFn4PvI45FkNoSmFZQTtyMYHT9a+iLjwxeC28iyureW3OCDNuV/zGQRWLrvhnUl0GaGK2DTbfl8gA8568c16GFzXL8Vb2VVN+tn9zsxe0jH4LHhH9iaa08wvUktJUPQscNnpg9CM8cVlm0/sz+2YXUtIqLGO2AR/+qvSr23k0y901dX3NHN5qiJ055Bx+orl7+xWPXdSVhutvMXb5hyRjt9M114hxp03M68JQliaqpw6/wBXLtux2RqNqKmCWx1IFaXi/c+nWt1DjeW2k56ZGf5is+2lAVl2YOM/MOpx0q9dM9z4Pul2hpIVLDB67eR+grzIKSaqT3Z4/F1SnQrYSvQ+GlO1+/Nu/n0K11qFjB4b0a2trUJfWpuXublgN1x5oGOFHQHIAJrjdQt5NSu7fyIVjeJWWRy3Mhz029sDipRrFy1g0YEcCNtAkPdh7/rSaPJ5N06x4lALAS5zuUnrmvSctLI9GULGW/2+wmSzLq6dUJ5AB7V6h4K+LfirwZ4Wg0TTItDksrITyq9zaStJhneU5KzKDyxA4HGK4W+hdriJ2OMvk+1V9YkSLSNQlz8wi2D3LED+tY8zuc1anGULy6Hc/wDDVfjj/oFeG/8AwHn/APj1H/DVfjj/AKBXhv8A8B5//j1fP9Fbnin0B/w1X44/6BXhv/wHn/8Aj1H/AA1X44/6BXhv/wAB5/8A49Xz/RQB9Af8NV+OP+gV4b/8B5//AI9R/wANV+OP+gV4b/8AAef/AOPV8/0UAfQH/DVfjj/oFeG//Aef/wCPVn+If2lfGOvaBqekXmm+H0ttQtZbSVooJg4SRCpKkykZwTjINeH0UAFegfBT/karr/ryf/0OOvP69A+Cn/I1XX/Xk/8A6HHQBxWrf8hW9/67P/6EaqVb1b/kK3v/AF2f/wBCNVKACiiigArqvh+27ULuAFAzwF1L+qkH+Wa5Wr2i3JtNUt5Q20BtrH/ZPB/Q0mrmlKXLNSO0j1EpcSHeqSLkFtmT9BTYtZMtyn2lWaMDGDjk+tVrgpHJJDbq1wynlycLxTZ7eOzPmXhVpXAaOJemfelyqx7jklqaTX8O7CxkLg5OetQy3vkFCZEZicYU9qki0+SeKNXSOHccL3+tVrW109tRa3vtU+y2yB98vkl2LAHaqgDucD2pWTFKbtsXbbWrM83DHeo4AH3jUkVx/aEipKjG3Z9xiX7xHbP+FY8lsIY7aaOKCR9o4LneT1yRnH4VrXkcSb3tGka3dgttdtGYm6AkFeemetOUCINyeppRWl2jFYLZ0jY7VXOSOenFdNcOug6QAhEt7N8oZv73r9BVHwhHLY6Y+o6rcTbD86iTqoHf8ayJ7y41a8ebZweATwEHoK5Ztzdux8/iVLOcX9Tpv91T1m+7/lLumT7bpw2Wc/eOO9aep2ryspgmGMg4TvVS2tkjUCTOwrkkevpWnZvCIoxIpErHAUdvSiT0PrYU1DSK07FGSDcpywyBks3QfWo1txJmGaQQkdOwb6mtuO1leZPtKoExwvUD3PrRfwwXBMYURyAZRx39c+1YxjNS56e/buejTxdOcFh8T8PR9Y/8DyOPmiDOljMssRVw6SRn7oFXtKS1WUBZEa4H/LS6few9CFPFadncoBLHeRCSRo/Ljdv6+vtVjSrYRslneW0Epi2+U7L1XpjOO1dlKtCUb/ejnr4eph58stuj6Nd0RItrcyqEtp9Wu16NID5cf4dB+VV9TjvA0cDrBFNuzGEfdtPcAf1r0zw/ouqvYR21paqbfoty+FAA7EHr9RWjF8PrYlLjW78LIrbj9n+QE+hZuefYCuTF5xhcIrTkk+27+4wjiIQl77PNPDmm392ZHknuTMSI0SBFOffoTgeld/pvw2ju383VZbkjYNqzP8oP/XPgV6FoeiW+nWyQ6LZRxRMclsnnPUknJJrfj02NQDcyFf4gBxxXAsdmWN/3SjyR/mnp90dzmxGZO/uKx5+ngfw9pdlc3L2cj2sUQaVFzswmTu2ryTjP1Hat/wAKXVpqckNvYWdzDZEkJKkIWJk2gq6kcFWzwfY13sEERiVjgjHHoK4GK8n8Oa9dW2nXNq/h2eZQsrqFj02U/eiJHBVjyv8AdJx0IrSnkCxD5swqyqvttH7kec8VOumm3f10OR+Lwhi8RwWrzSCC3twyRjdtMrE8kdCQoz7CuElhVJdP1iOJTFZSeZtdRllPGOfzFd98a/sUV4og1F5LydC11AcusACnEz44TsvPqK8016+N1pMNsv7u3eNHkJ/jUjj6ZFexSwlOhaNCKil2Vj2sva+rxbOlnK64be7ld3Oo2zTN5u5RbRhyqxrxjeRksSST24xWH4ot7PTPD96qHNpFGqtASGK5YAFSeRyRxXUar4jmv9A0Kwnk3nT4I1kLMFR1OEV244zwAc15dr2o3N5PdWpjjht7htrFiC4VSGLZHGDgCiu5yl7pvh+Zx97TU9+/ZlRE8K+IViRUQawcKvT/AI9Lauz+LdhqGrfDjX9M0exlvr++tXtooY3jTlhjJLsoAHfnPoDXD/stuJPB2vMucHWD165+yW2f1rsfG2u3eleKfD9rFdSwWFzbX8tyIo0Zz5USspUsDggkkdj3yKuO2p8pif40/V/mYs3hrUtS1LWb640cxfa/CcOmRJcPCzicNcF4jtZgOHjyc7Tkc8HHB+LpZvD2m+ItAvLWC91rX9MsYbeNL6286IrAsRiMTOJWxIrOpRXBLnkYJr00/EWytdFtp7aw1vWfL0mHVbt4o4BJBA6FleXLom9grnbHnocDGK0tV8appa21zd6Hq40mcwD+0k8hoY/NKhdyiXzQAWAJCED6c0zA5LxToniIal4vtdP0Ka+t9cvbK6iu0uYUjiSOOBHVwzh9wMJIAUghhyDxSyeDtWm8VyXU+nJJZnxemqgvJGR9nXTjEJMZzxLgYxu74xzW3qfxNsrC8vYjoWvT29pfrpkl1DDE0ZuG27EUGQO24sqghcAsM4qyPiHYizmMul6rHqkeoLpn9lFImuWuGjEqqNshjwYzv3b9oAOSMYoA5qfS/GWkyXUWj2t3Fp15rN7c3B042jXPlvsMTJ9obywpPmbsgt0wOSaT4beEtd0jU/CM2p2LQR2Gk39rcEzRMY3kuo3jX5Dg5RSflG0YxxwK6FviPZFLKODRtan1G5vJrA6fHHF50M8S72VyZAgG0ghgxXBBzVFfiPc3viDw3b6PoN/dWOpW9606HyUnglt5Y4mQ7plUbGZ93XOV2k80Aej18V+C4LbT9O0yPX9ZvfD1xLZwXdhNPa74ZoTH8xLD5hnGFI9B1zX2pXwDYQlNO0q91SOdhcWcUdqqTK+5EwpBGSyg4bAwOTxR7V09YnsZPGUpyjGVrm/E+oS61p0H2C6udQg2yi1mlMwZmUMZNv8ADlSpyfTmvRvhdItlHPBA0jAXTCRihyWYEEsehIPHPTNTWME2g+JbGXS9LtF0uS3fzykbQSJ/dV2zjJJXaT1xUlvrC3MV3b20cdtImJDcRSBjFuBIeVQMn5hznkV1YdO3tN7ns16vtFyWOh1i4nttXkYrbyxuiqVjwd8YB4YeoyfzrzXxaz2ts13ptvLbNHIrQC3k8yJj2xnDxuB/DyPQ1zmvXmqajaO0kFzHNZSbnnt242kdh3B6+1cRq+qvcRJ9slladUzFMCMsOwb19s8itJ4tRTujOEHRV29j1yx1mebSTJF4ik06S5ZVEjuCkj8nk9UPHNZ/ifU728Nvpt4VtdRgQmK5lX93focFSH/h7+oPtXkdtcTXlsyySnbDll57nrXSQ65qeiymyuZku4LddiQu2+Mqw6qSPu/SsoYhVFZornTfMtjuvh/rE0101lLeXWjX0brJ+6LeVMi5yCvQdevSvXr3XdQtbDz7aOK5c4CI2QW9ORXk/wAP9UttV0qUXAhhW1ba6LkGNTyGQ9h7HipV1bWdEIvbOU694WklDAwj57dgcYx1Uj8vpXBi8qweJV61JS87a/etTCpTjUla2p3mo+OrOOS0g8TaDLvd1VGVUuFViuSRuwRjBzgGvLta0mJpbyOzuUljkn/dzsOgDAnOO/Sul1/UbfVvE3he6s5g1ofPO1ThxIE+6w7eh+tYdvZKYleyeTBmdjZOMeWckkj1GawwWTYfBzcqV7dm7r8S6TlQhL2b5eZalB7mHyYPtMkMTsTmMnkc9cVd0V4HuLi1Q7hIm51PYdKpNDb6gWLBRMocjcMY/rUlhc2Vq1h9haJA4VZk3MWVyDkc9a7sRhk4No8LPqDxGX1YdbXXqtUcFe2edXFi8ciQRbljA5yB3/Sr1rAsRWPy2UEBFYHnA/lzXRa+kNtqE8hxvkVSG9OxxVKFf3W9lIULwDXOtYqR15divreEpVu6V/Xr+Jn3KkmOILucsAT1C1R8emOz8LRxIFD3NwF467UGT+pFakbBj0O3071x3xGvPN1C0slPy2sILD/bf5j+m2ph70x4uXLSZyFFFFdJ4oUUUUAFFFFABRRRQAV6B8FP+Rquv+vJ/wD0OOvP69A+Cn/I1XX/AF5P/wChx0AcVq3/ACFb3/rs/wD6EaqVb1b/AJCt7/12f/0I1UoAKKKKACiiigDsLS6nvrW2IEaAr5ZbGcsBg8dz0q4unQBd91PK0/XcTjAFN+F3k3d9c2E5Ak2GeAn+8v3gPcrz/wABr6J+C3w28KeMdF1268R6fNezQaobeNheTxARi3gYDajqPvOxzjPNTfWx6sa8Y0VN69D5/aOOGC1JuVvJJ4hOY4Sx8puV2t/tcc1Si0+7umdnXZuJ4AyeTX2knwL+Hifc0O4X6andj/2rVDWvhf8ACjw/DHLraw6XFK22N7zXrmBXPXALTDJoafQX16H8p8rWeiBBG5fG3g5HNdJpVo1wq27QQ+XGxdpgDvYEAbPTHGa+h4vhf8MbjT7e/sbK6v7OeRY45rHVL65VixwDmORvlz1boOpIFai/BfwKoKrpl8oPUDV7zn/yLWcoTfU58ZjZ1KEqeH92T6vp/wAE+V9e1db69NjbtmG3ODjgOwH8h0qKxbYRER0XOPevqUfAr4dq25dCnDDuNTu8/wDo2mH4N/Ddb9LQ6dIL2SNpVh/ti78xkUgMwXzclQWUE9MsPWlGjZWJy2pRy+gqMI37vu+rPnW2uYo/vOFTHerUMMlxYXDRuUllOVI4219Df8KO+H+c/wBjXOf+wpd//HamX4M+B0GE02/Ue2r3o/8AatT7B3vc73mcGrKLPnLSFu4C9vexttUFll65U9vrWlbrFDaSSOhDsdmGGSRj+VUvCTPfeH7N28+edLaB2wpctlQCxP1I/OpdYeQyNbov71PldW6gDtV021LQ6rcyGSWtvLE8Zky5x5bY+7z0rb8NalBo2pWjajbJe20IIYyRhmUn7rLnuDj8M1iaVAqLJmV5XYbjuHTPQCteS0MyOnQ8ZH69a5MVh1PmT66aaHbGtOdH2En7v9bHVa78QNSju1SK3SxtA6jzZFMxcdxxwv610NgLrU0sb20S1vrvLTI3msP3fQKDjrXnelO7+IIrPIujcRHaSdqKMZZWz6BSa2NBuhol5Pf+DdSjuzbW7XraP8zCeLcA6xsAfmHXGPStMtyvCYO0qVNc3d6v72csqEYRut0dr4f+IOoy68+kahoE1tLGhcnO9iAcfwjH512l14usLeymlmeNbqK3adrZ22zMgGTtQ8k+1fM/i3x1a3nxNTXNE+1JYo0JcnMcjlR82Vz2Jxjviuo1T4g+H/EdvLBfWdw7xtuM3lHeR/MV6k5QTtImplsayhOMbJ7+pp6x8UbvxvfyaRoM40PTI2Am1OVwHK/7CnGCferl54nOo6SPCHhCzGpQmMxTzSgFps9XJPyoM/xHJJ6L3ry3w5DJfagrxPe6dbz7op7tZSjXHPC852gDjI57V67aaBPp+nWckF5LpdvA++NdMAPm8dZSwy+en1rlhVlJ8p1YjB4eglFLbb17vr8jg/G+n3XhDRLnSvEq3FzJqdvKbaW0lLqk23IEnALuTty7cbc4Arz6W7uxf6dp5nkiuooFkhaNdwkdQAgz2HB5rvPiRrjahHbR6neahNe286NaI6IqGF8h5H4HOF2gDHJrPj08W9yl+CEngTeZePwUZ+tdNSooJEU1UcXKW/4fIsbw41CzuNf1NtHstOj1ie2ktE82NyFG0yL3zI2FyOgz0rkda1C1g0q11WT7HaxMDHZWMZZ5J1HyiVg2QkeV/iOSScDArrtZ1d9O0q+/tFZ9B8PNHJBLpiXam/1m4UMAJmUb4Y1BG7OBtHckV55rzX/hrRrfWtciiuNa12xkt7S2vELtbWpUILkDOFJG5EBHAy3pQ/eVzzZYp0+Z39D6W/ZatHsfB/iC3mv7TUJU1py9xaSeZEzG2tyQrYGdpO0kcZBxkV6D4q8K/wBv6tpt79s+z/Y7e7g2eVv3+fGEznIxtxnHOfavj/4S/E3xf4N8NT2WgWmgzWUtwLh2vFcyBvLSPgLKuRiNeME5zXdr8ffHDS7BF4W3h5EeM2dx5iBcYYjzsYbdxz2NZWPO9hVqyule56J4l8G+JdI01tL8ICe6+26HBpN5M1tB5LGJGjV8vcK8RKsd2ElGMYGRV3WPhA2p6hNcS6pp7iVrV1kutL+0XFsYVjGyCUygRo3l5IC5yx5NeW33x7+IFppNxqR07w81pDcx2bSCzmx5roXCj/SM9Ae1O0/48fEG48Q6ZpN3Y+GrWe7uktZN1pOzQM0gQll88dM596LPcTwtVNq2x7tceBvOt7uL+0dvn6/BrmfI+75ckT+V97nPlY3dt3Q45o+I/hnba3e6reXE9lPPdalDqUEV7YC5gjZLVbcpJGWHmKVBPVSCVI+7k+XD4wfEGf7Mmn2GjXVzcXNxaxRDS5181oSA5jb7Th1yQOOevHFVZPjj40iuTBcRaFazDCmO50udG3/xLxcnocj1PoOlDTW5dPBVqivBX+a/zPYvD3gH+ybrR5/tGmRHT7u4ujDpulpZQv5sXl7QiscYHO4lienpiO08A3mm3ml3ulazBHeWV1qMpNxZGWOSK8nEzptEikMpVQG3dj8vOB5Fc/Gvx3HF5kUPhyRducnT51yfQf6R+tUrz4/eMrbS0uSvho3DHBtzYzgjHXn7R/So5kU8BiF9n8V/mfVNfn/4RdLWyspRbvLPGiTpNaFWkjYAbdykdB3616hZ/tB+N7i7W3Nv4YSRlBBNpNjn1Pn8VxOjeDb5UtxHeQI1tECrxttkbHGAeazqNNaHq5Xh6mHlKVVWT80dPZ/EWWLUEfUxFqMRiER2RmNscHDxnhiD3H4V1Wn2Wl614U0230WS4SFJnF29o+TMrhgySN97+Lv6V4rrljfQXpRbhpPs3/LwScjnv3zVaDxHqul6lNcWV28F6zfNPA21ZB/tL0P1pQrSp7HoVqcXrHQ7fX9Ri8La/qGnQpPNo20Okci5aPcoBOe/Iry7XIraDUWS3neWyb51YcHp6VsXus6pc2w+2TtMfmAlDAkg9QfUVlPp7TwB1kjJAyUB5A7ZrWrV9pqY1KbcbdR+i2sNrcpJdrcTQMm7/RcMQT2IPB960b828tk0Q+2XF1HIqWUjuERYBuLxup5zkjGD3Ndl4K02GLTkJghMbA58w5O719qzPEj2ltKbPyoJGYEhUGVTPQnHf/Gs1LoRGH2TMh1e1jvphHDcWHmQpHFISZAFAwyuB95T+Yr0Xw94r0LSDF5RjMDAK7KGBUkYKN/fX0Jrz97UC3AimgiIxlVOYycdPUVd+0M0PlXkJ27Bgph8ewNa+2lYpwWzOg8bXNomvQ6v4caOxP2dkfGGG/tkdsjjNc8us3mojZE5F+oXYrYUrxywI65zWdrNwF+0/ZtvlqirnaQWJPPX0qjbr5kUD3G6IBiPMT7/ANKn2jTNo2UbHolj4av4dP8At13qsJ3Sqk7R8uA42qM9hxkn0qxciO6uIIrS28q0EgCY+YnAA3Z644P4mpfhPott4z8Vnw/Lq+pw28FpPeNcWpjDTFJIEjB3owwBJJ29K9es/gRo9n/x7+JvE68luZLVuT1PMFbOpc8zE4qnFypVE/8Ah/meL6pZi8t2VFxNsClwuWA7iuZvkeCFEc7mGEAPpg19JJ8D9LjPyeJvEo6/xWnf/t3qjefs/wDh18z3XiPxIBGpJdprVQo7k/uMVzxg1DlPEyaTwGH9hV1Sbtbt+B83WsyQ3AjuWOxQXeTHAUDJ/TNeX6pePqGo3N3J9+aQuR6ZPSvtWH9nrwhqmnrNb+JfEF1Z3cYZZYbm2ZJUIyCrLDyCO4PNVP8AhlTwP/0FfEn/AIEQf/GaqEOU6sXiVWso7HxVRX2r/wAMqeB/+gr4k/8AAiD/AOM0f8MqeB/+gr4k/wDAiD/4zVnGfFVFfav/AAyp4H/6CviT/wACIP8A4zXzB8ZvClj4I+JOseHtKluZrKz8ny3uWVpDvhRzkqAOrHsOKAOJooooAKKKKACvQPgp/wAjVdf9eT/+hx15/XoHwU/5Gq6/68n/APQ46AOK1b/kK3v/AF2f/wBCNVKt6t/yFb3/AK7P/wChGqlABRRRQAUUUUAXNJv59L1K2vbVts0Dh1/w+h6V9y/swS28/hHXp7Jy9vNq3moSckbrO1OD7gnH4V8HV9q/sVf8ks1X/sMy/wDoiClbW5XO+Xl6Hv8AXm3xP1Kx0jx38Ob7Vb22sbKK+vPMuLmVYo0zZygZZiAMkgfU16TXLa5410vQfFEOla3dWWnW0lk12Ly7ulhTcJFTy/mwMndnOe3SmSeWXd6U1TxDrPhOeS28PX+uaLFFPaExRXU3nqty6YxuVlKKzDh8HrzV7Vhq48K+L9bsNT1V9Rh1ua0QvqUyQ2tp9pVZCqDcq7Yy53lGKAZHQCvWdS8R6JpZtBqes6bZm7x9n+0XSR+dnGNm4jd1HT1pt74m0Gxv/sN7remW16Tt+zzXcaSZ27sbSc9OfpzQB4kuuXsem3Qj8SQt4ZbVrGO9uNM1y41JrC3ZJPNJvHRWVWdYQcMSgZuVyK00HhX/AIWR4evh4l1CbR5LG8trW+m1u4WN7hbi3ZYVm8weYOX4LNvwAd21ceojxdol5YalNomt6HfTWVubiRf7RQRxLtJDSuu4xpxyxBwOcGpB4r0FNRt9MuNc0ePVpgm2y+3RmViwBUKpIZs5445FAG5RRRQB8R+G2l/4RzT/ACdyE2cStscjcNoPNadntUSSTMfuksXOT/8AXrK8JEP4dsAGx/o0eQD2CitOC3H2gtIoIY8AjIFZUpNPU+mSTivQW0vEmmGyGctIcBwvHHtT/wC3Lc3P2cuAoOWkHRcdQR2qnrh3yiW3dMpxsHADD+tctqOvRqnnQ7jM2Vk4BGQOK1qxUtWbYfl3Z6Vo2o3dvs1DQ7qEX0aPsM8fmRyBgVOR6jOR/WvPtPu7/wANeIFutP1FoLu0m3Bo3AY5OCCMY59OmKqahqeqWk7f2rqCCeaJZozAyuoDAEK23gcdqoSzRedb39vA9zOZNz7uI2fqMD0HpWEW9nsbc8dbK91Yt380uoazd3RZTPcTSTvtfd5e5iSCQOTk9hW1/ampvarFby3zKnQFeG+nciur0HUrmy02eS0jsP7Rv1PnzyWaOV3KQ3ltgbTnBx09qpSkyXdlbNZx2qww4F1JJnzZTgHc3YYGcV0e0g35mbqSS5bWSMjSdft7SPyNUgkIMZX5MhY2LZJwep966aHX5IbUXcWp3Qjij8iJvNOOR8u1D/Fk9SKw5VhvZ3hjha6k5URom8sR1P096p2F3BZ+MrO9iknRbSeO4YgZG5PmAAPckbcnoKFCLehm6jqOy3NSB7PV9Ph1SRit5bTw6Tb2khMp8tUdpJpC3ViTnA4BNJ4jvGayjiggS78uaM3LyE+W/wA2VjYZBOQuCFP1Ip0WpiRpLm5l827u55LqU7ejuxYjp9BWTA97JIrXk093aWkcxtYcZEG9tzlAO5NRV5ZOz6HQoShFR/pf5nO+NtZ1O78WHxF4jis7q5lkR/shjK27RRkbIyqnIT5QOuT3Ncl4o13VfFfiG61bWZ2utQumySBgKAOFUdlA4A9q9E8ceFILXwJ4Z1ie/ml1zXXM6WEQBjjtVHyk985K9ePmI/hNcHbadLI8ipuG373OMj0FaK9rnhVKMKs/3S0WgnhhEOqQw3g3RupjjLgkKx6YHpnit57+8uLq6vb+U3N1IVjDbNoyihRGAOgAAAHoKy7ixEHlyB0ZXABCk/u2/un3Awcjjmug026sYjO90hJurVYpSxDNG7SBXljQjBbYpx0xnOaz8juo0/Ya72N2XSNKnOoGyvm1e2huLeA3PlCFCzRksVU85DAqD1IFLqlnHa20moMJLiTzUnnlklLSSlWBJLnJB4PNd98LNKs9aS6i0i3s7jw1peoNBbyXyLHd3Cyo20SAffxIyldwHGfTFcbAk8mmLa36IcxvHP5bD5GGV/n6VvU0gmjfDyVW66rf5nSzeFLLRtf8N3NpHJp19EZ1vZXvWeykaaJ2gkWRvuiUBtxXleOAcE+b+JhdXWlR+I4rV7bTry6aKB1lGFmRASqrkttHZj1rpdX8Q6rr+k6baSJbxSabbw6XHsRGaUxbvmLkAqCCo2jrzVXU/DUE2hwXDTvM/mlFmSPAi28eW4I+97A8ACrU7wuctLDzgt7O5b8WahHo1h4cmtpr/VbS5slN7dXEeIWuCFZkhkAG4qGwRyBgc5zjgtWZXv7gWgLQS7ZMsMHJ4C/nXoLjVLfTItM+1NJBDHLFbLL84j3hehPYbFwO3PrXI6lYTafq1tK8hKS5YzlQfm74B4XrWE3GSubw56atJ3IdEsIkkdb1/KYYYnyjtX6titnUDb6WIrq21BLy3kPlTW4Y8E5IK9OahiEuoOyaE04unbYzuPMacAclQeFUevvWlb+Cr9HgGpXKxXEzY/1YYhQOuK5+SUloP6wluym2gPc2JuY5YLGV3CiGW6OZF9Sc/hSyWHh+CFFnS7tLhQCXS4jlAPtzyK6F/DVlbkR3VzPcxxruCmNdue3NSWOh6I9t5stnEjuflEmMY9eKfJbqZvFJnANdxWl/M0NyjWspyzxpyp6E4PTPtVyytNM1C9+a/SDjaHACktjhsV02o+HLB7m2S0SNlkyJBGVzH7jIrn9S8K6jpscl7EkLx7sqH5OwHvnv607M1WIi9NiM29+s1tBLcCGzkZh59uSPMx0yOxNSWzrptpd39qEWIN5Kgjkgf1JqibqzvbGSO2sRDqMjgRpDIQpI5JIzgYGTWXHq0yWSQIUkj35VT6jvUqLLVRW8y3qqXhkhDJHJcXOZPL8kbh7ZrJu7K9i2sYsZBIEZ3Y+uKuz60bqF1n3RSsMF41BZh6Z7Vc0vWRbWCLNbSu+NimMYB9Mn8afK2Yym+g3TLWO6CtMjbYIfMcM5yXPAzn064rRmeOABYwDIFALf1+tWmtoItQcWqu0ssayvJMMZYINw44Chshe561maxbTXWi3l5FD5cdi0Ty5IXbvbaOCcsSew7AmkyYy6s9O/ZZuDP8Wb3cACuizjjp/r7evrOvkX9kwP/wALQumYja2izkADp+/t6+uq2Wx42Od68vl+SOB+Pf8AyRzxb/14t/MVha5pum+E/iL4ei8FW1rptxdQXbalZWKiOI26QlkleJflBEoQB8ZO4jJr0Dxbe6bbafb22tWYvbPUbqKwMDxLIjNI2BvVuCuevX6GpdG8NaFokc0ei6LpmnRzcSraWscIk/3goGfxpnIeceDta8R+JpfDiza/dWyS+GbXVLkWttb77id2YNy8ZCg45AA9sVjaH448aro1p4iura8uLe7028vXtbr7CluGSFpY0thFIbhsFQjBwTgkkKRivarLStPsWiNlYWlsYoFtozDCqbIl5WMYHCjsvQVVs/DOg2WrS6rZ6JplvqcpYyXkVpGkzlvvEuBuOe/NAHkniqPUr3wh4aurzxzPdteahpF2VjgtE8rfdRjzI8R/6sFgRvDcouWI3KfarCCS2s4YZrqa8kRdrTzhA8h9WCKq5+igVg6V4X8PfY9QhXwlp2nw3btHcwPZ24F0qtwzBMhlP3hu555APFb1hZ2un2cNpYW0NraQrsjhgjCIi+iqOAPpQBPXwB+1H/yXbxN/26/+ksVff9fAH7Uf/JdvE3/br/6SxUAeVUUUUAFFFFABXoHwU/5Gq6/68n/9Djrz+vQPgp/yNV1/15P/AOhx0AcVq3/IVvf+uz/+hGqlW9W/5Ct7/wBdn/8AQjVSgAooooAKKKKACvtX9in/AJJZqv8A2Gpf/REFfFVfQv7PXxr8OfDjwXe6Rrllq89zNqD3atZxRsgRo41AJaRTnKHt6UAfZ9cfqmgTXnxDj1SSyimsk0Wa0Er7TiV5FO0A88qG5xjHFeYf8NV+B/8AoFeJP/AeD/49XUt8a9OVbZj4Y8SbbhBJCR9jIdSMgj/SOmKCowlP4Vc5m28A+I7TSbNLy21uc3Phyz0m4t9Nl05jE0aOJIpGuQ2EJYEGInnOQcKa7jQvC17ZHxez2W172yt7a1keVHeTZaCMqWGOjjGSAD1xWZJ8bNOjTc/hfxKozjlbTr/4EVE/xz0lJFR/DXiUO3QbbTJ/8mKC/YVf5X9xX1rwPrDeG7C007TI0lTwVf6RKkckaD7VIkGyM8gHLLId33QckkZ5r+K9D8dapC+lNaXz6fDJYNZpavYi32x+U0hmaQmbzA6vjy9o4HJq7N8edGhjMkvhvxMqcc+Xa9zgf8t6Rfj3opBI8N+JiB1Pl2v/AMfpXQewq/yv7j2CivDL39pfwpZSKl1oniaNmGQPItzn8pqgH7UXg0nA0fxL/wCA8H/x6i6J9lPazPnrw5qkMFnZAOf+PaNJEI5PyjkV11n4h8LIxn1u81Yxw27b7K0RUaWU8Lhyeg65rx+zuGhiQHhlUD6YqS5klcq0h3GQbhz/ADrJaO6PouaLppdbGzDfXswkVGGJP3gWQ5bH19feodWWWGJPkVI9ucoTknvuzVjS7G6iOjqLmxuf7TT5EhbzXtRv2/vlUbl7tgZOK6DxBp9jYw2cEF9p+r/bGmh3Wt2WeNo32l3j2jardVBOcVprJamaxCdkjhtJtTe3JiMvlr97pnP0Fblppc6T/wCjuzLE2MMDw2PSs6y83RNUSdoWwCQFcYyOh5rpPEivNp8d3p1yPKA5jDYJ+nqaw2ZtSfJuWdI1W6sZZHneE2/R2Vh8p91rdj123jGPNWSNzwByK4PRtL1CVgi2cc7v+8ZJQcqv9M13+nWttBE1rPHH5jjcpPDDHbHpUSinqa83OV5NVvXsplslgijZSBLIdoA7k45xWJHp11o93Baajayxec2czBgzMRkHBHGR29K2NTt9sc+xo5Y1Qgxkdj0P1Bql4n1U3ktpeHzluX8trgzXDXJaRUwXJblc8YHQVtSkopq4+TkaaRsl43MaR7flbI44BArnfE2r+RZS29ozKWwrSoT8o78juelUodRMlw0BkEScMzhuW9gO1aGh+H7vxJ4wtNE0zypHuAZDbSSbFXapbDHucA8U+W45VUottmDYi31K9uEgt57XTVj3lWk810RQOA2B1bPGAOa2LfSJIpBbyDzGukL2mB8zNxlSemRWq2i3eh+Ib6z1LTJdOuiqFreQZymSMqRwykjqOKNS3z2wjttzyo2+GID7rDvnt0NXeUXYygl0dzidUgSKdViicSbSWQ/eUg8g+mKk0e8e312O6WFLkgsFR1JBzkdPbP51o+Jb+3VJWi3SyzQqXYn5txOCXb26YqLwtBz5kvygAsWIxt9OaErsbknKzPoD4J3Ed547i/siOK1g/sqQ3JaIHznEo255DEqT1PpgV55rFxM+o6pcgOZjezCYyqFcuHwSQOACQTgdKb4fkhsru0nRy80QYrLHKUZ0YYMZKn7vX3NZ1+pj84ouwMS5C8KATk4FVUldF0qXJWlUT3RY8OXGn2vi3TJJ5Qym+leaJ7dmjUSQ4Ryc4Pzk4AHbJrf8Dw3E/hbTNM1GGd4ntbqWBncNGzrPhyFHQ84JOfauLsbWO9sNZuS0ZggFujEvhyXZlUovU98ntXQWt5vuNCuDeC0lsbR7ElYiI0iBJU8fxMSc+9OMvcsxTppyvFmlGmzKu6OqHCg9dp4/Sue8WaYl9pxhRgFR1YynJCgH5jgc9K6qxsri+0+OSxt7AzWkby3KCQi5aIEfOVbqvPGKyJZIoWF0GzGw3BVOcn0/GuezjuTJpppFDwVqFrY2VxKsoWVhuJU4JA6A+3tTta8TrpsypJJvubnJBVecen0rlLrSxaau8qyyRpMfNiUHhQeo/Cp7/Rpb0w3STZ8ro5GSQe1ZttuzZwNWlqS3njGZwgSOQ7WGVVcbqz9S8T+eoRo5kUDBGf5elR6jYPDE3lhlc5AJPI/wrKtZkjnEWpRmSEAqwjO1iSDg/njNVGCNIq5o2eoS2Vw8tvIuxiHBYnIz2zWxNrtzcWrqLsuNpYxNIQMjsDXHTwbraMoST0bPQVCGlMeGz6AiuhWQOPMdPpOn/wBoXMcc2bO/k8x5bkuNixYx09STisK70xrC4ntyS8lvy6k43j1WrOnTSyTtEkTSB4whBGS3PArp9T0OfUbSGdBbwX0KALGp5KjOQx7tV2U9UZ35Hqzm9GurUmVWjijMoKiIrkkdsMehrd0m9LIk906xC3uIlt4XjDea+cknsFQDPuTWRDpgu3isCkkcquSsw6BercVe1OwaSzgMEm6CyUvEhAycsCcnqxNRJOOjLilLU6Lzo2ZXWbzPNc+Y69ehrF1po9Wch5El2RhRxwoUY49/enWsalJoo1eAP8zg9cexouFht2ZU8oBSV3ADAB5xjuaxUNRtq56X+zDEkPxSnWL7v9i3GP8Av/bV9V18b/A3xZoXhPx82oa1ePBaPpc9sHjt5J/nMsDAYjVjyEY5xjivoBfjd4BfG3WLpsnAxpV5yfT/AFVbLY8rFRcqraX9WNP4q6R/bmk6NZPZy3lu2sWjXEaKx/dCT5i2OigdTXneueFr+1fUrCw00W3hW28R+ebI6VLd2zQNYxkEW0TI0sXnlsqmQG5IIU100nx/+GcUjJJ4kZHU4ZW0+6BB9CPKpv8Aw0H8MP8AoZv/ACQuv/jdM5TF8OeD47298LWup6dNqGixT6lJ5VzpMtpbwqwiKIIJGcpHndtVz+AwKW48GJbHVdWstBePWIfFlo1pPHbN5iWolt1Yx8cRbDIGx8pAOenGz/w0H8MP+hm/8kLr/wCN0f8ADQfww/6Gb/yQuv8A43QBy13YXkcE1hqXhO2u7O513Wbj7ZqOgTan5Aa4zHshjwwEgORJuVcL1PFeo/CWG+t/hv4eg1WO5ivIrVY5EuUZZFwSACG5HAHWuX/4aD+GH/Qzf+SF1/8AG6P+Gg/hh/0M3/khdf8AxugD1WvgD9qP/ku3ib/t1/8ASWKvqr/hoP4Yf9DN/wCSF1/8br5A+PfiHS/FXxY13WdBuvtem3PkeVN5bR7tsEaN8rAEfMpHI7UAef0UUUAFFFFABXoHwU/5Gq6/68n/APQ468/r0D4Kf8jVdf8AXk//AKHHQBxWrf8AIVvf+uz/APoRqpVvVv8AkK3v/XZ//QjVSgAooooAKKKKACiiigAr2z9n/wAYaOuqjRPGr3E0Etu1npkhZQlqZM78k85PAU84JI78eJ0tBUJOLuj7X8UWekWVobbTdDvYTAy2/wBqu5Axl4DbtpOc543celcY0KxjBidVYkrlslSTyRWF8LviS3iO1t9E1mdIdZhg+zwXLf8AL7GOiOT/AB8Dn+LHr16uWdfNWIB2kzhiFI2g8Upant4aalC6dzLvVItoYpMMglXacYyd2cmqd5biOCV1IAyckVelmea4jjeN36qZMbfoPyqvMJZ7HbJGUdieRyTjrWUjq1PPfFGlG+tiV4ljyyj1NcnptukiEMMv7jpXqslnM7b1XO75Tjk1w+vaXJp179riAMTMN47KT/SpjKzJcVzXMu9svLRXUKFJ546VXhiLYxknPCgdq3LaIvJlgqqccHkUj26rexsdscRPzsRgAVra5qopG94QXSoNLvdPGhPqWvXUoaxvLW5eG4tmCZ2gAfMowTxz+mKJ1hdV8SWV9LZWlpPb2qWxFqmz7Q6ggyv6uc8n2rsPAuoQeGfDsniGz/svUtZluZLO1gJK3dm2xlEuc8x7CSflPOOeuPNL+zk0+7kR8xzQngj5s+hznvVaqFzCEIOo2lt+Z0OsxrqFjc2vytdxfOq9SR161m+B7ZJJpGKEzx85Y8L9Pf3rQtp0WztrzYN7KVdlx1965+PXBpusTzWqB45OqNwDUVd0zSSitWeiXAFgrTRyy/aZ2VUQPzIwP8hWimlmadbq6VjOBwB91B3ql4dtpJ5DfXLJJdvGAoUcRLjlV/qa6i2R7rUtN04F0bUrmO03RjcY1c/MwHsMnmuWU3sb05KK5n0LOjeGv7YsLy9hSPybJd08jOBkgZ2gdScVQutAtbiAEwoVbnzANpxXpc3iWLwFpg8I+HbOaaSwUo97fqAMsd2dq4Mhw3XgcdTXHpfIYgblskhi2RgEn2HQe1TWtTsk9SKNadZuTVo9DxvxvoRskW5gYK6v85VSCMdDxUWjaqW0WCzvrqZLRLr7YiI+Mzkbd+R827HHWut8Yuj6Vd+Uw2rHsZm6Z9q8z8NfZY/EllBrGpjTNI8wyvei2afGFOMIOSScD0Gcmt6UnJamNecabuz0XXZL/VLqzmOtXss8SiK3+1uZiqk8AseSpz0Ncddaxqtqs3n2nluXkCTL8qOyHkj1/Cum1a6tILZ7mxa4ls0mDRzXCiN3jDcMRngmuV1iyvtStNR1qOBf7KSaOAs7AFHkzt2KeSOOSBW8VdmE52jpojk1na4d/NMh8zkKv8RJ6fnXUaTb6nZaVe/arC4cuFMGZFCIQfmLqeW44AGMGqWhRRtf27sD58MXzBhgb9xwPyrt9OjiT7bqmriK8srEpusWmMRvnY4WFCAScfebHYY4zRe2hnTjK3O2Zngk6g9xJFDaCY3uLOFdm/ypJD8pXnCscEAn3q/eXBlXy+UJLx4Iwdw4I59K07XWLaXOv6vrz6HrUbBNN03RNMSSKG2G5SQvAVvnfaWbcOvORjm31Fxpz6RpjzS2L3f2q3SWICXOCgBIzyV5IzjNaSS5TrpVpSdmjX8IRec0lyyjzI22RsO21s9frzWvcWVxqWqXUUccshvd3lmHLNJIAWbcO/c1W8P6T/Z+j3Fwbm1H2Z0+0wtIfOZ5OMoMYKjoeeMVZtNVkg1uMaVJIksMnnb4WwYnKlchux2k8Vg20bqd27HYWcGh+ItNtdY8Ta1dXE9zGLie4ktVS2kmRSgtIwAGLBQD8uQNpJ5IrhLDDRxtsGWJYhRgL7CrGp2N7daE4N4sVnpVu7IWlwUR5AWUE9WYnOBSRfLLHEjny1CxR7mHAAwBROd0RThy3u7+XYyfEEM08DCGIefG2Y9vJA74HeneHb3ZCqsj4G7aCMEqO596vXsRRIZSTt3OgkA4VxyVJ9cdqx3uUgcHKvEw3quBj3ArCSOatBbo09dvLSRnFnGGLc7ZDkrkcZx1NcbKymbF1Gm1if3if4Gukg1KOC4jvdJcRTx52sVDBWxgnByKxbrTWmEjSSKzM2eOfm61VP3Tmu0UzYrJGTZTBx3UDn6VlsnzpGdqFss2eiD3NdDpkdnpcMjXV0FlYFmdVzzjhFHck96zJ08+KNI7fbL3fOBnsM+1bpt7GsZaXZVguJ7OR3guPL565xkduK6jTUv721guIme2SM7vNK/NL9B6e5qnosGl2VqtxqcaXN1FIckn5UAHChf4ue5rXbXXv4ZFSGVAw2FcjG09SD69qv3ktCZWk7sqXJNnDK5SRTMBFLcMcn5uoHp6Vk3d2sNjiM74RgSFshk54A9a1NTukOnXtskZ3MgK855DDAH0Hes3Sbe8j1SBrDf9utpBdQMiBwjJ8+8huCBjPPFFr6spSaTsWmvHtLmS2vobm0ubdgkkMsRRkJwQCDyDzmpL5JbhBv8ALQKCUAXl8nuTWXqE9xca6dUvrmW6nvJPOuJJuskhGScDjHsOBWnZTRiKS5mBl80kRs5PyY7iqslqReXKmzPu7b7KVnjLqqjlAPzP51U1TXG0mwW3gIa+kG5ZAf8AVq3f/exW54j1uDStO3thryZf3MOMjH99vb2715bNI80rySsWdjlie5qb8xz16/IuWO4w8nJpKKKDzgooooAKKKKACiiigAooooAKKKKACvQPgp/yNV1/15P/AOhx15/XoHwU/wCRquv+vJ//AEOOgDitW/5Ct7/12f8A9CNVKt6t/wAhW9/67P8A+hGqlABRRRQAUUUUAFFFFABRRRQA+N2R1dGKupyGBwQfWvob4XfEaPxNbR6Jr06w62MLBctgLeY4Cse0mO/8X16/O1OUlSCpII5BHak0a0qsqUro+rdcmjsJ1eVWQvujCqvXA5/GqjMHUFctGw3biMD61wXgD4kw6gltpHjKVA0eBb6jIM/RZT6f7f5+teoXts8UZWTGW4UqQQVPOR6g+tYTTW571CtCrG8dzn54yHdScOfn3KcVieJLe3mtGjUyEuhD7j1PbFdVdooUZwCFGCTzXNaqjSxsysCY+cge9ZLc1aPO9LuWCBHZsjjpmr0e5psnqvI3DNZ11GY766ROhckAdgeRVuwvN7hZFI4wT610RehaR03hkmyvIriOOHzYyWDhOQCOh9vaqN3b2fkyFbQICxIYZz17+lTadcpuVWJAJwSo6j61e1D7P9nc7jsXDAZ4/wDr1alYb3uzm7WdINGu1mUNCkmQR6nsK5qHTbq9zPCExngFsE/SuhnicEMqK0czfdYblz24oj024YfvWCRD+BMgfkKlyUrLoZVIc78i1ouuaobiGwLx20n3TK33jXounTSWV5Z3ktzLI1mxlUCUxbm2kDDJ8y8n6Hoa8wvJY7W3k2YWXIwzDLjJ61s6jrEEti8N1cpNkDa0YwZBj0B4rCUEnoaxbtY6j+3Zrnzr+a4e6uJGLzTzS7tx+p7ADH4Vg3HjO9vBKumaaZVzt8xn4/z+NYMVvealHHFKDBAzBAuCEiX++V6t9K1XmttOgMdvuMEKhVLgZc9yRUqmm7sU5cq5YmRq+q6jqsz2d6scCqgyqnhfViaz7/7JeT29hE42PKieYDlYgSBnNbMdlHq8bvuge5lGXLHhFxwParuheGLRABczpL5Yw4UYBz2Ht712UKDlscFSak7M5oaTcm21NJbya4S0YLawxsZI58PgnI4AABNXbu5n1fw6LyeT/jyuokaItuKDGAR3xgYr0azGi2OgmdtQtbaZgyx2AieWYsH2/vCBtjBHILHkV5HD5uoahe2kMnk201yC6RLuL4bhVx17nrit5xUNjmvuhdPl843cg+QuSwfufQCug8T+JYtW0vRdM03SLTS7PTYvnZJDJPPKww7u/H3j0GMj1xxUGs6O5ibVNItr2Pw9Ne/YLE3RQSyEDOMKcHnPIyPemS2MtpLeeHr22lguIZPNXcgBDBejdyME45xUqF9Tpi00vILK2lneWK33m4aEyDysMwA9ckU7QJZ5bg5kG8DDMRyfoR/DTptP8y0t3MEUYMe7cWBLGl+yXVjNbygbmCj92D/B6D+lKUdATk5bnZ2qKtvIGs4pVkXZIij5iMgkjPfj8elbPi54NU8Yazrek20dnaXkccccBRRkKgBdgvCtnsM9KwraVZoY7iHOdwDLu2sPb2rfsLcXUf2e2kRrhkaQwySCNSEGTh24PHOOK5dfhNW9VJ7o5xbg2loY7kfaYiu2Qnj9PTNXtWFrZ3MVw8g1DS7pFbJTy3hkP3l46qDyDVCe7t7iZkQhhjcAw5x79qybq8ZLZ7SAKSm1489SB1T6ULazNFVUtDWutUmt/Bt34ZSzidpdUGpW9+0x/dYUDYqY5JAIznGGPGa5m8lgvbSMLF8ynJ2sDsYdQa3LbxLqdpoN/p2n3q/YL1DvhlhVxCxxl0Y8o+ARn3/GuEgSayupZQkggySyk7iVz1Hr9ae6JatfTc6PSYdKmYPPLfwqXIljgUGTAHUBjgZOKLaDTnhjNy+oRXQLs6iVShTPy9O/aqdreP5kj2xaSPA2uOcH6VZeRnIkWIKV+RyecL61pG3UwcVct2Oj/aMSQgRLhuSASo7cnqT7VuT6f4am+Gsdo5ew8cadecNGrzNqEbkZJOAqrtJ4z8pT/a5zbWSXKKW8wdiwxgY9KlWPybVm+VgZPlC8bR7nuaJVeXYmVC+7C50azeNorUzJbqxJDKPMk9Cx7fQVDqapDZ2kMUKIqwmJ2jzukYnO5j2OMAAVeindI1l5Rn/hPNVNcvIY9PLLmN88IBksalYiWxpGkrlGC0tIPnEokIIRucn6cda1EiSOeOYQo+w5ZHB2yYP3GxyQcciud8NxtcX22b5YxtbgfjXUSgxqFfIOcKQPve/1p3kayhGOhz3iKBry2V45FikjYsQq4UZJO0D0Gaz9X1SDR7K0Vts1wsZ8qE9j/eb0Ht3p/irX4NMV7aDbLqJPzjqkfpn1b2/OvOp5pJ5nlmcvI5yzHqTV810ediK6h7sB13czXdw89w5eVzlmNQUUUHmt3CiiigAooooAKKKKACiiigAooooAKKKKACvQPgp/yNV1/wBeT/8Aocdef16B8FP+Rquv+vJ//Q46AOK1b/kK3v8A12f/ANCNVKt6t/yFb3/rs/8A6EaqUAFFFFABRRRQAUUUUAFFFFABRRRQAV6B4C+I954fjTT9TV77Ru0ZP7yD3jJ7f7J4+lef0Umk9y6dSVN80WfUMd5aazpovtIuYru3fjenBT/ZZeqn2Nc/qG2LzI04PQ59a8Q0LWr/AEO9F1ply8MnRgOVcejDoR9a9O8N+NdI1i7CaxGLKZ0KnDkRlv7yk9D7Hj3rD2Nnc9zDY+FT3amjMe+jC3sbN/ECje5zUZhCMxRsDGeKv61bkZI3fMc8jGfQ1kpM6Y8w+gOTRtodr01RsWzNGgAx93cfpVPVL8StHaqV2sfmb2rOvtXdSyRLsfBXf3xWdp0c93qMMcHzSFuD6U+axk6lmdNBcxiWCSUgRqMKuOSPWt1dXtUcJGyMB98gEj9KfpmiR2wYkl5WA3E8ge1T3dnb29vKWRVO3qe9Q2noacyZzOpMNS1JAkYaPaQ6s3lhgOmD7VpaYixwQ21taDzSR5jj5gPXJqNNPEsWWfaT0KjkCrdnY3dqpWK4DxtyPMXkfiKG0h2S2NJ0UAqx2qcE4747fSuX121a8u8WsoDKuGHGB/ia3W0wvlpZ2kZh61Tltf7KuLS+W3glNrIsrQuTtmAP3Gxzz60Rcb3bM6lraGHqH9oQCG1tAERxnzSdufqKoxX1zZYbzA2zOXQng+4PFd9rGs6F4i02P7LpraXqCFmeBbjeqkngDcAcdK5ZYRIgtSAochXYjhQTjLe3vXWqkujPNcWtTMa4v78SmW6m2zLtx5h2uv8AdwO1WdJsvLZILy/j0/T4XLNLEhLktgkf3mA2gYrS0vQyL14YjHM6E8hsIQOrA8cVr6xBZHSLaCVc3Mkp/dqPupjgg55z9KU5Nlcqepytw1zqkdvAslxNY2u5IBMd3lgnJwOw7496vRabHsKmUxvJjcXJBPsTnpWpGLYSrHCrLsA+YDsagubyRpnsbYmWdjt3nkKK0guVFJNuyLejpFcoq43Rr8p3YwMdxVq7jQTxyOQEThR0LVW8nds+1lrh44wm77pAHQcVTImW8RInnVJMkbzux7DPSo5rs6FE2IY3l82a3Ked/d6gmltte02OaSz16GZIpI2jxHII9spwFckg/KOScc1iTS3MM5QHdngsvykfWq090PORrg7oieSwyKp0lJ3Zm5rYn1q3uby5a5h1V7ophEnAwjqowMDA4xXNm9vLeZJblN21sb8c4rqryZIIVeCSLZ/zxU461TvYvtluYtyx5Hf/AD1qJRsgUbakwciJGTa8E3zHJ+Xaev0NVbrTTDFLErDyCd8cqHO3PVT6iq+mzS6UDbXS+ZbtyvGR71NcNJOWFlKTbDBaIrjafasGmmbxehRsy2nahHbunloy5JY8Me+PStkuP4FIwc5x6/0pZ4rXVEhBcfaYvuE8E+ufWobiVre62XB3RsuVJHBp6GUo2d0Rqfss4cuzQEjPOdhPYe1bEdyWjwgAAP8AEetZLId2YAhLqA6ycjb6Cq13e3dq7q8IlhIIEi8censaOVMd7nT22pbI8ylCzfKO9BjjlV2fHznt1bHauHjuorqRUcTRxKcjYc5PYVYuvFMdlcqBGWSMcIDgk+/pVQglqRUkoq7Z2UEsccTSSBLeGIZZ2IUADuTXE+KfGrTlrbR2ZU6NckYY/wC76D36/Sub17XrzWpy1wwSEHKQx8Iv+J9zWRVtXPMq4py0iOJJOSck02iimcgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFegfBT/karr/AK8n/wDQ468/r0D4Kf8AI1XX/Xk//ocdAHFat/yFb3/rs/8A6EaqVb1b/kK3v/XZ/wD0I1UoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKANvSfEV3YqkMuLq0XpDLzt/3T1FaN3q2mzRpJA88cnUxumcfiOtcnRUuCZ008XVpqyehrzXlvJube2fTbWx4b1jTNPWSS4kmErjbhU4ArkKKXIivrtS99D0y28Z6bbwiNJp9qk4DITmqz+MLGa5UyvL5YOeY+przyijkRf9oVfI9Sh8Y6KOZJJhn0hqU+M9FdZF+03CKv3R5BO/8c8V5RRUujBj/tGt5Hrv/CbaCuGS4uQwHTyetZWt+LdKu7CSKB5g7D/nnivN6KXsIieYVXvY6aLXLe3uYLmADz4XDqZIg6kj1ByD9DWhb+LW+2GUXUtnC+0TQWu6NZgGDEHHTJ9OB2FcTRWtjN4yb6I7zxH4utdS1K6k0wSabp85yLUO0xXjvIwBbJ+lLp/i7ToFY3FtK0+Nolj7j3Dc5rgqKYfXJ2toegXXjDTvLK2sNwCRyXwOfwo0LxNpdvIJb+WdpM8kR5rz+im3fcccbUirKx6ldeM9CMheETsW4+aPAA/OiTxjohYOjzhsAY8r+VeW0VKVg+u1D0YeJ9HeYu804Dfe/dHn0702/wDEmiTqux5hj+HyuP5153RVubYvrc/I6u51fTzch7d5FTGCNnT6Vbh8SWMUu4mR8LhSFxz75riaKTdyvr1TyO7k8T6dcWzJOJA3QFUqjFr9vAA0M0u4HkMmQwrkqKlxTD67U8j0GTX9BeeGdWmV4x08s4J9aut4s0CdDHdec8fQHyufrXmNFTyIHjqr7Haza3pMdyDDLcSQ56MuCtO1DxHp5twlo0pDH50ZP5e9cRRTUEtSXjKjNObVpfJMNqohjyTuH3z9TWaTzmkoqjnlOU3eTCiiigkKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr0D4Kf8jVdf9eT/wDocdef16B8FP8Akarr/ryf/wBDjoA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28197=[""].join("\n");
var outline_f27_34_28197=null;
var title_f27_34_28198="Prevention of prosthetic joint infections";
var content_f27_34_28198=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of prosthetic joint infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28198/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28198/contributors\">",
"     Elie Berbari, MD, FIDSA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28198/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28198/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28198/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28198/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28198/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/34/28198/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periprosthetic joint infection occurs in 1 to 2 percent of joint replacement surgeries and is one of the leading causes of arthroplasty failure. Treatment of these infections requires multiple surgical interventions and prolonged antibiotic therapy, and is associated with a failure rate in upwards of 10 to 20 percent of cases. Given the difficulty in treating prosthetic joint infections (PJIs), prevention of infection is clearly desirable.",
"   </p>",
"   <p>",
"    The issues relating to the prevention of PJIs will be reviewed here. The clinical manifestations, diagnosis, and treatment of these infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=see_link\">",
"     \"Clinical manifestations and diagnosis of prosthetic joint infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BEFORE AND AFTER JOINT REPLACEMENT SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion will emphasize general prevention measures before and during joint replacement surgery that are consistent with the guidelines from the National Surgical Infection Prevention Project (",
"    <a class=\"graphic graphic_table graphicRef61121 \" href=\"UTD.htm?23/28/24011\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], the guidelines from the Medical Letter (",
"    <a class=\"graphic graphic_table graphicRef87204 \" href=\"UTD.htm?25/4/25676\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/3\">",
"     3",
"    </a>",
"    ], and an Advisory Statement from the American Academy of Orthopaedic Surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/4\">",
"     4",
"    </a>",
"    ]. The recommendations discussed here are emphasized and tracked by the Surgical Care Improvement Project (SCIP), a national quality partnership of organizations interested in improving surgical care by significantly reducing surgical complications. A general discussion of preventing surgical site infection is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preoperative antimicrobial prophylaxis is standard for all patients undergoing joint replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Data supporting this recommendation come from trials that included patients undergoing joint replacement as well as other orthopedic procedures, such as surgical repair of hip and other closed fractures and internal fixation by nails, plates, screws, or wires [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for preoperative antimicrobial prophylaxis also comes from a later prospective observational study of 1922 patients who underwent elective total hip arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/8\">",
"     8",
"    </a>",
"    ]. Surgical site infection (SSI) (superficial and deep) occurred in 50 patients (2.6 percent). The major risk factor for infection was the administration of antimicrobial prophylaxis after incision (odds ratio 2.8), with a trend toward lower rates of SSI in the 1679 patients (87 percent) who were given antimicrobial therapy within 60 minutes prior to incision. A similar benefit of antimicrobial prophylaxis soon before incision has been noted in patients undergoing elective clean or clean-contaminated surgery (",
"    <a class=\"graphic graphic_table graphicRef79097 \" href=\"UTD.htm?22/46/23275\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon such observations, antimicrobial therapy should be given within 60 minutes of the first incision (usually at the induction of anesthesia). Standard practice in the setting of a proximal tourniquet has been to complete infusion of the antibiotic before inflation of the tourniquet, although data from a single-center randomized blinded controlled trial involving 908 patients suggest that administering prophylactic antibiotics just prior to tourniquet release is equally effective [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/10\">",
"     10",
"    </a>",
"    ]. These data also suggest that administering antibiotics after obtaining intraoperative cultures and immediately before tourniquet release may be reasonable for patients undergoing replacement arthroplasty in whom the risk of preexisting infection of the prosthesis is highly suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended regimen for patients with relatively normal renal function is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 g IV if less than 80 kg and 2 g IV if more than 80 kg) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    (1.5 g IV) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Timing of prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    because of its greater intrinsic activity against staphylococci, narrower side effect profile and antimicrobial spectrum, and much lower cost, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    has been recommended as an alternative choice [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with type I allergy to beta-lactams can receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . Vancomycin is administered at a dose of 1 g (10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    parenterally and repeated once postoperatively at 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Due to a prolonged infusion time, vancomycin should be initiated within two hours of the incision. Clindamycin is administered at a dose of 600 to 900 mg IV and repeated twice postoperatively at six hour intervals. Clindamycin provides less reliable coverage against coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus (MRSA).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is also commonly used in patients at high risk for MRSA or in institutions in which there is a \"high rate of MRSA infection\" even though current guidelines do not clearly define minimum criteria for \"high rates\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to the optimal duration of antimicrobial prophylaxis, a meta-analysis of patients undergoing hip fracture surgery concluded that one dose of an intravenous antibiotic seemed as effective as multiple doses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/5\">",
"     5",
"    </a>",
"    ]. However, we agree with a review from the National Surgical Infection Prevention Project that there is insufficient evidence to support single-dose regimens but that therapy beyond 24 hours after surgery is not likely to be beneficial, and continuing therapy until suction drains are removed is not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/2,12\">",
"     2,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the Medical Letter guidelines and the American Academy of Orthopaedic Surgeons Advisory Statement that repeat dosing is warranted when major blood loss occurs during the procedure or, in patients with normal renal function, the procedure lasts more than one to two times the half-life of the antibiotic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In such settings, we suggest administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 g IV if less than 80 kg and 2 g IV if more than 80 kg) at two to five hour intervals or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    (1.5 g IV) at three to four hour intervals. The duration of prophylaxis should not exceed 24 hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Repeat dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The National Surgical Infection Prevention Project guidelines also made the following recommendations (",
"    <a class=\"graphic graphic_table graphicRef61121 \" href=\"UTD.htm?23/28/24011\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients should be carefully screened for occult or minor infections prior to joint replacement. Postponing surgery should be considered if there is any active infection. Optimal control of hyperglycemia should be achieved prior to elective surgery in patients with diabetes mellitus. Preoperative urine cultures should be obtained if there are signs or symptoms or a recent history of a urinary tract infection.",
"     </li>",
"     <li>",
"      Immunosuppressive medications should be tapered to the lowest dose possible. It is uncertain whether",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      should be temporarily discontinued in patients with rheumatoid arthritis (RA) undergoing elective orthopaedic surgery. A systematic review found that continuing low doses of methotrexate seemed to be safe during the perioperative period in patients with RA in the absence of relevant comorbid conditions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      risk factors associated with infection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/13\">",
"       13",
"      </a>",
"      ]. When possible, the discontinuation of TNF-alpha blockers several weeks prior to elective orthopedic surgery is suggested [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Any evidence of a wound infection or wound skin necrosis that occurs in a patient who has undergone joint replacement should be promptly and aggressively treated with local wound measures and antibiotic therapy directed against the likely pathogens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other techniques to prevent infection include use of laminar flow in the operating room and body-exhaust surgical suits [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. It is not clear that any of these measures are essential. As an example, prospective and controlled studies demonstrated a decrease in rates of surgical site infections in total hip and knee prosthesis procedures when laminar airflow technology was used [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, the value and cost-effectiveness of laminar airflow is questionable when surgery occurs in modern facilities that have high rates of air exchange and when antimicrobial prophylaxis is given [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. In a case control study of 26,505 patients undergoing total hip or knee replacement, the infection rate was 1.8 percent and laminar flow ventilation was not a significant factor in reducing infections in a univariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of antibiotic-impregnated cement can reduce the rate of infection (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC PROPHYLAXIS PRIOR TO INVASIVE PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence to suggest that patients with prosthetic joints undergoing procedures should receive antibiotic prophylaxis in the absence of other indications, such as heart valve disease requiring endocarditis prophylaxis or a surgical procedure for which antibiotics are given to prevent a surgical site infection. Several organizations have issued guidelines to this effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dental procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral infections in patients with prosthetic joints should be promptly treated with agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (150 to 300 mg orally every six hours).",
"   </p>",
"   <p>",
"    Dental procedures are not associated with an increased risk of prosthetic joint infection (PJI) and use of antibiotic prophylaxis prior to dental procedures does not alter the risk of subsequent total hip or knee infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. There have been fewer than 25 reported cases of late-onset PJI after dental procedures, and the association between dental treatment and PJI in these cases is circumstantial, at best. In addition, there are no experimental observations suggesting a link between bacteremia induced from a dental source and PJI.",
"   </p>",
"   <p>",
"    In view of these observations, the American Academy of Oral Medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/23\">",
"     23",
"    </a>",
"    ], the American Dental Association in conjunction with the American Academy of Orthopedic Surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/24\">",
"     24",
"    </a>",
"    ], and the British Society for Antimicrobial Chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/25\">",
"     25",
"    </a>",
"    ] all advise against universal use of antimicrobial prophylaxis prior to dental procedures if the goal is solely to prevent the development of PJI.",
"   </p>",
"   <p>",
"    In 2003, the American Dental Association (ADA) and the American Academy of Orthopedic Surgeons (AAOS) issued a joint statement indicating that antibiotic prophylaxis for preventing infection of implanted hardware is not warranted for dental patients with pins, plates or screws, nor is it routinely indicated for most patients with total joint replacement undergoing routine dental procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2003 statement does state that antibiotic prophylaxis prior to dental procedures with increased risk for bacteremia (such as extractions, periodontal procedures, dental implants, and root canals, but not routine procedures) may be &ldquo;considered&rdquo; for individuals at potential increased risk of hematogenous joint infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/24,26-28\">",
"     24,26-28",
"    </a>",
"    ]. Such individuals include patients within two years of joint replacement surgery, patients with immunocompromising conditions (such as rheumatoid arthritis, systemic lupus erythematosus, drug or radiation induced immunosuppression), and patients with comorbidities (such as previous PJI, malnourishment, hemophilia, HIV infection, diabetes, or malignancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/20,24,29\">",
"     20,24,29",
"    </a>",
"    ]. In such cases the potential risk of antimicrobial therapy must be balanced against the small theoretical benefit.",
"   </p>",
"   <p>",
"    In 2009, the AAOS, independent of the ADA, released an online Information Statement in contradiction to the above guidelines issued in 2003; this statement advocates use of antibiotic prophylaxis for any patient with a prosthetic joint replacement undergoing any procedure that may cause bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/26\">",
"     26",
"    </a>",
"    ]. This statement was not published in a peer reviewed journal, and no new scientific data or new approach to the available data was cited to justify changing the 2003 guidelines previously developed jointly by the ADA and the AAOS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/30\">",
"     30",
"    </a>",
"    ]. There was no indication that the earlier recommendations resulted in any adverse events.",
"   </p>",
"   <p>",
"    In 2010, the American Academy of Oral Medicine (AAOM) issued a response to the 2009 AAOS statement indicating that the risk of adverse drug reactions or drug-resistant bacterial infections and the cost of antibiotic medications do not justify antibiotic prophylaxis for all patients with prosthetic joint replacement undergoing any procedure that may cause bacteremia. We are in agreement with the authors who conclude that the 2009 AAOS statement should not replace the 2003 joint consensus statement [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/31\">",
"     31",
"    </a>",
"    ]. A new joint consensus statement is anticipated in 2012.",
"   </p>",
"   <p>",
"    In 2011, administrative data for 1997 to 2006 from the Medicare Current Beneficiary Survey (MCBS) was reviewed in a case control study including cases with PJI and matched controls with total arthroplasty but no PJI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/32\">",
"     32",
"    </a>",
"    ]. There was no significant association between dental procedures and risk for PJIs, and the authors suggested that the 2009 AAOS statement should be reconsidered in light of these data.",
"   </p>",
"   <p>",
"    It is our practice to advise against the use of antimicrobial therapy for patients with prosthetic joints undergoing routine dental procedures, such as cleaning, scaling of teeth, or filling of a dental cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Urologic and gastrointestinal procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Urological Association and the American Academy of Orthopedics issued similar recommendations for patients with a prosthetic joint who undergo a urologic procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/33\">",
"     33",
"    </a>",
"    ]. Most such patients do not need antibiotic prophylaxis to prevent bacteremia and possible secondary seeding of the joint. However, the guidelines state that prophylaxis can be considered in some patients, especially those with immunosuppression undergoing a higher risk procedure for bacteremia, such as lithotripsy or surgery involving bowel segments.",
"   </p>",
"   <p>",
"    The American Society of Gastrointestinal Endoscopist (ASGE) issued guidelines against the use of antimicrobial prophylaxis prior to gastrointestinal endoscopies in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28198/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of prosthetic joint infection (PJI) is important due to the difficulty in treating PJIs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"       \"Treatment of prosthetic joint infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preoperative antimicrobial prophylaxis is standard for all patients undergoing joint replacement. The recommended regimen is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      (1 g if less than 80 kg and 2 g if more than 80 kg) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"       cefuroxime",
"      </a>",
"      (1.5 g) given intravenously at the induction of anesthesia and repeated for two doses postoperatively at two to five and three to four hour intervals, respectively. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Before and after joint replacement surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with type I allergy to beta-lactams can receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (1 g [10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      IV and repeated once postoperatively at 12 hours) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (600 to 900 mg IV and repeated twice postoperatively at six hour intervals). Vancomycin is also commonly used in patients at high risk for methicillin-resistant Staphylococcus aureus (MRSA) or in institutions in which there is a \"high rate of MRSA infection,\" even though current guidelines do not define minimum criteria for \"high rates.&rdquo; (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Before and after joint replacement surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest NOT administering antibiotic prophylaxis prior to dental procedures for immunocompetent patients with history of prosthetic joint implantation more than two years previously (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Dental procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence to suggest that patients with prosthetic joints undergoing procedures (eg, dental, urologic, gastrointestinal) should receive antibiotic prophylaxis to prevent a subsequent infection of the prosthesis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antibiotic prophylaxis prior to invasive procedures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/1\">",
"      Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/2\">",
"      Bratzler DW, Hunt DR. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis 2006; 43:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/3\">",
"      Antimicrobial prophylaxis for surgery. Treat Guidel Med Lett 2012; 10:73.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Orthopaedic Surgeons (AAOS). Advisory Statement. Recommendations for the use of intravenous antibiotic prophylaxis in primary total joint arthroplasty 2004 file://www.aaos.org/about/papers/advistmt/1027.asp (Accessed on January 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/5\">",
"      Southwell-Keely JP, Russo RR, March L, et al. Antibiotic prophylaxis in hip fracture surgery: a metaanalysis. Clin Orthop Relat Res 2004; :179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/6\">",
"      Boxma H, Broekhuizen T, Patka P, Oosting H. Randomised controlled trial of single-dose antibiotic prophylaxis in surgical treatment of closed fractures: the Dutch Trauma Trial. Lancet 1996; 347:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/7\">",
"      Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: Prophylaxis and treatment. Drugs 2006; 66:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/8\">",
"      van Kasteren ME, Manni&euml;n J, Ott A, et al. Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor. Clin Infect Dis 2007; 44:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/9\">",
"      Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992; 326:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/10\">",
"      Soriano A, Bori G, Garc&iacute;a-Ramiro S, et al. Timing of antibiotic prophylaxis for primary total knee arthroplasty performed during ischemia. Clin Infect Dis 2008; 46:1009.",
"     </a>",
"    </li>",
"    <li>",
"     The diagnosis of periprosthetic joint infections of the hip and knee. Guidelines and evidence report. Adopted by the American Academy of Orthopaedic Surgeons Board of Directors ",
"June 18, 2010",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/12\">",
"      Gillespie WJ. Prevention and management of infection after total joint replacement. Clin Infect Dis 1997; 25:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/13\">",
"      Pieringer H, Stuby U, Biesenbach G. Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment? Semin Arthritis Rheum 2007; 36:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/14\">",
"      Tobin EH. Prosthetic joint infections: controversies and clues. Lancet 1999; 353:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/15\">",
"      Lidwell OM, Lowbury EJ, Whyte W, et al. Effect of ultraclean air in operating rooms on deep sepsis in the joint after total hip or knee replacement: a randomised study. Br Med J (Clin Res Ed) 1982; 285:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/16\">",
"      Fitzgerald RH Jr. Total hip arthroplasty sepsis. Prevention and diagnosis. Orthop Clin North Am 1992; 23:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/17\">",
"      Marotte JH, Lord GA, Blanchard JP, et al. Infection rate in total hip arthroplasty as a function of air cleanliness and antibiotic prophylaxis. 10-year experience with 2,384 cementless Lord madreporic prostheses. J Arthroplasty 1987; 2:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/18\">",
"      Lidwell OM. Clean air at operation and subsequent sepsis in the joint. Clin Orthop Relat Res 1986; :91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/19\">",
"      Persson U, Montgomery F, Carlsson A, et al. How far does prophylaxis against infection in total joint replacement offset its cost? Br Med J (Clin Res Ed) 1988; 296:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/20\">",
"      Berbari EF, Hanssen AD, Duffy MC, et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998; 27:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/21\">",
"      Wahl MJ. Myths of dental-induced prosthetic joint infections. Clin Infect Dis 1995; 20:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/22\">",
"      Berbari EF, Osmon DR, Carr A, et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. Clin Infect Dis 2010; 50:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/23\">",
"      Eskinazi D, Rathbun W. Is systematic antimicrobial prophylaxis justified in dental patients with prosthetic joints? Oral Surg Oral Med Oral Pathol 1988; 66:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/24\">",
"      American Dental Association, American Academy of Orthopedic Surgeons. Antibiotic prophylaxis for dental patients with total joint replacements. J Am Dent Assoc 2003; 134:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/25\">",
"      Simmons NA, Ball AP, Cawson RA, et al. Case against antibiotic prophylaxis for dental treatment of patients with joint prostheses. Lancet 1992; 339:301.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Orthopedic Surgeons Information Statement: Antibiotic prophylaxis for bacteremia in patients with joint replacements. February 2009. file://www.aaos.org/about/papers/advistmt/1033.asp (Accessed on January 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/27\">",
"      Tong DC, Rothwell BR. Antibiotic prophylaxis in dentistry: a review and practice recommendations. J Am Dent Assoc 2000; 131:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/28\">",
"      Hanssen AD, Osmon DR, Nelson CL. Prevention of deep periprosthetic joint infection. Instr Course Lect 1997; 46:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/29\">",
"      Poss R, Thornhill TS, Ewald FC, et al. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res 1984; :117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/30\">",
"      Morris AM, Howie S. Recommendations for antibiotics in patients with joint prosthesis are irresponsible and indefensible. J Can Dent Assoc 2009; 75:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/31\">",
"      Little JW, Jacobson JJ, Lockhart PB, American Academy of Oral Medicine. The dental treatment of patients with joint replacements: a position paper from the American Academy of Oral Medicine. J Am Dent Assoc 2010; 141:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/32\">",
"      Skaar DD, O'Connor H, Hodges JS, Michalowicz BS. Dental procedures and subsequent prosthetic joint infections: findings from the Medicare Current Beneficiary Survey. J Am Dent Assoc 2011; 142:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/33\">",
"      American Urological Association, American Academy of Orthopaedic Surgeons. Antibiotic prophylaxis for urological patients with total joint replacements. J Urol 2003; 169:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28198/abstract/34\">",
"      ASGE STANDARDS OF PRACTICE COMMITTEE, Banerjee S, Shen B, et al. Antibiotic prophylaxis for GI endoscopy. Gastrointest Endosc 2008; 67:791.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7667 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28198=[""].join("\n");
var outline_f27_34_28198=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BEFORE AND AFTER JOINT REPLACEMENT SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIBIOTIC PROPHYLAXIS PRIOR TO INVASIVE PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dental procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Urologic and gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7667\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7667|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/28/24011\" title=\"table 1\">",
"      Prevent prosthetic jt infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/4/25676\" title=\"table 2\">",
"      Antimicrobial prophylaxis for orthopedic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/46/23275\" title=\"table 3\">",
"      Timing of surgical prophylaxis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=related_link\">",
"      Clinical manifestations and diagnosis of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_34_28199="Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy";
var content_f27_34_28199=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atrial fibrillation and other atrial tachyarrhythmias in hypertrophic cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28199/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28199/contributors\">",
"     Perry M Elliott, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28199/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28199/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28199/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28199/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28199/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28199/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/34/28199/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease most often (60 to 70 percent) caused by mutations in one of several sarcomere genes which encode components of the contractile apparatus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link\">",
"     \"Genetics of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCM is characterized by left ventricular hypertrophy of various morphologies, with a wide array clinical manifestations and hemodynamic abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef58156 \" href=\"UTD.htm?11/9/11411\">",
"     figure 1",
"    </a>",
"    )&nbsp;. Depending in part upon the site and extent of cardiac hypertrophy, HCM patients can develop one or more of the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LV outflow obstruction (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diastolic dysfunction",
"     </li>",
"     <li>",
"      Myocardial ischemia",
"     </li>",
"     <li>",
"      Mitral regurgitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These structural and functional abnormalities can produce a variety of symptoms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Presyncope or syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In broad terms, the symptoms related to HCM can be categorized as those related to heart failure (HF), chest pain, or arrhythmias. Patients with HCM are prone to both atrial and ventricular arrhythmias, the incidence of which increases with age (",
"    <a class=\"graphic graphic_figure graphicRef56594 \" href=\"UTD.htm?27/46/28397\">",
"     figure 2",
"    </a>",
"    ). Many of these arrhythmias are asymptomatic, but some can precipitate hemodynamic collapse and sudden cardiac death. Thus, the evaluation of arrhythmias and their clinical consequences is one of the primary aims of management in patients with HCM.",
"   </p>",
"   <p>",
"    The evaluation and management of atrial fibrillation and other supraventricular tachycardias in patients with HCM will be reviewed here. Other issues related to ventricular arrhythmias and sudden cardiac death, as well as other clinical manifestations, natural history, diagnosis and evaluation, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link\">",
"     \"Natural history of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ATRIAL FIBRILLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with HCM atrial fibrillation (AF) is a relatively common arrhythmia that has major adverse implications (",
"    <a class=\"graphic graphic_figure graphicRef56594 \" href=\"UTD.htm?27/46/28397\">",
"     figure 2",
"    </a>",
"    ). These patients often tolerate the rhythm particularly poorly; they are at markedly increased risk of stroke and drug therapy is difficult, and AF often signals a marked clinical deterioration.",
"   </p>",
"   <p>",
"    In a case-control study of 104 HCM patients diagnosed between 1960 and 1985, AF was present in approximately 5 percent of patients at the time of diagnosis of HCM and developed in an additional 10 percent during the five years following diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/1\">",
"     1",
"    </a>",
"    ]. In another series of 480 consecutive HCM patients followed for 9 years, AF occurred in 22 percent, for an incidence of approximately 2 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/2\">",
"     2",
"    </a>",
"    ]. In both of these series, AF was paroxysmal in approximately two-thirds of cases. The incidence of AF in these reports is four to six fold higher than that of the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors predispose to the development of SVTs, particularly AF, in patients with HCM. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe and diffuse hypertrophy",
"     </li>",
"     <li>",
"      Mitral regurgitation (MR)",
"     </li>",
"     <li>",
"      Atrial dilatation (eg, left atrial dimension &gt;40 mm)",
"     </li>",
"     <li>",
"      Restrictive left ventricular physiology",
"     </li>",
"     <li>",
"      Increasing age",
"     </li>",
"     <li>",
"      Heart failure (HF) symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these risk factors, the presence or severity of an outflow tract gradient does not appear to be associated with an increased incidence of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited data on atrial pathology in HCM, but some studies have shown extensive atrial fibrosis similar to that seen in patients with long-standing HF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/5\">",
"     5",
"    </a>",
"    ]. Myocyte disarray, present in the ventricular myocardium, has not been reported in the atria, and the expression of sarcomeric protein mutations in atrial tissue has not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted, AF is often poorly tolerated in HCM patients and may be associated with significant clinical deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AF and other atrial arrhythmias can be problematic in HCM patients for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid ventricular rates reduce diastolic filling time, further impairing LV filling, particularly in patients with diastolic dysfunction.",
"     </li>",
"     <li>",
"      Organized atrial contraction (ie, \"atrial kick\") may be an important contributor to left ventricular filling in patients with diastolic dysfunction, and such patients may be particularly vulnerable to the loss of atrial contraction with the development of atrial fibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the presence and degree of diastolic dysfunction have a significant impact on a patient's ability to tolerate atrial tachyarrhythmias. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of AF in patients with HCM can be divided into acute symptoms and long-term consequences.",
"   </p>",
"   <p>",
"    The acute symptoms associated with AF include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Palpitations",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Lightheadedness, presyncope or syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a series of 52 patients, the acute onset of AF was associated with worsening of symptoms in 89 percent of patients; almost all of whom returned to their usual symptom class with reversion to sinus rhythm or, to a lesser extent, with control of the ventricular rate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the long-term, both paroxysmal and chronic AF are associated with increased HF symptoms in patients with HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]. In addition, AF is associated with an increased incidence of stroke and HF-related death, but not SCD. The relationships between AF, stroke, and mortality are discussed in the following sections.",
"   </p>",
"   <p>",
"    The impact of AF in HCM on functional status was illustrated in a series of 480 patients, 22 percent of whom had paroxysmal or chronic AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/2\">",
"     2",
"    </a>",
"    ]. The development of AF was associated with an increased risk of severe functional limitation (odds ratio for NYHA class",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    2.8). The risk was greater in patients with outflow obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to functional deterioration, AF has been associated with an increase in mortality in adults with HCM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 202 adults with HCM, the 57 with AF had a significant increase in mortality at 15 years (24 versus 3 percent in patients without AF) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results were noted in the series of 480 adults mentioned above [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/2\">",
"       2",
"      </a>",
"      ]. At a mean follow-up of 9.1 years, intermittent or permanent AF increased the rate of HCM-related death (3 versus 1 percent per year in sinus rhythm, odds ratio 3.7), primarily due to HF, not SCD. The risk of death was associated with the presence of outflow obstruction and age of onset before age 50 and was similar in paroxysmal and chronic AF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although AF is not generally associated with an increased risk of SCD, there are case reports in which AF with a rapid ventricular response degenerates into ventricular tachycardia and ventricular fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/6,10,11\">",
"     6,10,11",
"    </a>",
"    ]. Thus, it is possible that the initial episode of AF with rapid AV conduction is fatal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;AF in HCM significantly increases the risk for stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. In the series of 480 patients cited above, stroke was markedly increased in the patients with AF compared to those in sinus rhythm (odds ratio 17.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for treatment of AF in patients with HCM were included in the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines on atrial fibrillation and the 2011",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the diagnosis and treatment of HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapeutic options for AF are similar to those for patients without HCM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Rhythm control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical or electrical cardioversion can restore sinus rhythm and antiarrhythmic drugs can be used to suppress recurrences of AF. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that the weight of evidence or opinion was in favor of the usefulness of antiarrhythmic drugs to prevent recurrent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the guidelines concluded that the available data were insufficient to recommend one antiarrhythmic drug over another,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"     disopyramide",
"    </a>",
"    (when combined with ventricular rate-controlling agents) are generally preferred [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, the incidence of side effects with long-term use of amiodarone may make it a difficult drug for younger patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In HCM patients with AF who fail antiarrhythmic drug therapy, pulmonary vein isolation with catheter-based radiofrequency ablation may be considered as it is in patients without HCM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, in HCM patients with AF who undergo cardiac surgery, a surgical maze procedure can be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;If maintenance of sinus rhythm is not possible or is not felt to be necessary, the ventricular rate can be controlled with pharmacologic or nonpharmacologic means. Beta blockers, nondihydropyridine calcium channel blockers or the two drugs in combination are usually adequate to control the ventricular rate.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    can increase inotropy, which could exacerbate HF symptoms in the majority of HCM patients who have preserved systolic function. As a result, digoxin is usually avoided in these patients. When the ventricular rate cannot be controlled with medications, AV nodal ablation with pacemaker implantation will provide definitive control of the ventricular rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since AF in patients with HCM carries a significant risk of thromboembolism, all such patients, even those with paroxysmal AF, should be treated with chronic oral anticoagulation, to a target INR of 2.0 to 3.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/2,13,14\">",
"     2,13,14",
"    </a>",
"    ]. This includes patients treated with rhythm control. In patients with a CHADS2 score of 2 or greater, high quality evidence supports this recommendation in patients with or without HCM. In patients with HCM with CHADS2 score of 1 or 0, moderate quality evidence supports this recommendation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ATRIAL FLUTTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of atrial flutter therapy are similar to those of AF. Some patients are amenable to radiofrequency ablation therapy, although this is often unsuccessful in patients with type II flutter, which is common in HCM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=see_link\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREEXCITATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCM in association with the preexcitation syndrome has been described in patients with mutations in the PRKAG2 or LAMP2 genes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The proteins encoded by these genes are involved in carbohydrate metabolism rather than sarcomere structure, and LAMP2 mutations are associated with glycogen storage disease IIb (Danon disease). Progressive conduction system disease requiring pacemaker implantation is common with PRKAG2 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/20\">",
"     20",
"    </a>",
"    ], while progression to end-stage HF in early adulthood is common with LAMP2 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristics of these disorders are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=see_link&amp;anchor=H17#H17\">",
"     \"Genetics of hypertrophic cardiomyopathy\", section on 'PRKAG2 and LAMP2 genes and WPW syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43315?source=see_link\">",
"     \"Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER SUPRAVENTRICULAR TACHYCARDIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsustained supraventricular tachycardias (SVTs) are commonly found during ambulatory electrocardiographic monitoring in patients with HCM. The majority of these events are asymptomatic and self-limited. Up to 25 percent of HCM patients will have such arrhythmias, but they rarely require therapy (",
"    <a class=\"graphic graphic_figure graphicRef56594 \" href=\"UTD.htm?27/46/28397\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"       \"Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to the evaluation and management of AF in patients with HCM.",
"   </p>",
"   <p>",
"    Patients with HCM are at an increased risk of developing AF and can be less tolerant of the arrhythmia than other patients. For this reason, we favor a more aggressive approach to the maintenance of sinus rhythm in HCM patients than in other settings. In addition, patients with HCM and AF are at an increased risk of thromboembolic events, including stroke and the threshold to introduce",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , anticoagulation or both should be low. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical significance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In HCM patients with paroxysmal or chronic AF with CHADS2 score of 2 or greater, we recommend chronic oral anticoagulation to a target INR of 2.0 to 3.0 for thromboembolic prophylaxis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In HCM patients with paroxysmal or chronic AF with CHADS2 score of 1 or 0, we recommend chronic oral anticoagulation to a target INR of 2.0 to 3.0 for thromboembolic prophylaxis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with paroxysmal or chronic AF, we suggest a rhythm control strategy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This can be accomplished with cardioversion for patients with persistent or chronic AF, and if necessary, an antiarrhythmic drug to maintain sinus rhythm. There are few data to support the selection of a particular antiarrhythmic agent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      is probably the most effective and is generally preferred, although the incidence of side effects with long-term use may make it a difficult drug for younger patients. As an alternative,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      may be used, although due to the possibility that disopyramide may accelerate AV conduction, it must be given in combination with an AV nodal blocking agent, such as a beta blocker or a nondihydropyridine calcium channel blocker [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28199/abstract/13,23\">",
"       13,23",
"      </a>",
"      ]. In selected cases, catheter based radiofrequency ablation or a surgical maze procedure may be appropriate. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the lack of controlled data demonstrating a benefit from maintaining sinus rhythm in HCM patients, and also because of the complications associated with antiarrhythmic drugs, some patients and physicians will select a rate control strategy, particularly in asymptomatic patients. This is a reasonable option in the majority of patients, although there is a small subset in whom restoration of atrial contribution to stroke volume may be important.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a rate control strategy is selected or if rhythm control is unsuccessful, we suggest the use of beta blockers, calcium channel blockers, or the two drugs in combination, rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Digoxin is a positive inotrope, and in HCM patients with preserved systolic function, it may exacerbate outflow obstruction. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=see_link&amp;anchor=H9#H9\">",
"       \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\", section on 'Mechanism of obstruction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If rate control is not achieved with medications, patients should undergo AV nodal ablation with placement of a permanent pacemaker for definitive rate control. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Treatment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/1\">",
"      Robinson K, Frenneaux MP, Stockins B, et al. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990; 15:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/2\">",
"      Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/3\">",
"      Tani T, Tanabe K, Ono M, et al. Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2004; 17:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/4\">",
"      Savage DD, Seides SF, Maron BJ, et al. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1979; 59:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/5\">",
"      Ohtani K, Yutani C, Nagata S, et al. High prevalence of atrial fibrosis in patients with dilated cardiomyopathy. J Am Coll Cardiol 1995; 25:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/6\">",
"      Stafford WJ, Trohman RG, Bilsker M, et al. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986; 7:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/7\">",
"      Bonow RO, Frederick TM, Bacharach SL, et al. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. Am J Cardiol 1983; 51:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/8\">",
"      Spirito P, Chiarella F, Carratino L, et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. N Engl J Med 1989; 320:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/9\">",
"      Cecchi F, Olivotto I, Montereggi A, et al. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995; 26:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/10\">",
"      Suzuki M, Hirayama T, Marumoto K, et al. Paroxysmal atrial fibrillation as a cause of potentially lethal ventricular arrhythmia with myocardial ischemia in hypertrophic cardiomyopathy--a case report. Angiology 1998; 49:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/11\">",
"      Boriani G, Rapezzi C, Biffi M, et al. Atrial fibrillation precipitating sustained ventricular tachycardia in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 2002; 13:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/12\">",
"      Higashikawa M, Nakamura Y, Yoshida M, Kinoshita M. Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation. Jpn Circ J 1997; 61:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/13\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/14\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/15\">",
"      Liu X, Ouyang F, Mavrakis H, et al. Complete pulmonary vein isolation guided by three-dimensional electroanatomical mapping for the treatment of paroxysmal atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Europace 2005; 7:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/16\">",
"      Kilicaslan F, Verma A, Saad E, et al. Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 2006; 3:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/17\">",
"      Gaita F, Di Donna P, Olivotto I, et al. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol 2007; 99:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/18\">",
"      Chen MS, McCarthy PM, Lever HM, et al. Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004; 93:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/19\">",
"      Matsui Y, Fukada Y, Imai T, et al. Combined cox maze procedure, septal myectomy, and mitral valve replacement for severe hypertrophic obstructive cardiomyopathy complicated by chronic atrial fibrillation. Ann Thorac Cardiovasc Surg 2003; 9:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/20\">",
"      Murphy RT, Mogensen J, McGarry K, et al. Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. J Am Coll Cardiol 2005; 45:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/21\">",
"      Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005; 352:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/22\">",
"      McKenna WJ, England D, Doi YL, et al. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J 1981; 46:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28199/abstract/23\">",
"      Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997; 336:775.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4926 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-59FAC149C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28199=[""].join("\n");
var outline_f27_34_28199=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ATRIAL FIBRILLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Rhythm control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Rate control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ATRIAL FLUTTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREEXCITATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER SUPRAVENTRICULAR TACHYCARDIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4926\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4926|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/9/11411\" title=\"figure 1\">",
"      Morphologic variants HCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/46/28397\" title=\"figure 2\">",
"      Relationship between age and arrhythmias in HCM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29386?source=related_link\">",
"      Genetics of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43315?source=related_link\">",
"      Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/19/24888?source=related_link\">",
"      Maintenance of sinus rhythm after cardioversion in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_34_28200="Initial treatment of the Raynaud phenomenon";
var content_f27_34_28200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Initial treatment of the Raynaud phenomenon",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28200/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28200/contributors\">",
"     Fredrick M Wigley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28200/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28200/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28200/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28200/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/34/28200/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Raynaud phenomenon (RP) is an exaggerated vascular response to cold temperature or to emotional stress, which is manifested clinically by sharply demarcated color changes of the skin of the digits. Treatment includes patient education and general measures taken by the patient to prevent and treat attacks and, in severe cases, may include pharmacologic interventions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical sympathetic blockade to prevent and treat digital ischemia.",
"   </p>",
"   <p>",
"    The initial treatment of the Raynaud phenomenon is reviewed here. The treatment of patients resistant to initial therapy, as well as the pathogenesis, clinical manifestations, and diagnosis of RP, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=see_link\">",
"     \"Pathogenesis of the Raynaud phenomenon\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1644434\">",
"    <span class=\"h1\">",
"     PRIMARY AND SECONDARY RP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Raynaud phenomenon (RP) is considered primary if the symptoms occur alone without any associated disorder; secondary RP refers to the presence of the disorder in association with a related illness, such as systemic lupus erythematosus or systemic sclerosis (scleroderma). Primary RP is sometimes also referred to as idiopathic RP or Raynaud disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with primary RP are generally not significantly disabled by the attacks, although the quality of life may be affected by the need for cold avoidance and by the lack of normal finger sensation. An initially conservative, nonpharmacologic approach is, therefore, most important for these patients, although pharmacologic therapy may ultimately be necessary. By comparison, patients with secondary RP are more likely to have severe attacks, and disease management is more likely to be based upon pharmacologic agents, while continuing nonpharmacologic measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1644624\">",
"    <span class=\"h1\">",
"     GOALS AND OVERVIEW OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of therapy are to improve quality of life and to prevent ischemic tissue injury. At least a moderate reduction in the intensity of attacks and the prevention of digital ulcers or tissue injury are achievable in most patients. However, abolishing cold sensitivity and eliminating all Raynaud events is not likely with available treatment options, particularly in patients with secondary RP, due to the complexity and sensitivity of the regulation of thermoregulatory vessels in the skin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=see_link\">",
"     \"Pathogenesis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of the treatment depends upon the severity of disease and upon the presence or absence of an underlying disorder; this is particularly important in patients with an underlying systemic rheumatic disease related to systemic sclerosis, as such patients can have a structural component to their vascular disease in addition to the vasospastic component seen in all patients with RP. The symptoms of RP can be highly variable; emotional stress and ambient temperature may also influence symptoms, in addition to the specific medical therapy. The initial treatment of patients with the Raynaud phenomenon includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient education (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient education'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      General measures to maintain body warmth and to avoid other triggers of RP (see",
"      <a class=\"local\" href=\"#H3\">",
"       'General measures'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Pharmacotherapy with calcium channel blockers for vasodilation, if general nonpharmacologic measures are inadequate (see",
"      <a class=\"local\" href=\"#H188847410\">",
"       'General measures insufficient'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H188847417\">",
"       'Calcium channel blockers'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Behavioral therapies, the use of which depends upon patient preference and upon the availability and cost to the individual patient (see",
"      <a class=\"local\" href=\"#H3057213\">",
"       'Behavioral therapy'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients who do not respond to initial therapies, further steps include the addition or substitution of other pharmacologic agents, such as topical nitrates or phosphodiesterase 5 inhibitors. Patients with digital ischemia that has not responded to oral or topical vasodilators may require hospitalization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment with anticoagulants, intravenous prostanoids,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sympathectomy or other interventions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27741388\">",
"    <span class=\"h2\">",
"     Assessment of the response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical practice, a practical approach to assessing the response to therapy is to ask the patient a question similar to that used for the Raynaud Condition Score (RCS), a validated assessment tool used in clinical trials, which asks the patient to consider the impact of the condition on their life, taking into account the frequency of attacks, the duration of attacks, the disability it is causing, and the effect on daily quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The RCS uses a visual scale of 1 to 10; a change of about 1.5 is the minimum change considered clinically important [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measures such as the RCS and other patient-reported outcomes are the gold standard for assessment in clinical trials. Other such measures include a paper or electronic record of the number of daily attacks and of the duration of typical attacks. These data are then averaged over some defined period, usually weekly. A number of laboratory-based measures (eg, laser Doppler, thermography, cold challenges) have been used, but none has become a standard measure for clinical trials or daily patient care. Ambulatory monitoring of skin temperature has been proposed as a potential outcome measure but has not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We advise that all patients should be educated regarding both the potential causes of a Raynaud attack and the general measures to help prevent and terminate an episode. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\", section on 'Provoking factors'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'General measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinical trials have demonstrated a 10 to 40 percent reduction in the frequency and severity of Raynaud attacks among placebo-treated patients with either primary or secondary RP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. These findings suggest that a positive attitude, attention to the patient, and general education may be important factors in controlling attacks, and they emphasize the importance of placebo-controlled trials in evaluating the efficacy of a specific therapy.",
"   </p>",
"   <p>",
"    We also reassure patients with primary RP about the excellent prognosis in most patients, and we try to eliminate fears or unfounded misconceptions about RP and its management. Sympathetic tone and sensitivity to sympathetic mediators are enhanced in the patient with RP, and higher levels of anxiety correlate with more frequent attacks at temperatures over 60&ordm;F (16&ordm;C) and with more severe attacks at all ambient temperatures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;We counsel all patients with RP to undertake a series of general measures that help to prevent or diminish the severity of attacks of RP, including changes in lifestyle and drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Such measures are often sufficient for control of symptoms in patients with primary RP, while most patients with secondary RP will also require treatment with medications or correction of the underlying condition. In our experience, these precautions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of cold exposure, especially sudden changes such as walking into the frozen food section of a grocery store",
"     </li>",
"     <li>",
"      Use of strategies to keep the whole body warm, including dressing warmly (eg, with thermal underwear, layered clothing, and a heat-conserving hat)",
"     </li>",
"     <li>",
"      Use of strategies to keep the digits of the hands and feet warm (eg, winter gloves, chemical hand warmers, and heavy wool stockings)",
"     </li>",
"     <li>",
"      Knowledge of methods to help terminate an attack of RP. These include placing the hands under warm water or in a warm place (such as the axilla) or rotating arms in a whirling or windmill pattern. Rubbing the hands together can help.",
"     </li>",
"     <li>",
"      Avoidance of rapidly changing temperatures, such as occurs when quickly moving from a hot environment (90&ordm;F) into an air-conditioned room (70&ordm;F). Avoiding sitting motionless in cool breezes or in humid cold air is also recommended.",
"     </li>",
"     <li>",
"      Avoidance of smoking, which is advised since regular smokers are sensitized to the vasoconstrictive properties of cigarettes. The response in patients with RP does not appear to be different from that in normals [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/11\">",
"       11",
"      </a>",
"      ]. Avoiding second hand smoke is prudent.",
"     </li>",
"     <li>",
"      Avoidance of sympathomimetic drugs (such as decongestants, amphetamines, diet pills, herbs containing ephedra), which is generally recommended, although studies evaluating the degree of the impact of over-the-counter preparations (such as cold medications) have not been performed [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Avoidance of some of the medications used for migraine headaches, including serotonin agonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"       sumatriptan",
"      </a>",
"      ) or caffeine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"     </li>",
"     <li>",
"      Avoidance of repeated trauma to the fingertips by all patients with RP and avoidance of vibrating tools by patients with vibration-induced RP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Control or limitation of emotional stress, because the thermoregulatory vessels are constricted by increased sympathetic tone. Stress plus cold exposure is an especially potent trigger for RP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An aggravating role of estrogen use is suggested by the finding that postmenopausal women using unopposed estrogens have a higher prevalence of RP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the exact impact of estrogens is not fully defined.",
"   </p>",
"   <p>",
"    We do not routinely stop caffeine-containing drinks in patients with RP, although some experts have recommended doing so. The impact of caffeine on RP has not been defined, and its xanthine-related properties may result in systemic vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It was initially thought that nonselective beta blockers could cause RP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/17\">",
"     17",
"    </a>",
"    ]. However, subsequent studies showed that beta blockers did not induce vasoconstriction in patients with RP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with RP undergoing surgery, the risk of attacks from increased cold exposure in the operating room can be reduced by keeping patients warm. The choice of medications in patients undergoing an attack in this setting should be individualized based upon the specific clinical circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188847410\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES INSUFFICIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We initiate pharmacotherapy in patients in whom general nonpharmacologic treatment measures alone are insufficient to adequately reduce the frequency and severity of attacks. We prefer to use one of the calcium channel blockers that have proven effective for primary and secondary RP as the initial choice for drug therapy. (See",
"    <a class=\"local\" href=\"#H188847417\">",
"     'Calcium channel blockers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional oral and parenteral agents of benefit for RP and digital ischemia related to RP include other vasodilators, sympatholytic agents, prostaglandins, and an endothelin-1 receptor antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. These therapies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197221250\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188847417\">",
"    <span class=\"h3\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend use of the slow-release or long-acting preparations of the dihydropyridine calcium channel blockers (CCBs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    , in the nonurgent management of RP that has not responded adequately to general measures. Other dihydropyridine CCBs that may be beneficial include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=see_link\">",
"     isradipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    . The efficacy and safety of these medications have been documented in systematic reviews and in meta-analyses of randomized trials. (See",
"    <a class=\"local\" href=\"#H188847424\">",
"     'CCBs: Efficacy and safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Effective doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    range from 30 to 180",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and effective doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    range from 5 to 20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    We start with the lowest dose and gradually increase, if needed, depending upon the response. Some experts feel that amlodipine may be better tolerated in patients with low blood pressure at baseline or with problematic lowering of blood pressure with use of nifedipine, but this has not been systematically evaluated. The duration of a drug trial at a given dose is determined by the frequency of attacks, which dictates how long of a period of observation is needed to assess whether there has been a clinically meaningful reduction in the frequency and severity of acute attacks, and by the degree to which the drug is tolerated.",
"   </p>",
"   <p>",
"    We generally titrate the dose slowly in nonurgent situations, usually adjusting the dose every four weeks and no more frequently than every 7 to 10 days. In more urgent situations, a short-acting agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    rapid release) is preferred to allow more rapid dose adjustment in more severely affected patients. In hospitalized patients under close observation, the dose of nifedipine may be increased in 10 mg increments over four- to six-hour periods as required. Some patients with primary RP or with only limited involvement with secondary RP may need treatment only in the winter months.",
"   </p>",
"   <p>",
"    The major side effects associated with the dihydropyridines include headache, dizziness, flushing, tachycardia, and edema. Maximal doses of the calcium channel blocker (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    15 to 20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may lead to significant edema.",
"   </p>",
"   <p>",
"    We generally discontinue CCBs and other vasodilators during pregnancy if possible, as RP often improves during pregnancy in association with increased blood volume. We prefer to use CCBs rather than angiotensin receptor blockers for digital ischemia during pregnancy, if required. If beta blockers are needed for blood pressure control, the selective agents are preferred, as some studies suggest that non-selective beta blockers sometimes worsen the symptoms of RP.",
"   </p>",
"   <p>",
"    In addition, the relative benefits and tolerance of long-acting compared with short-acting preparations have assumed increasing importance with the suggestion that short-acting dihydropyridine preparations may increase cardiovascular risk. We, thus, prefer to use long-acting rather than short-acting formulations of CCBs for the treatment of RP. (See",
"    <a class=\"local\" href=\"#H188847424\">",
"     'CCBs: Efficacy and safety'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individual responses to the CCBs may vary. If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    is ineffective at the highest tolerated dose, then another of the potentially effective calcium channel blockers may be substituted, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22295?source=see_link\">",
"     nisoldipine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=see_link\">",
"     isradipine",
"    </a>",
"    of the dihydropyridine group or such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , a nondihydropyridine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/4,21-30\">",
"     4,21-30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188847424\">",
"    <span class=\"h4\">",
"     CCBs: Efficacy and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of many of the calcium channel blockers (CCBs) in the treatment of both primary and secondary RP have been documented in meta-analyses of randomized trials and in systematic reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/19,31-33\">",
"     19,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2005 meta-analysis of randomized trials involving 361 patients with primary Raynaud phenomenon showed benefit from the use of CCBs overall and of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      in particular [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/32\">",
"       32",
"      </a>",
"      ]. The frequency of attacks was reduced by an average of 2.8 to 5 per week, and the severity of attacks was reduced by one-third. Relatively low doses of CCBs were employed in some of the trials.",
"     </li>",
"     <li>",
"      A 2001 meta-analysis of randomized trials involving 109 ambulatory patients with RP due to systemic sclerosis (scleroderma) supported the view that these drugs are also moderately efficacious in patients with secondary RP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/31\">",
"       31",
"      </a>",
"      ]. CCBs reduced the frequency of attacks compared with placebo (weighted mean difference -8.3 attacks over two weeks, 95% CI -15.7 to -0.9) and also reduced the severity of attacks (standardized mean difference -0.69, 95% CI -1.21 to -0.17).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Much variability in the response to CCBs is observed in clinical trials, although approximately 60 percent of patients experience less intense and fewer attacks at doses of 10 to 20 mg three to four times daily of short-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/31\">",
"     31",
"    </a>",
"    ]. This variability occurs, in part, because patients with secondary RP (particularly scleroderma) are less likely to benefit from nifedipine (and other calcium channel blockers) than are those with primary RP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\", section on 'Vascular'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CCBs differ in their vasodilating potency, and responses in individuals vary.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     Nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/49/22295?source=see_link\">",
"     nisoldipine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/903?source=see_link\">",
"     isradipine",
"    </a>",
"    of the dihydropyridine group, as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    (a nondihydropyridine), are effective in RP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/4,21-30\">",
"     4,21-30",
"    </a>",
"    ]. However, not all calcium channel blockers appear to be beneficial. In one report,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , a nondihydropyridine CCB, was ineffective at doses of 40 to 80 mg four times daily in a group of patients with severe RP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, plain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    was not effective in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/35\">",
"     35",
"    </a>",
"    ] and was only minimally different from placebo in another [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many published studies have used short-acting preparations of the calcium channel blockers in the treatment of acute digital ischemia due to RP. However, we prefer to use extended-release formulations for management of RP, given the ease of administration and the safety of the extended-release agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A large clinical experience suggests that long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    is effective in managing patients with RP and has fewer adverse reactions than rapid-acting preparations. The frequency of adverse events with the long-acting form of nifedipine is illustrated in the following trial:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In this trial, 313 patients with primary RP were randomly assigned to receive sustained-release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      , placebo, or two different forms of biofeedback therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/4\">",
"       4",
"      </a>",
"      ]. The majority of patients receiving nifedipine were taking 60 mg daily, and others received 30 mg daily. The patients were evaluated during one winter month approximately one year after initiation of treatment. Nifedipine-treated subjects had a 66 percent reduction in attacks compared with the placebo group, a significant improvement. Adverse results were few, resulting in discontinuation of therapy in only 14 percent of patients receiving nifedipine and in 9 percent of those receiving placebo.",
"      <br/>",
"      <br/>",
"      The most common adverse effects present significantly more often in patients receiving nifedipine compared with placebo and biofeedback were edema and flushing (24 and 8 percent, respectively, versus 0 percent). Headache was reported by 17 percent of those receiving nifedipine, by 11 percent receiving placebo, and by one patient being treated with biofeedback. The frequency of dizziness was comparable between groups (7 to 8 percent), and tachycardia was experienced by 2 of the 77 patients taking nifedipine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Objective improvement in digital blood flow following treatment with a CCB has been difficult to substantiate. In one study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    caused a decrease in skin temperature recovery time following cold provocation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/37\">",
"     37",
"    </a>",
"    ]. CCBs may have additional biological properties that are beneficial in RP, including inhibition of platelet activation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also some concern that non-selective systemic vasodilators may cause acute worsening of digital ischemia as a result of a decrease in systemic blood pressure and, consequently, digital perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/39\">",
"     39",
"    </a>",
"    ]. While this is a theoretical concern, it is rarely seen as a complication in our experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H781703\">",
"    <span class=\"h3\">",
"     Unable to use CCBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative therapies may be required in patients in whom calcium channel blockers (CCBs) are contraindicated or are poorly tolerated at low doses (eg, patients with severe gastrointestinal dysmotility, severe pulmonary artery hypertension, significant cardiac disease with edema, and low blood pressure). The treatment alternatives, which are discussed in detail elsewhere, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phosphodiesterase-5 inhibitor, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link&amp;anchor=H782103#H782103\">",
"       \"Treatment of the Raynaud phenomenon resistant to initial therapy\", section on 'Phosphodiesterase type 5 inhibitors'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Topical nitrates (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link&amp;anchor=H782864#H782864\">",
"       \"Treatment of the Raynaud phenomenon resistant to initial therapy\", section on 'Topical nitrates'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An alternative oral agent, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"       prazosin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=see_link&amp;anchor=H781713#H781713\">",
"       \"Treatment of the Raynaud phenomenon resistant to initial therapy\", section on 'Other alternatives to CCBs'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3057213\">",
"    <span class=\"h2\">",
"     Behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with primary RP in whom general measures alone are insufficient and who are open to behavioral therapies, several different types of such therapy may be used, but the degree of benefit has not been established. While some patients try behavioral therapy alone, most use it in addition to medications. Behavioral therapies, such as autogenic training (a form of relaxation), biofeedback, and classical conditioning, can be helpful for selected patients with primary RP but are unlikely to be of significant benefit in secondary forms of RP. Consistent high quality evidence for benefit compared with placebo in patients with primary RP is lacking.",
"   </p>",
"   <p>",
"    In patients in whom general measures alone are insufficient, we base the decision to refer a patient with primary RP for a behavioral therapy upon patient preference for such an intervention and upon cost, convenience, and availability of these approaches. We do not refer patients for biofeedback alone. Stress reduction techniques may benefit patients in whom emotional stress is a major trigger of attacks.",
"   </p>",
"   <p>",
"    The evidence for benefit from these approaches is mixed, and the quality of studies varies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Many trials lack placebo controls. Data from some small randomized trials and observational studies of a variety of behavioral therapies suggest a modest reduction in the frequency and severity of attacks of RP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. However, the magnitude of benefit varies and, in studies with placebo controls, sometimes does not significantly exceed that seen with placebo. When compared, the benefit of behavioral techniques has been less than the effects of medications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/4,41\">",
"     4,41",
"    </a>",
"    ]. However, multiple studies have demonstrated that normal subjects can voluntarily control peripheral blood flow and skin temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/46-49\">",
"     46-49",
"    </a>",
"    ], and normal individuals can increase finger temperature using temperature biofeedback with instruction about warming [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/47,50,51\">",
"     47,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biofeedback",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    autogenic training are the two most frequently used behavioral interventions for the treatment of RP. Another approach is based upon classical conditioning techniques. The goal of these behavioral interventions is to train patients with RP to voluntarily control their peripheral circulation. (See",
"    <a class=\"local\" href=\"#H3057220\">",
"     'Biofeedback training and autogenic training'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3057227\">",
"     'Classical conditioning'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3057220\">",
"    <span class=\"h3\">",
"     Biofeedback training and autogenic training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies in patients with RP demonstrated that biofeedback alone or in combination with various relaxation procedures reduced the occurrence of vasospastic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/13,42,52,53\">",
"     13,42,52,53",
"    </a>",
"    ]. In biofeedback training, patients are comfortably seated with thermistors attached to the fingertips. Patients are then asked by the therapist to alter the temperature in the fingers while readings of the skin temperature are &ldquo;fed back&rdquo; to the patient using auditory or visual signals. Autogenic training teaches the use of relaxation inducing self-statements that suggest warmth and heaviness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/54\">",
"     54",
"    </a>",
"    ]. This method has been used alone or in combination with temperature biofeedback.",
"   </p>",
"   <p>",
"    Study quality varies; evidence for benefit from these techniques includes the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial involving 19 patients that compared autogenic training alone or in combination with temperature biofeedback demonstrated improvement in response to cold stress and in the number and intensity of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/42\">",
"       42",
"      </a>",
"      ]. Another trial showed benefit from autogenic training for patients with primary RP but showed no additional benefit from skin temperature feedback [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study, temperature biofeedback combined with cold exposure resulted in greater reductions in the frequency of attacks of RP compared with biofeedback alone (93 versus 67 percent); these reductions in symptoms in both biofeedback groups were greater than those seen with autogenic training or with electromyographic biofeedback (33 and 17 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/43\">",
"       43",
"      </a>",
"      ]. At one-year follow-up, only the temperature biofeedback groups showed significant finger temperature increases during control voluntary testing, while the electromyogram and autogenic-trained groups showed significant decreases in temperature. Benefits of the biofeedback training were maintained after two to three years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several well-designed studies have shown little or no benefit from psychological interventions, including biofeedback:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial involving 313 patients with primary RP found significant benefit from treatment with sustained release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      compared with control (66 percent reduction in attacks), while results with temperature biofeedback were not significantly reduced compared with control biofeedback [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial in 36 patients with primary RP that compared skin temperature biofeedback, electromyographic relaxation, and no treatment found a comparable decrease in the number of vasospastic attacks in all three groups [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In secondary RP due to systemic lupus erythematosus (SLE) or to scleroderma (SSc), benefit from temperature biofeedback was suggested in several uncontrolled trials [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/56-59\">",
"       56-59",
"      </a>",
"      ]. However, the only controlled trial in secondary RP, involving 24 patients with SSc, failed to demonstrate symptom improvement immediately after treatment or increased finger temperature in response to voluntary control or cold stress [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3057227\">",
"    <span class=\"h3\">",
"     Classical conditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classical conditioning has been examined alone and in combination with temperature biofeedback training to treat RP with mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/60\">",
"     60",
"    </a>",
"    ]. The classical conditioning procedure involves pairing the unconditioned stimulus of warm water applied to the hands with a conditioned stimulus of exposure of the whole body to cold. After repeated pairings, exposure to cold alone elicits vasodilation in the hands, which is the conditioned response. Using a classical conditioning procedure to induce vasodilation or biofeedback therapy, subjects with primary RP exhibited significant increases in digital temperature during a cold stress, relative to untreated control subjects. This regimen led to significant improvement relative to controls in both finger temperature and in the number of attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OTHER INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other treatments have been proposed and have been subjected to limited study; sufficient evidence is lacking at present to support their use in place of other interventions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acupuncture has been reported to improve primary RP, but there is not enough evidence to determine effectiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Therapeutic gloves [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/62\">",
"       62",
"      </a>",
"      ] and low-level laser therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/63,64\">",
"       63,64",
"      </a>",
"      ] are reported to improve RP, but the data are limited. Spinal cord stimulation has been used for treatment in RP, but no controlled study is available [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A literature review and meta-analysis of the efficacy of complementary and alternative medicine in the treatment of RP found that most studies were inconclusive and that there is a need for well-designed studies in this area of treatment for RP [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3060717\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary RP is a benign condition; it is often transient in nature and may improve or disappear with time in one-third or more of patients over 7 to 14 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28200/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. However, many patients with primary RP have significant impact on their quality of life due to cold and uncomfortable fingers and hands. This is particularly true in individuals who have occupations that do not allow effective cold avoidance. By comparison, patients with secondary RP are more likely to have severe attacks and sustained or progressive disease. Patients with associated systemic rheumatic disease, particularly systemic sclerosis (SSc, scleroderma), may develop persistent digital ischemia requiring aggressive intervention, which is not always effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials have demonstrated a 10 to 40 percent reduction in the frequency and severity of Raynaud attacks among placebo-treated patients with either primary or secondary RP. A significant component of this placebo response may be due to reinforcement of the importance of general nonpharmacologic measures that the patient can take to prevent and treat attacks. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Patient education'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'General measures'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/4/35905?source=see_link\">",
"       \"Patient information: Raynaud disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=see_link\">",
"       \"Patient information: Raynaud phenomenon (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goals of therapy in patients with the Raynaud phenomenon (RP) are to improve quality of life and to prevent ischemic tissue injury. At least a moderate reduction in the intensity of attacks and the prevention of digital ulcers or tissue injury are achievable in most patients. However, abolishing cold sensitivity and eliminating all Raynaud events is not likely with available treatment options, particularly in patients with secondary RP. (See",
"      <a class=\"local\" href=\"#H1644624\">",
"       'Goals and overview of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We advise that all patients should be educated regarding both the potential causes of a Raynaud attack and the general measures to help prevent and terminate an episode. Patients with primary RP are unlikely to develop damaging digital ischemia and, thus, are considered good candidates for nonpharmacologic therapies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General measures that help to prevent or diminish the severity of attacks of RP include avoiding cold exposure, maintaining warmth of the whole body, smoking cessation, and avoiding sympathomimetic medications and emotional stress. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'General measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend use of the slow-release or long-acting preparations of the dihydropyridine calcium channel blockers (CCB),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      (30 to 180",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      (5 to 20",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      in the nonurgent management of RP that has not responded adequately to general measures (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We start with the lowest dose and gradually increase as needed depending upon the response. (See",
"      <a class=\"local\" href=\"#H188847417\">",
"       'Calcium channel blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some behavioral therapies are associated with a modest improvement in frequency and severity of attacks of RP, although the magnitude of this response may not be significantly greater than that with placebo. Therefore, our enthusiasm for the use of these therapies is low and is also based upon patient preference and cost. Behavioral therapies that may be of benefit include stress reduction, particularly if emotional stress is a major trigger of attacks; biofeedback in combination with other techniques (but not biofeedback alone); autogenic training; and classical conditioning. (See",
"      <a class=\"local\" href=\"#H3057213\">",
"       'Behavioral therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3057220\">",
"       'Biofeedback training and autogenic training'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3057227\">",
"       'Classical conditioning'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/1\">",
"      Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007; 9:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/2\">",
"      Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/3\">",
"      Khanna PP, Maranian P, Gregory J, Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis 2010; 69:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/4\">",
"      Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000; 160:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/5\">",
"      Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/6\">",
"      Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000; :CD000953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/7\">",
"      Brown KM, Middaugh SJ, Haythornthwaite JA, Bielory L. The effects of stress, anxiety, and outdoor temperature on the frequency and severity of Raynaud's attacks: the Raynaud's Treatment Study. J Behav Med 2001; 24:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/8\">",
"      Wigley FM. Clinical practice. Raynaud's Phenomenon. N Engl J Med 2002; 347:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/9\">",
"      Bowling JC, Dowd PM. Raynaud's disease. Lancet 2003; 361:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/10\">",
"      Goldman W, Seltzer R, Reuman P. Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: a retrospective case-control study of rheumatology patients. Arthritis Rheum 2008; 58:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/11\">",
"      Goodfield MJ, Hume A, Rowell NR. The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon. Br J Rheumatol 1990; 29:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/12\">",
"      Falkiner S. Diagnosis and treatment of hand-arm vibration syndrome and its relationship to carpal tunnel syndrome. Aust Fam Physician 2003; 32:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/13\">",
"      Freedman RR, Ianni P. Role of cold and emotional stress in Raynaud's disease and scleroderma. Br Med J (Clin Res Ed) 1983; 287:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/14\">",
"      Fraenkel L, Zhang Y, Chaisson CE, et al. The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women. Ann Intern Med 1998; 129:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/15\">",
"      Umemura T, Ueda K, Nishioka K, et al. Effects of acute administration of caffeine on vascular function. Am J Cardiol 2006; 98:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/16\">",
"      Echeverri D, Montes FR, Cabrera M, et al. Caffeine's Vascular Mechanisms of Action. Int J Vasc Med 2010; 2010:834060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/17\">",
"      Marshall AJ, Roberts CJ, Barritt DW. Raynaud's phenomenon as side effect of beta-blockers in hypertension. Br Med J 1976; 1:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/18\">",
"      Franssen C, Wollersheim H, de Haan A, Thien T. The influence of different beta-blocking drugs on the peripheral circulation in Raynaud's phenomenon and in hypertension. J Clin Pharmacol 1992; 32:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/19\">",
"      Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review. Curr Opin Rheumatol 2007; 19:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/20\">",
"      Herrick AL. Contemporary management of Raynaud's phenomenon and digital ischaemic complications. Curr Opin Rheumatol 2011; 23:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/21\">",
"      Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med 1983; 308:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/22\">",
"      Smith CD, McKendry RJ. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon. Lancet 1982; 2:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/23\">",
"      Sauza J, Kraus A, Gonz&aacute;lez-Amaro R, Alarc&oacute;n-Segovia D. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial. J Rheumatol 1984; 11:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/24\">",
"      Kallenberg CG, Wouda AA, Kuitert JJ, et al. Nifedipine in Raynaud's phenomenon: relationship between immediate, short term and longterm effects. J Rheumatol 1987; 14:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/25\">",
"      Sarkozi J, Bookman AA, Mahon W, et al. Nifedipine in the treatment of idiopathic Raynaud's syndrome. J Rheumatol 1986; 13:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/26\">",
"      Kahan A, Amor B, Menkes CJ. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis 1985; 44:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/27\">",
"      Gj&oslash;rup T, Hartling OJ, Kelbaek H, Nielsen SL. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon. Eur J Clin Pharmacol 1986; 31:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/28\">",
"      Leppert J, Jonasson T, Nilsson H, Ringqvist I. The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud's phenomenon: a single-blind dose-response study. Cardiovasc Drugs Ther 1989; 3:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/29\">",
"      La Civita L, Pitaro N, Rossi M, et al. Amlodipine in the treatment of Raynaud's phenomenon. Br J Rheumatol 1993; 32:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/30\">",
"      Kallenberg CG, Wouda AA, Meems L, Wesseling H. Once daily felodipine in patients with primary Raynaud's phenomenon. Eur J Clin Pharmacol 1991; 40:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/31\">",
"      Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/32\">",
"      Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 2005; 44:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/33\">",
"      Huisstede BM, Hoogvliet P, Paulis WD, et al. Effectiveness of interventions for secondary Raynaud's phenomenon: a systematic review. Arch Phys Med Rehabil 2011; 92:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/34\">",
"      Kinney EL, Nicholas GG, Gallo J, et al. The treatment of severe Raynaud's phenomenon with verapamil. J Clin Pharmacol 1982; 22:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/35\">",
"      Wigley FM, Wise RA, Malamet R, Scott TE. Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm. Arthritis Rheum 1987; 30:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/36\">",
"      Kahan A, Amor B, Menk&egrave;s CJ, et al. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial. Angiology 1987; 38:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/37\">",
"      White CJ, Phillips WA, Abrahams LA, et al. Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study. Am J Med 1986; 80:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/38\">",
"      Takahara K, Kuroiwa A, Matsushima T, et al. Effects of nifedipine on platelet function. Am Heart J 1985; 109:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/39\">",
"      Wise RA, Malamet R, Wigley FM. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial. J Rheumatol 1987; 14:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/40\">",
"      Rose GD, Carlson JG. The behavioral treatment of Raynaud's disease: a review. Biofeedback Self Regul 1987; 12:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/41\">",
"      Stetter F, Kupper S. Autogenic training: a meta-analysis of clinical outcome studies. Appl Psychophysiol Biofeedback 2002; 27:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/42\">",
"      Keefe FJ, Surwit RS, Pilon RN. A 1-year follow-up of Raynaud's patients treated with behavioral therapy techniques. J Behav Med 1979; 2:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/43\">",
"      Freedman RR, Ianni P, Wenig P. Behavioral treatment of Raynaud's disease. J Consult Clin Psychol 1983; 51:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/44\">",
"      Freedman RR, Ianni P, Wenig P. Behavioral treatment of Raynaud's disease: long-term follow-up. J Consult Clin Psychol 1985; 53:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/45\">",
"      Surwit RS, Pilon RN, Fenton CH. Behavioral treatment of Raynaud's disease. J Behav Med 1978; 1:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/46\">",
"      Taub E, Emurian CS. Feedback-aided self-regulation of skin temperature with a single feedback locus. I. Acquisition and reversal training. Biofeedback Self Regul 1976; 1:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/47\">",
"      Keefe FJ, Gardner E. Learned control of skin temperature: Effects of short and long term biofeedback training. Behav Ther 1979; 10:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/48\">",
"      Grabert JC, Bregman NJ, McAllister HA. Skin temperature regulation: the effects of suggestion and feedback. Int J Neurosci 1980; 10:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/49\">",
"      Surwit RS. Behavioral treatment of Raynaud's syndrome in peripheral vascular disease. J Consult Clin Psychol 1982; 50:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/50\">",
"      Keefe FJ. Conditioning changes in differential skin temperature. Percept Mot Skills 1975; 40:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/51\">",
"      Keefe FJ. Biofeedback vs. instructional control of skin temperature. J Behav Med 1978; 1:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/52\">",
"      Jacobson AM, Hackett TP, Surman OS, Silverberg EL. Raynaud phenomenon. Treatment with hypnotic and operant technique. JAMA 1973; 225:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/53\">",
"      Surwit RS. Biofeedback: a possible treatment for Raynaud's disease. Semin Psychiatry 1973; 5:483.",
"     </a>",
"    </li>",
"    <li>",
"     Luthe W, Schultz JH. Autogenic therapy, Grune &amp; Stratton, New York 1969. p.76.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/55\">",
"      Guglielmi RS, Roberts AH, Patterson R. Skin temperature biofeedback for Raynaud's disease: a double-blind study. Biofeedback Self Regul 1982; 7:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/56\">",
"      Peterson LL, Vorhies C. Raynaud's syndrome. Treatment with sublingual administration of nitroglycerin, swinging arm maneuver, and biofeedback training. Arch Dermatol 1983; 119:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/57\">",
"      Freedman RR, Ianni P, Wenig P. Behavioral treatment of Raynaud's phenomenon in scleroderma. J Behav Med 1984; 7:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/58\">",
"      Sappington JT, Fiorito EM. Thermal feedback in Raynaud's phenomenon secondary to systemic lupus erythematosus: long-term remission of target symptoms. Biofeedback Self Regul 1985; 10:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/59\">",
"      Yocum DE, Hodes R, Sundstrom WR, Cleeland CS. Use of biofeedback training in treatment of Raynaud's disease and phenomenon. J Rheumatol 1985; 12:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/60\">",
"      Jobe JB, Sampson JB, Roberts DE, Kelly JA. Comparison of behavioral treatments for Raynaud's disease. J Behav Med 1986; 9:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/61\">",
"      Appiah R, Hiller S, Caspary L, et al. Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture. J Intern Med 1997; 241:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/62\">",
"      Ko GD, Berbrayer D. Effect of ceramic-impregnated \"thermoflow\" gloves on patients with Raynaud's syndrome: randomized, placebo-controlled study. Altern Med Rev 2002; 7:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/63\">",
"      Hirschl M, Katzenschlager R, Ammer K, et al. Double-blind, randomised, placebo controlled low level laser therapy study in patients with primary Raynaud's phenomenon. Vasa 2002; 31:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/64\">",
"      Hirschl M, Katzenschlager R, Francesconi C, Kundi M. Low level laser therapy in primary Raynaud's phenomenon--results of a placebo controlled, double blind intervention study. J Rheumatol 2004; 31:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/65\">",
"      Neuhauser B, Perkmann R, Klingler PJ, et al. Clinical and objective data on spinal cord stimulation for the treatment of severe Raynaud's phenomenon. Am Surg 2001; 67:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/66\">",
"      Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford) 2009; 48:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/67\">",
"      Carpentier PH, Satger B, Poensin D, Maricq HR. Incidence and natural history of Raynaud phenomenon: A long-term follow-up (14 years) of a random sample from the general population. J Vasc Surg 2006; 44:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28200/abstract/68\">",
"      Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 2005; 52:1259.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7540 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.150-4CB4CD1434-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28200=[""].join("\n");
var outline_f27_34_28200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1644434\">",
"      PRIMARY AND SECONDARY RP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1644624\">",
"      GOALS AND OVERVIEW OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27741388\">",
"      Assessment of the response to therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188847410\">",
"      GENERAL MEASURES INSUFFICIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H197221250\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H188847417\">",
"      - Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H188847424\">",
"      CCBs: Efficacy and safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H781703\">",
"      - Unable to use CCBs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3057213\">",
"      Behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3057220\">",
"      - Biofeedback training and autogenic training",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3057227\">",
"      - Classical conditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OTHER INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3060717\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=related_link\">",
"      Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=related_link\">",
"      Pathogenesis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/4/35905?source=related_link\">",
"      Patient information: Raynaud disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=related_link\">",
"      Patient information: Raynaud phenomenon (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28138?source=related_link\">",
"      Treatment of the Raynaud phenomenon resistant to initial therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_34_28201="Gallstone disease in pregnant women";
var content_f27_34_28201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Gallstone disease in pregnant women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28201/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28201/contributors\">",
"     David C Brooks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28201/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28201/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28201/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28201/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28201/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28201/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/34/28201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31120830\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy increases the risk of gallstone disease due to decreased gallbladder motility and increased cholesterol saturation of bile [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/1\">",
"     1",
"    </a>",
"    ]. In pregnant women with symptomatic gallbladder disease, supportive care will be satisfactory in most cases, but the recurrence of symptoms during the same pregnancy is frequent. Some pregnant women will require surgery because of repeated attacks of biliary colic or because of acute cholecystitis, choledocholithiasis, or gallstone pancreatitis. Pregnant women with symptomatic gallbladder disease who undergo primary surgical management appear to have better outcomes than those managed conservatively, thus favoring surgical intervention during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Acute cholecystitis is the second most common non-obstetrical surgical emergency in pregnant women after acute appendicitis, as shown in the table (",
"    <a class=\"graphic graphic_table graphicRef71938 \" href=\"UTD.htm?12/62/13291\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The issues specific to gallstone disease in pregnant women will be reviewed. The diagnosis and management of gallstones in the general population and other hepatobiliary problems in pregnancy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link\">",
"     \"Epidemiology of and risk factors for gallstones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link\">",
"     \"Treatment of acute cholecystitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14726?source=see_link\">",
"     \"Intercurrent hepatobiliary disease during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210627445\">",
"    <span class=\"h1\">",
"     INCREASED RISK OF GALLSTONES IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is a major risk factor for the development of cholesterol gallstones. Increases in reproductive hormones during pregnancy induce a variety of physiologic changes in the biliary system, which ultimately cause bile to become supersaturated with cholesterol, thereby promoting gallstone formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supersaturation occurs as a result of estrogen-induced increase in cholesterol secretion and progesterone-induced reduction in bile acid secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnancy induces a qualitative change in bile acid synthesis characterized by relative overproduction of hydrophobic bile acids such as chenodeoxycholate, thereby reducing the ability of bile to solubilize cholesterol [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Progesterone-induced slowing of gallbladder emptying further promotes the formation of stones by causing bile stasis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes normalize one to two months following delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210627438\">",
"    <span class=\"h1\">",
"     INCIDENCE AND COURSE IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a literature review, the prevalence of biliary sludge in pregnant women ranged from 5 to 36 percent and the prevalence of gallstones ranged from 2 to 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/9\">",
"     9",
"    </a>",
"    ]. A prospective study of 272 women recruited in the first trimester and followed for almost one year postpartum found that new biliary sludge developed in 67 women and gallstones developed in 6 women during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/10\">",
"     10",
"    </a>",
"    ]. Women with biliary sludge generally remained asymptomatic, but 28 percent of those with gallstones experienced biliary pain during pregnancy. About half of the study population (115 women) was studied again in the postpartum period. Of these, 92 had sludge and 23 had stones. The sludge disappeared in 56 affected women (61 percent) and stones disappeared in 6 women (28 percent) by several months postpartum.",
"   </p>",
"   <p>",
"    Although the prevalence of gallstones has been reported to be higher in multiparous versus nulliparous women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], increasing age and obesity as well as genetic background may account for the persistence and further growth of the stones that develop during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More serious complications of gallstones, such as acute cholecystitis, choledocholithiasis, gangrenous gallbladder, or pancreatitis, develop in less than 10 percent of symptomatic patients. The incidence of acute cholecystitis in pregnant women with gallstones is 0.05 to 0.08 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31120837\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of gallstone disease during pregnancy is similar to that in the nonpregnant state. It is helpful to categorize presentation into the following clinical groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gallstones on imaging studies, but without symptoms (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=see_link\">",
"       \"Approach to the patient with incidental gallstones\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Typical biliary symptoms and gallstones on imaging studies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link&amp;anchor=H1067517491#H1067517491\">",
"       \"Uncomplicated gallstone disease in adults\", section on 'Category 2 patients (typical biliary symptoms and gallstones)'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atypical symptoms and gallstones on imaging studies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link&amp;anchor=H22973264#H22973264\">",
"       \"Uncomplicated gallstone disease in adults\", section on 'Category 3 patients (gallstones but atypical symptoms)'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Typical biliary symptoms, but without gallstones (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link&amp;anchor=H150685460#H150685460\">",
"       \"Uncomplicated gallstone disease in adults\", section on 'Next steps if the ultrasound is negative'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most patients, the first symptoms experienced from gallstones are recurrent pain attacks generated by the gallstones (biliary colic). Patients with biliary colic complain of epigastric or right upper quadrant pain. The onset of the pain is typically between one and three hours postprandially, and typically lasts for as long as four to six hours. The pain gradually resolves, although resolution may often be hastened by analgesics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link&amp;anchor=H2#H2\">",
"     \"Uncomplicated gallstone disease in adults\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less frequently, the initial symptoms are those of one of the complications of gallstones, most commonly acute cholecystitis. The presentation of acute cholecystitis is similar to that in nonpregnant women: right upper quadrant pain, Murphy&rsquo;s sign, fever, tachycardia, anorexia, nausea, and vomiting. There is often a history of fatty food ingestion about one hour or more before the initial onset of pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215897\">",
"    <span class=\"h2\">",
"     Differential clinical diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnant women with right upper quadrant or epigastric pain, both pregnancy-related and nonpregnancy-related clinical diagnoses must be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376465651\">",
"    <span class=\"h3\">",
"     Pregnancy-related conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy-related conditions include severe preeclampsia and HELLP syndrome (ie,",
"    <strong>",
"     H",
"    </strong>",
"    emolysis,",
"    <strong>",
"     E",
"    </strong>",
"    levated",
"    <strong>",
"     L",
"    </strong>",
"    iver enzymes,",
"    <strong>",
"     L",
"    </strong>",
"    ow",
"    <strong>",
"     P",
"    </strong>",
"    latelet count), acute fatty liver, abruptio placentae, uterine rupture, and intraamniotic infection. These conditions can usually be differentiated from gallstone disease by the clinical setting in which they occur and by obtaining the appropriate diagnostic studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36554?source=see_link\">",
"     \"Approach to abdominal pain and the acute abdomen in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension and proteinuria are requisite criteria for preeclampsia, and common in HELLP syndrome. Both conditions do not occur until after 20 weeks of gestation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute fatty liver also occurs in the second half of pregnancy, usually in the third trimester. The most frequent initial symptoms are nausea or vomiting (approximately 75 percent of patients), abdominal pain (particularly epigastric, 50 percent), anorexia, and jaundice. Serum aminotransferase elevations are usually higher with fatty liver than in gallbladder disease, ranging from modest increases to up to 1000",
"      <span class=\"nowrap\">",
"       IU/L.",
"      </span>",
"      About one-half of patients have signs of preeclampsia at presentation or at some time during the course of illness. Hypoglycemia is a feature of severe acute fatty liver, but is not present in preeclampsia or HELLP syndrome. Severe acute fatty liver is also characterized by hepatic insufficiency, renal failure, and disseminated intravascular coagulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link\">",
"       \"Acute fatty liver of pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An acute abruption (ie, decidual hemorrhage leading to the premature separation of the placenta prior to delivery) classically presents with vaginal bleeding, abdominal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      back pain, and uterine contractions. The fetal heart rate pattern may be nonreassuring, and prompt delivery is often indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"       \"Placental abruption: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most uterine ruptures occur in laboring women with a prior cesarean delivery or prior uterine surgery. Signs and symptoms of uterine rupture can include nonreassuring fetal heart rate tracing or fetal death, uterine tenderness, peritoneal irritation, vaginal bleeding, and shock. Uterine rupture prior to the onset of labor is rare and usually due to sharp or blunt abdominal trauma. (See",
"      <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=see_link\">",
"       \"Uterine rupture after previous cesarean delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Signs and symptoms of intraamniotic infection include fever, abdominal pain, uterine tenderness, leukocytosis, maternal and fetal tachycardia, and uterine contractions. It is common in the setting of premature rupture of the fetal membranes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=see_link\">",
"       \"Intraamniotic infection (chorioamnionitis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415577526\">",
"    <span class=\"h3\">",
"     Nonpregnancy-related conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpregnancy-related conditions include appendicitis, gastroesophageal reflux, peptic ulcer disease, hepatitis, and right-sided pneumonia, and these conditions are reviewed separately. The location of the appendix migrates cephalad with the enlarging uterus as shown in the figure and thus, appendicitis can present with right upper quadrant pain (",
"    <a class=\"graphic graphic_figure graphicRef51960 \" href=\"UTD.htm?2/1/2070\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H24#H24\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215890\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, gallstones may be an incidental finding on an ultrasound examination obtained for obstetrical indications, or detected during the sonographic evaluation of a pregnant woman presenting with upper abdominal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H743428\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210627277\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is a reliable and safe method for identifying gallstones in pregnant women. Gallstones and sludge are easily visualized on ultrasound, with sensitivity and specificity approaching 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experienced ultrasonographers can often make an accurate diagnosis of acute or chronic cholecystitis (sensitivity 85 to 95 percent, specificity 95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/15\">",
"     15",
"    </a>",
"    ]. The diagnosis of acute cholecystitis can be determined using criteria such as gallbladder wall thickness, pericholecystic fluid, and the ultrasonographic Murphy&rsquo;s sign. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H18#H18\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216221\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance cholangiopancreatography (MRCP) is not typically used in the evaluation of biliary colic or acute cholecystitis, but may be useful in some complicated cases, such as women with choledocholithiases or pancreatitis if ultrasound is not revealing. Noncontrast magnetic resonance imaging is an accepted, alternative imaging modality for pregnant women when other nonionizing forms of diagnostic imaging are inadequate, and when the examination provides important information that would otherwise require exposure to ionizing radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. There are no known harmful fetal effects of noncontrast magnetic resonance during pregnancy; however, the use of magnetic resonance during the first trimester is not recommended since information is limited regarding fetal safety during the period of organogenesis. The administration of gadolinium&nbsp;during pregnancy is controversial and we avoid gadolinium whenever possible but realize that, at times, it may&nbsp;be needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H743400\">",
"    <span class=\"h3\">",
"     Other imaging modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other imaging modalities, such as computed tomography and plain radiographs, are generally avoided in pregnancy for the evaluation of the gallbladder disease because they are inferior to ultrasound and magnetic resonance imaging, and expose the fetus to ionizing radiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Imaging studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link&amp;anchor=H7#H7\">",
"     \"Uncomplicated gallstone disease in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210627284\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies should be normal in patients with uncomplicated biliary colic, both during asymptomatic periods and during attacks of symptoms. However, laboratory studies can be helpful for excluding other diagnoses (eg, cholecystitis, severe preeclampsia, HELLP syndrome, pancreatitis). Although the choice and order of testing varies depending upon the clinical presentation and suspicion for a particular diagnosis, the following are reasonable screening tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver biochemical tests (serum AST, ALT, total bilirubin, alkaline phosphatase) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"       \"Approach to the patient with abnormal liver biochemical and function tests\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serum amylase and lipase (to evaluate for pancreatitis)",
"     </li>",
"     <li>",
"      Complete blood count (to evaluate for leukocytosis, anemia, and thrombocytopenia)",
"     </li>",
"     <li>",
"      Urinalysis (to evaluate for proteinuria)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The white blood cell count and alkaline phosphatase level are normally elevated in pregnancy (",
"    <a class=\"graphic graphic_table graphicRef81137 \" href=\"UTD.htm?37/33/38424\">",
"     table 2",
"    </a>",
"    ), which reduces the diagnostic usefulness of these tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/7/14454?source=see_link\">",
"     \"Normal reference ranges for laboratory values in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevation in the serum total bilirubin is",
"    <strong>",
"     not",
"    </strong>",
"    common in uncomplicated cholecystitis, since biliary obstruction is limited to the gallbladder. Mild elevations in serum aminotransferases and amylase, along with hyperbilirubinemia and jaundice, may occur as a result of the passage of small stones, sludge, or pus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant elevations of the transaminases and alkaline phosphatase or direct bilirubin should raise the possibility of a common bile duct stone, cholangitis, or the Mirizzi syndrome (a gallstone impacted in the distal cystic duct causing extrinsic compression of the common bile duct). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=see_link\">",
"     \"Approach to the patient with suspected choledocholithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44565?source=see_link\">",
"     \"Mirizzi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with severe preeclampsia or HELLP syndrome have elevated liver enzymes (typically at least twice normal) and thrombocytopenia, in addition to hypertension and proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link&amp;anchor=H5#H5\">",
"     \"HELLP syndrome\", section on 'Laboratory criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31120844\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For pregnant women with biliary colic, the initial management is supportive care, which is usually successful. However, if recurrent bouts of biliary colic occur, which is common with conservative therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/19\">",
"     19",
"    </a>",
"    ], primary surgical management during pregnancy is appropriate.",
"   </p>",
"   <p>",
"    Pregnant women with complications of gallstones including acute cholecystitis, choledocholithiasis, cholangitis, or biliary pancreatitis require supportive care with hospitalization, intravenous fluids, antibiotics, analgesia, and bowel rest, followed by prompt intervention with surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ERCP.",
"   </p>",
"   <p>",
"    No randomized trials of the treatment of biliary disease in pregnant women have been performed. The following studies provide useful information for decision making. The first study is by far the largest series describing outcomes of pregnant women with biliary disease and the others represent findings from available case reports and small series in order to assess the risks and benefits of expectant management and surgery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of hospital discharges from 1999 to 2006 from the Healthcare Cost and Utilization Project-Nationwide Inpatient Sample (HCUP-NIS) identified 36,929 pregnant women hospitalized with biliary tract disease (eg, gallstones, cholecystitis, cholangitis, biliary pancreatitis, other biliary diseases) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/20\">",
"       20",
"      </a>",
"      ]. Of these, 9714 underwent cholecystectomy; most (89 percent) were performed laparoscopically. Compared with pregnant women who were managed nonoperatively, those who underwent surgery had significantly lower maternal complication rates (4.3 versus 16.5 percent) as well as lower fetal complication rates (5.8 versus 16.5 percent). Pregnant women treated by high volume surgeons had fewer maternal (0.9 vs 14.3 percent) and fetal complications (3.9 versus 9.5 percent) than those treated by low volume surgeons. Patients who had laparoscopic cholecystectomies had significantly better outcomes with fewer maternal complications (3.8 versus 9.1 percent) and fewer fetal complications (5 versus 11.3 percent) than those who had open surgical procedures.",
"      <br/>",
"      <br/>",
"      However, the choice of surgery versus nonoperative management and laparoscopic versus open surgery in this retrospective study likely reflects patient-specific factors, such as a gangrenous gallbladder, and thus the results cannot be used to guide decision making.",
"     </li>",
"     <li>",
"      To determine the best treatment option for biliary disease (biliary colic, acute cholecystitis, gallstone pancreatitis) during pregnancy, one group constructed and applied an analytical model incorporating maternal and fetal well-being to decide between nonsurgical management and laparoscopic cholecystectomy and concluded a benefit to laparoscopy over conservative treatment for women presenting in the first or second trimester [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/21\">",
"       21",
"      </a>",
"      ]. This result derived from the very low risk of fetal mortality associated with laparoscopic surgery during pregnancy and the high rate of disease relapse (55 percent) and need for urgent surgery (19.5 percent) in patients treated nonoperatively. However, the applicability of this analysis to clinical decision making is limited for several reasons, including that it was based on data from retrospective, uncontrolled, and unblinded studies; the studies included women with a variety of biliary diseases; and it assumed the risk of perinatal morbidity (including prematurity risk) was the same for patients treated surgical and nonsurgically. Furthermore, like all models, the simulation attempts to reflect reality and could not capture all of the subtleties of real world choices.",
"     </li>",
"     <li>",
"      There are no strong data on the risk of preterm delivery with medical versus surgical management of gallstone disease in pregnant patients. Premature labor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      delivery overall appears to be uncommon (prevalence 0 to 10 percent), and is similar to the risk in the general obstetrical population [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/22-25\">",
"       22-25",
"      </a>",
"      ]. However, medical management has been associated with an increased risk of cesarean delivery. In one small retrospective review of 112 pregnant patients who presented with complications of gallstone disease (eg, acute cholecystitis, choledocholithiasis, pancreatitis), the cesarean delivery rate was significantly greater in those treated conservatively (n = 68) compared with those undergoing surgery, endoscopic retrograde cholangiopancreatography (ERCP), or both (34 versus 8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/19\">",
"       19",
"      </a>",
"      ]. This may have been related to an increased prevalence of labor induction among conservatively treated patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632050858\">",
"    <span class=\"h2\">",
"     Biliary colic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary colic is caused by the gallbladder contracting in response to hormonal or neural stimulation, usually due to a fatty meal, forcing a stone (or possibly sludge or microlithiasis) against the gallbladder outlet or cystic duct opening, and leading to increased intra-gallbladder pressure and pain. The stones often fall back from the cystic duct as the gallbladder relaxes. As a result, the discomfort progresses in less than an hour to a steady plateau that ranges from moderate to excruciating and remains constant for more than an hour, then slowly subsides over several hours. Biliary colic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link&amp;anchor=H2#H2\">",
"     \"Uncomplicated gallstone disease in adults\", section on 'Clinical features'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The management of biliary colic primarily involves pain control. Pain control in pregnant women with biliary colic can usually be achieved with intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    , which is preferable to&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    since it has less of an effect on sphincter of Oddi motility. Although nonsteroidal antiinflammatory drugs (NSAIDs) can produce effective analgesia for biliary colic, these drugs are generally avoided in pregnancy, especially after 32 weeks of gestation, because of adverse fetal effects (eg, premature closure of the ductus arteriosus, oligohydramnios) when used for more than 48 hours. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    can be used for mild pain.",
"   </p>",
"   <p>",
"    During an acute attack of biliary colic, patients should be instructed to avoiding eating to prevent the release of cholecystokinin. Intravenous hydration may be necessary if the attack is prolonged or associated with vomiting. When the pain has resolved, patients are encouraged to eat three meals daily, with each meal containing sufficient fat or protein to ensure good gallbladder contraction. In addition, their diet should be high in fiber and calcium, and low in saturated fats [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=see_link&amp;anchor=H8997696#H8997696\">",
"     \"Uncomplicated gallstone disease in adults\", section on 'Pain management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional imaging and repeat laboratory studies are indicated if symptoms do not resolve. Surgical therapy is favored in pregnant women with biliary colic who have recurrent symptoms during pregnancy. For these women, cholecystectomy is ideally performed in the second or early third trimester (see",
"    <a class=\"local\" href=\"#H210627363\">",
"     'Surgery'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/2,3,22,27\">",
"     2,3,22,27",
"    </a>",
"    ]. Most nonsurgical interventions are contraindicated in pregnant women. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    has been administered in the management of intrahepatic cholestasis of pregnancy, its safety and efficacy for the treatment of gallstones during pregnancy has not been evaluated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=see_link\">",
"     \"Dissolution therapy for the treatment of gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After delivery, cholecystectomy is indicated if the patient passed a common bile duct stone or had pancreatitis during pregnancy and the gallbladder was not removed. In women with less severe disease during pregnancy, postpregnancy management depends on findings on imaging studies and future reproductive plans. In the postpartum period, gallbladder sludge resolves in 61 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/10\">",
"     10",
"    </a>",
"    ] and approximately 30 percent of stones smaller than 10 mm disappear due, at least in part, to unsaturation of bile [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. If the sludge and stones disappear and future pregnancies are not planned, surgery can be avoided. However, if sludge and stones persist and future pregnancies are planned, surgery should be performed within three months after delivery to prevent recurrent attacks of biliary colic and the occurrence of more severe complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632051010\">",
"    <span class=\"h2\">",
"     Acute cholecystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pregnant women who are surgical candidates (ASA I or II) should undergo cholecystectomy during their initial hospitalization as prompt surgical intervention decreases relapse of disease and hospital readmission rates [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/23\">",
"     23",
"    </a>",
"    ]. In a review of 6 retrospective reports of 310 patients, the readmission rate for patients treated conservatively was 38 to 70 percent and each relapse of disease was more severe than the previous one [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/23\">",
"     23",
"    </a>",
"    ]. Conservative treatment failed in 27 percent of patients, who then required surgery. There were no significant differences in fetal or maternal morbidity and mortality between patients who were managed conservatively or surgically.",
"   </p>",
"   <p>",
"    Cholecystectomy is usually done within 24 to 48 hours after the patient has received antibiotics, hydration, and supportive care. Cholecystectomy can be technically difficult near term; therefore, decision making in these patients needs to be individualized and might include immediate surgery, delivery followed by cholecystectomy, or an attempt at medical management with surgery during pregnancy if the patient fails to improve within 24 to 48 hours. Definitive, prompt surgical therapy is required for any patient with signs of sepsis, when gangrene or perforation is suspected, or if patients develop progressive fever or intractable pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of acute cholecystitis\", section on 'Low-risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supportive care is generally a less preferable alternative to surgery. Symptoms of cholecystitis may abate within 7 to 10 days; however, there is a high risk of recurrence and of serious complications, such as gangrene, perforation, and fistula formation. The risk of recurrence has been estimated as 55 percent with disease in the first or second trimester, and 40 percent with disease in the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/21\">",
"     21",
"    </a>",
"    ], but serious complications are less common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although acute cholecystitis is primarily an inflammatory process, secondary infection of the gallbladder can occur as a result of cystic duct obstruction and bile stasis. Empiric antibiotic therapy is recommended in patients not undergoing immediate surgery. The most frequent isolates from the gallbladder or common bile duct are Escherichia coli, Enterococcus, Klebsiella, and Enterobacter.",
"   </p>",
"   <p>",
"    Monotherapy with a",
"    <span class=\"nowrap\">",
"     beta-lactam/beta-lactamase",
"    </span>",
"    inhibitor, such as one of the following, is appropriate in pregnancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      3 g intravenously every six hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      3.375 g intravenously every six hours",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       Ticarcillin-clavulanate",
"      </a>",
"      3.1 g intravenously every four hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <br/>",
"    An acceptable alternative is a third generation cephalosporin, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    1 g intravenously every 24 hours,",
"    <strong>",
"     plus",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    500 mg intravenously every eight hours.",
"   </p>",
"   <p>",
"    Fluoroquinolones and carbapenems are generally avoided in pregnant women because of potential fetal toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of acute cholecystitis\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7348166\">",
"    <span class=\"h2\">",
"     Choledocholithiasis and cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop symptomatic choledocholithiasis or cholangitis require supportive care with hospitalization, intravenous fluids, antibiotics, analgesia, and bowel rest, and prompt intervention with endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy followed by cholecystectomy.",
"   </p>",
"   <p>",
"    An ERCP accompanied by endoscopic sphincterotomy can be done safely and expeditiously in the hands of experienced gastroenterologists with little morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Although ERCP requires fluoroscopy, it can be performed safely during pregnancy with fetal shielding. If ERCP is not available or is unsuccessful, decompressive percutaneous cholangiocatheter placement may be appropriate in the patient with cholangitis. If the stone can&rsquo;t be cleared by ERCP, then open or laparoscopic cholecystectomy should be performed with intraoperative cholangiography followed by laparoscopic or open common bile duct exploration, if indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13976?source=see_link\">",
"     \"ERCP in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=see_link\">",
"     \"Approach to the patient with suspected choledocholithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216896\">",
"    <span class=\"h2\">",
"     Biliary pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstone disease is the most common cause of acute pancreatitis during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/32\">",
"     32",
"    </a>",
"    ]. In one series of 43 pregnant women out of 147,197 who were diagnosed with acute pancreatitis, 68 percent was associated with biliary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/33\">",
"     33",
"    </a>",
"    ]. Acute biliary pancreatitis is caused by a stone lodging in the ampulla of Vater, and is associated with maternal mortality if not recognized and treated appropriately.",
"   </p>",
"   <p>",
"    In 12 reports of gallstone pancreatitis that included a total of 212 patients, fetal mortality trended higher with conservative management (6 cases) compared with surgery (2 cases), suggesting the need for prompt intervention with ERCP with sphincterotomy or biliary stent placement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgery in women who do not respond promptly to supportive medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/23\">",
"     23",
"    </a>",
"    ]. Although many of these patients will improve rapidly with conservative management, ERCP and sphincterotomy are appropriate for patients with pancreatitis and concomitant evidence of cholangitis. There is no clear evidence that either ERCP with sphincterotomy or early operation have any impact on the course of the pancreatitis itself. Severe disease may be associated with considerable morbidity and mortality, but management should be conservative unless the patient develops evidence of superinfection. In patients with mild disease that resolves, early cholecystectomy, usually during the same hospitalization, is appropriate to prevent recurrence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13976?source=see_link&amp;anchor=H24#H24\">",
"     \"ERCP in pregnancy\", section on 'Acute biliary pancreatitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14726?source=see_link&amp;anchor=H10#H10\">",
"     \"Intercurrent hepatobiliary disease during pregnancy\", section on 'Acute pancreatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H210627363\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy does not appear to increase postoperative morbidity of cholecystectomy in pregnant women compared with nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/34\">",
"     34",
"    </a>",
"    ]. Surgery is more difficult in the pregnant patient, especially in the late third trimester, and any operation in this setting requires an experienced surgeon and anesthesiologist, and early involvement of the patient&rsquo;s obstetrician. General issues in the management of pregnant women undergoing nonobstetric surgery, including maternal and fetal monitoring and drug safety, are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=see_link\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632051361\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics should be administered to patients with acute cholecystitis undergoing cholecystectomy. The recommended antibiotics for pregnant women are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (1 to 2 g intravenously) or, in patients allergic to penicillins and cephalosporins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    plus one of the following:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    . Prophylactic antibiotics should be administered parenterally 30 to 60 minutes before an incision is made as the efficacy of antibiotic prophylaxis decreases if administered more than one hour before surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=see_link&amp;anchor=H1191970325#H1191970325\">",
"     \"Control measures to prevent surgical site infection following gastrointestinal procedures\", section on 'Other gastrointestinal surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cephalosporins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    have a good safety profile in pregnant women. Aminoglycosides are relatively safe, but carry a risk of fetal (and maternal) ototoxicity and nephrotoxicity, so drug levels should be monitored. Additional information about perioperative antibiotic use in pregnant women is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=see_link\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632051368\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnancy, increases in vitamin K dependent coagulation factors and type-1 plasminogen activator inhibitor coupled with decreases in protein S levels result in a hypercoagulable state, with an increased risk of a thromboembolic event in the postsurgical period. All pregnant women undergoing surgery should have pneumatic stockings placed and the need for pharmacologic thromboprophylaxis should be determined on a case-by-case basis (",
"    <a class=\"graphic graphic_table graphicRef50947 \" href=\"UTD.htm?34/54/35693\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=see_link&amp;anchor=H5#H5\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\", section on 'Thromboprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31120880\">",
"    <span class=\"h2\">",
"     Surgical technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current surgical treatment strategies include either laparoscopic cholecystectomy or open cholecystectomy. The surgical approach is based upon uterine size, the skills of the surgeon, maternal body habitus, past surgical history, and the availability of appropriate staff and equipment.",
"   </p>",
"   <p>",
"    Laparoscopic cholecystectomy is the gold standard for removal of the gallbladder in nonpregnant women and is the preferred route in pregnant women. It can be offered to women in any trimester requiring cholecystectomy, although it is technically more challenging near term [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/20\">",
"     20",
"    </a>",
"    ]. A laparoscopic approach may provide better surgical exposure than the open approach and reduces the need to manipulate the uterus away from the operative field. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=see_link\">",
"     \"Laparoscopic cholecystectomy: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is consistent evidence from observational studies that laparoscopy is not associated with an increased risk of fetal mortality, low birth weight, preterm delivery, or low Apgar scores [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Compared with an open approach, laparoscopic cholecystectomy offers earlier recovery, reduced postoperative pain with a reduction in opioid usage, smaller incisions, and fewer wound complications such as hernia or surgical site infections [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28201/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8727?source=see_link\">",
"     \"Laparoscopic surgery in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, if the laparoscopic procedure cannot be safely",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    effectively completed, the approach should be converted to an open cholecystectomy to avoid injury to surrounding structures. This reflects good judgment and should not be viewed as a failure or complication of the laparoscopic approach. Indications for choosing an open surgical approach or conversion to an open procedure are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36489?source=see_link&amp;anchor=H24392458#H24392458\">",
"     \"Open cholecystectomy\", section on 'Indications for open surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632051851\">",
"    <span class=\"h3\">",
"     Laparoscopic cholecystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few modifications to standard techniques for laparoscopic cholecystectomy are needed when the patient is pregnant. The patient should be placed slightly head-up and tilted towards to her left, allowing the uterus to fall away from the cava. Use of the open (Hasson) technique is recommended to gain access to the abdomen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8727?source=see_link\">",
"     \"Laparoscopic surgery in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link&amp;anchor=H651891364#H651891364\">",
"     \"Abdominal access techniques used in laparoscopic surgery\", section on 'Open (Hasson)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cannulas are generally placed in the usual locations, although as the uterus enlarges in the third trimester (",
"    <a class=\"graphic graphic_figure graphicRef72006 \" href=\"UTD.htm?23/4/23616\">",
"     figure 2",
"    </a>",
"    ), it can be advantageous to move the epigastric port into the left upper quadrant to provide greater perspective (",
"    <a class=\"graphic graphic_figure graphicRef56881 \" href=\"UTD.htm?3/41/3729\">",
"     figure 3",
"    </a>",
"    ). This modification should be determined after the pneumoperitoneum has been established. The gallbladder and the liver are retracted in the usual fashion and the dissection is begun around the cystic duct-infundibular junction. Typically, an avascular area can be identified on the lateral aspect of this junction.",
"   </p>",
"   <p>",
"    The technique of laparoscopic cholecystectomy is discussed in detail elsewhere and shown in the figures (",
"    <a class=\"graphic graphic_figure graphicRef52727 \" href=\"UTD.htm?25/19/25910\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66207 \" href=\"UTD.htm?25/3/25649\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=see_link\">",
"     \"Laparoscopic cholecystectomy: Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31120888\">",
"    <span class=\"h3\">",
"     Open cholecystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical technique of open cholecystectomy is modified only slightly during pregnancy. Patients are placed slightly head-up, and tilted towards the left, allowing the uterus to fall away from the cava. A subcostal incision is preferred, as it allows an easier approach to the gallbladder when the uterus is very large. The procedure is otherwise performed in standard fashion, as discussed in detail elsewhere.",
"   </p>",
"   <p>",
"    Operative cholangiography should be considered if the biliary anatomy is unclear",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if there is a substantial possibility of common duct stones. Radiation exposure to the fetus is not significant if shielded by a lead apron. If available, intraoperative ultrasound of the bile duct can be performed as an alternative to cholangiography and has equivalent diagnostic accuracy for common duct stones in experienced hands. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=see_link&amp;anchor=H972628573#H972628573\">",
"     \"Approach to the patient with suspected choledocholithiasis\", section on 'Intraoperative ultrasonography'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31120909\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal heart rate and uterine activity should be assessed in the recovery room, as appropriate for gestational age. Opioids and antiemetics can be used, as needed, to control postoperative pain and nausea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=see_link\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have had laparoscopic surgery can usually be discharged home on the day of surgery or the following day unless there are extenuating circumstances, such as contractions, vaginal bleeding, pain, or unremitting nausea. A two- to four-day stay is usually necessary after open surgery.",
"   </p>",
"   <p>",
"    Analgesic requirements should be met in consultation with the obstetrician. Short-term use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or narcotics is safe in pregnancy, although prolonged use of these medications (&gt;2 weeks) postoperatively should be avoided. Nonsteroidal antiinflammatory drugs (NSAIDs) should be avoided, especially after 32 weeks of gestation, because they may cause premature closure of the fetal ductus arteriosus. Epidural analgesia is an option for postoperative pain control after an open procedure and carries less risk of opioid-induced hypoventilation when compared to intravenous opioids.",
"   </p>",
"   <p>",
"    The patient can usually resume drinking clear liquids once the effects of anesthesia have worn off and then advance as tolerated to a low-fat diet.",
"   </p>",
"   <p>",
"    When the patient goes into labor, cesarean delivery is performed for standard obstetric indications; the presence of a recent abdominal incision does not preclude pushing in the second stage of labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31120923\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy decreases gallbladder motility and increases the cholesterol saturation of bile, increasing the risk for gallstones. (See",
"      <a class=\"local\" href=\"#H210627445\">",
"       'Increased risk of gallstones in pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute cholecystitis is the second most common nonobstetrical surgical emergency faced by pregnant women after acute appendicitis. (See",
"      <a class=\"local\" href=\"#H31120830\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presentation of gallstone disease during pregnancy is not significantly different than in the nongestational state. (See",
"      <a class=\"local\" href=\"#H31120837\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasonography offers the most reliable method for making the diagnosis of gallstones and acute or chronic cholecystitis. (See",
"      <a class=\"local\" href=\"#H210627277\">",
"       'Ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The white blood cell count and alkaline phosphatase level are normally elevated in pregnancy (",
"      <a class=\"graphic graphic_table graphicRef81137 \" href=\"UTD.htm?37/33/38424\">",
"       table 2",
"      </a>",
"      ), which reduces the diagnostic usefulness of these tests. However, significant elevations of the transaminases and alkaline phosphatase or direct bilirubin should raise the possibility of a common bile duct stone, cholangitis, or the Mirizzi syndrome. (See",
"      <a class=\"local\" href=\"#H210627284\">",
"       'Laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest supportive care for pregnant women with one episode of biliary colic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest cholecystectomy for pregnant women with recurrent biliary attacks (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Cholecystectomy is safest and easier to perform in the second or early third trimester, and can be technically difficult near term. Nonsurgical interventions such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      are generally contraindicated in pregnant women. (See",
"      <a class=\"local\" href=\"#H632050858\">",
"       'Biliary colic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that pregnant women with acute cholecystitis be treated with cholecystectomy rather than with conservative therapy alone during their initial hospitalization (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Prompt surgical intervention decreases relapse rates and hospital readmissions. (See",
"      <a class=\"local\" href=\"#H632051010\">",
"       'Acute cholecystitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive surgical therapy is required for any patient with signs of sepsis, when gangrene or perforation is suspected, or if patients develop progressive fever or intractable pain. (See",
"      <a class=\"local\" href=\"#H632051010\">",
"       'Acute cholecystitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that a laparoscopic approach be used to perform cholecystectomy in pregnant women rather than open surgery, when feasible and available (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Compared with an open approach, laparoscopic cholecystectomy provides better surgical exposure, earlier recovery, reduced postoperative pain with a reduction in opioid usage, smaller incisions, and fewer wound complications such as hernia or surgical site infections. (See",
"      <a class=\"local\" href=\"#H210627363\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a laparoscopic procedure cannot be safely",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      effectively completed, the approach should be converted to an open cholecystectomy to avoid injury to surrounding structures. This reflects good surgical judgment and should not be viewed as a failure or complication of the laparoscopic approach. (See",
"      <a class=\"local\" href=\"#H210627363\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with choledocholithiasis, cholangitis, or biliary pancreatitis require supportive care with hospitalization, intravenous fluids, antibiotics, analgesia, and bowel rest, followed by prompt intervention with ERCP",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgery. (See",
"      <a class=\"local\" href=\"#H7348166\">",
"       'Choledocholithiasis and cholangitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H216896\">",
"       'Biliary pancreatitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/1\">",
"      Everson GT. Gastrointestinal motility in pregnancy. Gastroenterol Clin North Am 1992; 21:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/2\">",
"      Glasgow RE, Visser BC, Harris HW, et al. Changing management of gallstone disease during pregnancy. Surg Endosc 1998; 12:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/3\">",
"      Davis A, Katz VL, Cox R. Gallbladder disease in pregnancy. J Reprod Med 1995; 40:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/4\">",
"      Cosenza CA, Saffari B, Jabbour N, et al. Surgical management of biliary gallstone disease during pregnancy. Am J Surg 1999; 178:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/5\">",
"      Dixon NP, Faddis DM, Silberman H. Aggressive management of cholecystitis during pregnancy. Am J Surg 1987; 154:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/6\">",
"      Lee S, Bradley JP, Mele MM, et al. Cholelithiasis in pregnancy: surgical versus medical management. Obstet Gynecol 2000; 95:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/7\">",
"      Everson GT. Pregnancy and gallstones. Hepatology 1993; 17:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/8\">",
"      Kern F Jr, Everson GT, DeMark B, et al. Biliary lipids, bile acids, and gallbladder function in the human female. Effects of pregnancy and the ovulatory cycle. J Clin Invest 1981; 68:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/9\">",
"      Mendez-Sanchez N, Chavez-Tapia NC, Uribe M. Pregnancy and gallbladder disease. Ann Hepatol 2006; 5:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/10\">",
"      Maringhini A, Ciambra M, Baccelliere P, et al. Biliary sludge and gallstones in pregnancy: incidence, risk factors, and natural history. Ann Intern Med 1993; 119:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/11\">",
"      Valdivieso V, Covarrubias C, Siegel F, Cruz F. Pregnancy and cholelithiasis: pathogenesis and natural course of gallstones diagnosed in early puerperium. Hepatology 1993; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/12\">",
"      Barbara L, Sama C, Morselli Labate AM, et al. A population study on the prevalence of gallstone disease: the Sirmione Study. Hepatology 1987; 7:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/13\">",
"      Liu B, Beral V, Balkwill A, Million Women Study Collaborators. Childbearing, breastfeeding, other reproductive factors and the subsequent risk of hospitalization for gallbladder disease. Int J Epidemiol 2009; 38:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/14\">",
"      Ramin KD, Ramsey PS. Disease of the gallbladder and pancreas in pregnancy. Obstet Gynecol Clin North Am 2001; 28:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/15\">",
"      Gilo NB, Amini D, Landy HJ. Appendicitis and cholecystitis in pregnancy. Clin Obstet Gynecol 2009; 52:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/16\">",
"      Oto A, Ernst R, Ghulmiyyah L, et al. The role of MR cholangiopancreatography in the evaluation of pregnant patients with acute pancreaticobiliary disease. Br J Radiol 2009; 82:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/17\">",
"      Chen MM, Coakley FV, Kaimal A, Laros RK Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol 2008; 112:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/18\">",
"      Kurzweil SM, Shapiro MJ, Andrus CH, et al. Hyperbilirubinemia without common bile duct abnormalities and hyperamylasemia without pancreatitis in patients with gallbladder disease. Arch Surg 1994; 129:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/19\">",
"      Othman MO, Stone E, Hashimi M, Parasher G. Conservative management of cholelithiasis and its complications in pregnancy is associated with recurrent symptoms and more emergency department visits. Gastrointest Endosc 2012; 76:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/20\">",
"      Kuy S, Roman SA, Desai R, Sosa JA. Outcomes following cholecystectomy in pregnant and nonpregnant women. Surgery 2009; 146:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/21\">",
"      Jelin EB, Smink DS, Vernon AH, Brooks DC. Management of biliary tract disease during pregnancy: a decision analysis. Surg Endosc 2008; 22:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/22\">",
"      Dhupar R, Smaldone GM, Hamad GG. Is there a benefit to delaying cholecystectomy for symptomatic gallbladder disease during pregnancy? Surg Endosc 2010; 24:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/23\">",
"      Date RS, Kaushal M, Ramesh A. A review of the management of gallstone disease and its complications in pregnancy. Am J Surg 2008; 196:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/24\">",
"      Lu EJ, Curet MJ, El-Sayed YY, Kirkwood KS. Medical versus surgical management of biliary tract disease in pregnancy. Am J Surg 2004; 188:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/25\">",
"      Tang SJ, Mayo MJ, Rodriguez-Frias E, et al. Safety and utility of ERCP during pregnancy. Gastrointest Endosc 2009; 69:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/26\">",
"      Venneman NG, van Erpecum KJ. Gallstone disease: Primary and secondary prevention. Best Pract Res Clin Gastroenterol 2006; 20:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/27\">",
"      Chiappetta Porras LT, N&aacute;poli ED, Canull&aacute;n CM, et al. Minimally invasive management of acute biliary tract disease during pregnancy. HPB Surg 2009; 2009:829020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/28\">",
"      Baillie J, Cairns SR, Putman WS, Cotton PB. Endoscopic management of choledocholithiasis during pregnancy. Surg Gynecol Obstet 1990; 171:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/29\">",
"      Jamidar PA, Beck GJ, Hoffman BJ, et al. Endoscopic retrograde cholangiopancreatography in pregnancy. Am J Gastroenterol 1995; 90:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/30\">",
"      Tham TC, Vandervoort J, Wong RC, et al. Safety of ERCP during pregnancy. Am J Gastroenterol 2003; 98:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/31\">",
"      European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/32\">",
"      Pitchumoni CS, Yegneswaran B. Acute pancreatitis in pregnancy. World J Gastroenterol 2009; 15:5641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/33\">",
"      Ramin KD, Ramin SM, Richey SD, Cunningham FG. Acute pancreatitis in pregnancy. Am J Obstet Gynecol 1995; 173:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/34\">",
"      Silvestri MT, Pettker CM, Brousseau EC, et al. Morbidity of appendectomy and cholecystectomy in pregnant and nonpregnant women. Obstet Gynecol 2011; 118:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/35\">",
"      Lanzafame RJ. Laparoscopic cholecystectomy during pregnancy. Surgery 1995; 118:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/36\">",
"      Lachman E, Schienfeld A, Voss E, et al. Pregnancy and laparoscopic surgery. J Am Assoc Gynecol Laparosc 1999; 6:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/37\">",
"      Affleck DG, Handrahan DL, Egger MJ, Price RR. The laparoscopic management of appendicitis and cholelithiasis during pregnancy. Am J Surg 1999; 178:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/38\">",
"      Corneille MG, Gallup TM, Bening T, et al. The use of laparoscopic surgery in pregnancy: evaluation of safety and efficacy. Am J Surg 2010; 200:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28201/abstract/39\">",
"      Curet MJ. Special problems in laparoscopic surgery. Previous abdominal surgery, obesity, and pregnancy. Surg Clin North Am 2000; 80:1093.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15095 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28201=[""].join("\n");
var outline_f27_34_28201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31120923\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31120830\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H210627445\">",
"      INCREASED RISK OF GALLSTONES IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H210627438\">",
"      INCIDENCE AND COURSE IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31120837\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H215897\">",
"      Differential clinical diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H376465651\">",
"      - Pregnancy-related conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H415577526\">",
"      - Nonpregnancy-related conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H215890\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H743428\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H210627277\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H216221\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H743400\">",
"      - Other imaging modalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H210627284\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31120844\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H632050858\">",
"      Biliary colic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H632051010\">",
"      Acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7348166\">",
"      Choledocholithiasis and cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H216896\">",
"      Biliary pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H210627363\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H632051361\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H632051368\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31120880\">",
"      Surgical technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H632051851\">",
"      - Laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31120888\">",
"      - Open cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31120909\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31120923\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15095\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15095|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/1/2070\" title=\"figure 1\">",
"      Changes in appendiceal position during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/4/23616\" title=\"figure 2\">",
"      Expected height of the uterine fundus by month of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/41/3729\" title=\"figure 3\">",
"      Laparoscopic cholecystectomy in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/19/25910\" title=\"figure 4\">",
"      Laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/3/25649\" title=\"figure 5\">",
"      Critical view of safety in laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15095|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/62/13291\" title=\"table 1\">",
"      Indications for nonobstetric surgery during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/33/38424\" title=\"table 2\">",
"      Normal reference ranges in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/54/35693\" title=\"table 3\">",
"      Perioperative VTE prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=related_link\">",
"      Abdominal access techniques used in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36554?source=related_link\">",
"      Approach to abdominal pain and the acute abdomen in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10374?source=related_link\">",
"      Approach to the patient with incidental gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40936?source=related_link\">",
"      Approach to the patient with suspected choledocholithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=related_link\">",
"      Control measures to prevent surgical site infection following gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6408?source=related_link\">",
"      Dissolution therapy for the treatment of gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13976?source=related_link\">",
"      ERCP in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14726?source=related_link\">",
"      Intercurrent hepatobiliary disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=related_link\">",
"      Laparoscopic cholecystectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8727?source=related_link\">",
"      Laparoscopic surgery in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=related_link\">",
"      Management of pregnant women undergoing nonobstetric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44565?source=related_link\">",
"      Mirizzi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/7/14454?source=related_link\">",
"      Normal reference ranges for laboratory values in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36489?source=related_link\">",
"      Open cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/9/15511?source=related_link\">",
"      Treatment of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31722?source=related_link\">",
"      Uncomplicated gallstone disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./uterine-rupture-after-previous-cesarean-delivery?source=related_link\">",
"      Uterine rupture after previous cesarean delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_34_28202="Approach to the long-term survivor of colorectal cancer";
var content_f27_34_28202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the long-term survivor of colorectal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28202/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28202/contributors\">",
"     David A Haggstrom, MD, MAS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28202/contributors\">",
"     Winson Y Cheung, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28202/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28202/contributors\">",
"     Larissa Nekhlyudov, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28202/contributors\">",
"     Kenneth D Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/34/28202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/34/28202/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/34/28202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H617978399\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death rates from colorectal cancer (CRC) have declined progressively since the mid-1980s in the US and in many other Western countries, and this has increased the number of long-term survivors. These survivors are experiencing the normal issues of aging, which may be compounded by the long-term effects of having had cancer and cancer therapy. Long-term survivors are at risk for a CRC recurrence (which is less common after the first five years following treatment), a new primary CRC, other cancers, and both short-term and long-term adverse effects of treatment. Additional issues for cancer survivors relate to psychological, reproductive, genetic, social, and employment concerns.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the approach to the long-term adult survivor of CRC during the phase of care that follows the completion of active treatment. A general overview of cancer survivorship and a more detailed discussion of posttreatment surveillance for colorectal cancer recurrence following treatment is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=see_link\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=see_link\">",
"     \"Surveillance after colorectal cancer resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2563742\">",
"    <span class=\"h1\">",
"     APPROACH TO CANCER SURVIVORSHIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transition from active treatment to posttreatment care is critical to long-term health. A committee established by the Institute of Medicine (IOM) to examine the range of medical and psychosocial issues faced by cancer survivors recommended the following components of survivorship care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/1\">",
"     1",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=see_link&amp;anchor=H11933970#H11933970\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\", section on 'General issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surveillance",
"      <strong>",
"      </strong>",
"      for cancer spread, recurrence, or second cancers; assessment of medical and psychosocial late effects",
"     </li>",
"     <li>",
"      Prevention of recurrent and new cancers, and of other late effects",
"     </li>",
"     <li>",
"      Assessment of medical and psychosocial late effects and intervention",
"      <strong>",
"      </strong>",
"      for consequences of cancer and its treatment, for example: medical problems such bowel problems and sexual dysfunction; symptoms, including pain and fatigue; psychological distress experienced by cancer survivors and their caregivers; and concerns related to employment, insurance, and disability",
"     </li>",
"     <li>",
"      Coordination",
"      <strong>",
"      </strong>",
"      between specialists and primary care providers to ensure that all of the survivor&rsquo;s health needs are met",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H889430\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are varying definitions and phases of cancer survivorship. The National Coalition for Cancer Survivorship [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/2\">",
"     2",
"    </a>",
"    ] and the National Cancer Institute define a person as a cancer survivor from the moment of a cancer diagnosis, through the balance of his or her life. Others have defined phases or &ldquo;seasons&rdquo; of survival in cancer patients, including the acute stage (diagnosis and treatment), extended stage (remission",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maintenance, with a main focus on surveillance for disease recurrence), and permanent stage (long-term survival or &ldquo;cure&rdquo;, with a focus on long-term risks of treatment and prevention of subsequent diseases) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/3\">",
"     3",
"    </a>",
"    ]. For the purpose of this overview, we define a CRC survivor as an individual who has completed treatment (ie, surgery, chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy) and who is without evidence of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617978414\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF CRC SURVIVORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the US, the lifetime incidence of CRC is approximately 5 percent (1 in 20) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Incidence rates are higher in men than in women, and among blacks compared with whites and other races; racial disparities are most evident in those under age 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/6\">",
"     6",
"    </a>",
"    ]. More than 90 percent of invasive CRCs are diagnosed in patients older than 50 years, with more than two-thirds diagnosed in patients older than 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/6\">",
"     6",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link&amp;anchor=H2#H2\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Death rates from CRC have declined progressively since the mid-1980s in the US (",
"    <a class=\"external\" href=\"file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-032005.pdf\">",
"     US cancer deaths male",
"    </a>",
"    and",
"    <a class=\"external\" href=\"file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-032006.pdf\">",
"     US cancer deaths female",
"    </a>",
"    ) and in many other Western countries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ]. This improvement in outcome has been attributed, at least in part, to early detection and removal of colonic polyps (which are a precursor to invasive cancer), diagnosis of CRCs at an earlier stage, and more effective treatments, particularly adjuvant therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link\">",
"     \"Adjuvant therapy for resected rectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of these improvements and the aging of the population, there are now more than one million people living with a history of CRC in the US alone, and this population continues to increase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/9\">",
"     9",
"    </a>",
"    ]. Of the 11.7 million cancer survivors living in the US as of January 2007, 1.11 million, or 9.5 percent, were CRC survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cancer is largely a disease of older persons, and the majority of CRC survivors in the US (approximately 60 percent) are over the age of 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/10\">",
"     10",
"    </a>",
"    ]. As a result, CRC survivorship often occurs in a background of comorbid illness [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17400954\">",
"    <span class=\"h1\">",
"     TREATMENT, PROGNOSIS, AND NATURAL HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15753839\">",
"    <span class=\"h2\">",
"     Overview of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among newly diagnosed CRCs in the US, approximately 39 percent of cases are localized at diagnosis, and an additional 37 percent are locoregional (node-positive) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/12\">",
"     12",
"    </a>",
"    ]. The 70 to 80 percent of patients with locoregional CRC at diagnosis are eligible for curative-intent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In addition, a minority of the 20 percent of patients who present with metastatic disease may be eligible for curative-intent surgery; this is most likely in those with a limited number of isolated liver or lung metastases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of potentially resectable colorectal cancer liver metastases\", section on 'Surgical resection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15754038\">",
"    <span class=\"h3\">",
"     Colon cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following curative intent surgery, six months of adjuvant chemotherapy is a standard approach for patients with node-positive (stage III, (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    )) colon cancer. The intent of adjuvant chemotherapy is eradication of micrometastases, which decreases disease recurrence and increases cure rates. An",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -containing regimen provides a greater degree of benefit than does a fluoropyrimidine-only regimen, at least in non-elderly patients, and this has become a standard approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11066?source=see_link&amp;anchor=H17#H17\">",
"     \"Adjuvant therapy for resected colon cancer in elderly patients\", section on 'Oxaliplatin-based regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefits of adjuvant chemotherapy are less certain for patients with node-negative tumors. Nevertheless, it is often recommended to patients with higher-risk stage II disease (inadequately sampled lymph nodes, T4 primary lesion, tumor perforation, lymphovascular or perineural invasion, poorly differentiated histology) despite the lack of direct data from randomized controlled trials to support benefit for adjuvant chemotherapy in this high-risk subset. In this setting, a fluoropyrimidine based chemotherapy regimen is usually chosen, although patients with higher-risk stage II disease may be offered an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30586?source=see_link&amp;anchor=H589530408#H589530408\">",
"     \"Adjuvant chemotherapy for resected stage II colon cancer\", section on 'Clinicopathologic variables'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment for stage I disease is surgical resection alone.",
"   </p>",
"   <p>",
"    The role of adjuvant RT in patients with resected colon cancer is poorly defined. Nevertheless, current guidelines suggest that adjuvant RT be offered to the following subgroups of patients who have an estimated risk of local recurrence that is 30 percent or higher: T4 (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) primary of the ascending or descending colon, or a positive resection margin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H35#H35\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Adjuvant RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15754045\">",
"    <span class=\"h3\">",
"     Rectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to colon cancer, rectal cancers have a higher rate of local failure after surgery alone (mainly because of the difficulty in obtaining optimal surgical clearance of the radial margin), particularly if the tumor is more advanced. As a result, the combination of postoperative chemotherapy and radiation therapy (which is typically administered concomitantly with chemotherapy as a radiosensitizer) is a standard approach after resection of node-positive rectal cancer, and in most cases, after resection of transmural node negative (T3-4, N0) tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=see_link&amp;anchor=H3#H3\">",
"     \"Adjuvant therapy for resected rectal cancer\", section on 'Combined chemotherapy plus RT'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Combined modality therapy may be administered preoperatively (neoadjuvant therapy). This approach results in a more favorable long-term toxicity profile and better local control. Upfront chemoradiotherapy may also enhance the ability to perform sphincter preservation in some patients with low-lying rectal cancers. Indications for neoadjuvant therapy in patients with rectal cancer are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H2#H2\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Indications for neoadjuvant treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15750451\">",
"    <span class=\"h3\">",
"     Prognosis and natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five-year survival rates for all stages of colon and rectal cancer are 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/5\">",
"     5",
"    </a>",
"    ]. Disease stage is the most important prognostic factor. As an example, five-year survival rates for colon cancer, stratified by stage, in data collected from the SEER database between 1991 and 2000 were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/15\">",
"     15",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=see_link&amp;anchor=H35#H35\">",
"     \"Overview of the management of primary colon cancer\", section on 'Prognosis'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I (T1-2N0) - 93 percent",
"     </li>",
"     <li>",
"      Stage IIA (T3N0) - 85 percent",
"     </li>",
"     <li>",
"      Stage IIB (T4N0) - 72 percent",
"     </li>",
"     <li>",
"      Stage IIIA (T1-2 N1) - 83 percent",
"     </li>",
"     <li>",
"      Stage IIIB (T3-4 N1) - 64 percent",
"     </li>",
"     <li>",
"      Stage IIIC (N2) - 44 percent",
"     </li>",
"     <li>",
"      Stage IV &ndash; 8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Five-year survival stratified by tumor stage at diagnosis for rectal cancer, derived from the SEER database and stratified according to the 2010 AJCC staging criteria, is illustrated in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef60598 \" href=\"UTD.htm?0/63/1009\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/16\">",
"     16",
"    </a>",
"    ]. However, these outcome estimates were derived from studies in which surgical resection was not preceded by neoadjuvant therapy. Outcomes may differ in patients who undergo pathologic staging after preoperative treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41514?source=see_link&amp;anchor=H20#H20\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'Category IIA factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=see_link&amp;anchor=H3154313#H3154313\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Prognosis and the extent of tumor regression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite potentially curative surgery and the use of modern adjuvant therapy, more than 40 percent of patients who present with stage II or III disease will have a disease recurrence following primary therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/17\">",
"     17",
"    </a>",
"    ]. Over 90 percent of recurrences develop within five years, most within the first three years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients who develop recurrent disease will die from it, although a small subset, mainly those with isolated limited metastatic disease to the liver or lungs, may be eligible for additional curative intent surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five year survival rates approaching 40 percent have been reported in patients undergoing partial hepatectomy for limited hepatic metastases (",
"      <a class=\"graphic graphic_table graphicRef74509 \" href=\"UTD.htm?23/60/24524\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=see_link\">",
"       \"Management of potentially resectable colorectal cancer liver metastases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although isolated lung metastases are less common than liver involvement, metastasectomy has also been used to treat carefully selected patients with lung metastases, with five-year survival rates of 35 to 45 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Outcomes by histology\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=see_link\">",
"       \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intensive postoperative surveillance programs have been justified in the hope that early detection of asymptomatic recurrences will increase the proportion of patients who are potentially eligible for curative therapy. Guidelines for posttreatment surveillance are presented below. (See",
"    <a class=\"local\" href=\"#H976608196\">",
"     'Surveillance for disease recurrence and second primaries'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15754422\">",
"    <span class=\"h1\">",
"     POSTTREATMENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of CRC are recommended to undergo regular follow-up, which includes surveillance for disease recurrence or new primary tumors (polyps and invasive cancers), and evaluation and management of treatment-related late effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H976608196\">",
"    <span class=\"h2\">",
"     Surveillance for disease recurrence and second primaries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following treatment for a stage II or III CRC, posttreatment surveillance usually consists of periodic history and physical examination with serial assay of the serum concentrations of the tumor marker carcinoembryonic antigen (CEA), annual surveillance CT scans, and colonoscopy to detect metachronous primaries (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 3",
"    </a>",
"    ). Following treatment for stage I colorectal cancer, posttreatment surveillance consists only of periodic history and physical examination and colonoscopy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15754623\">",
"    <span class=\"h3\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment cancer surveillance is recommended for CRC survivors who have undergone definitive curative-intent therapy. The purpose of surveillance is early identification of recurrent disease, for the potential of cure by further surgical intervention, and screening for second primary cancers and polyps.",
"   </p>",
"   <p>",
"    Although five of six randomized controlled trials comparing an intensive versus less intensive surveillance strategy in patients with CRC failed to demonstrate a significant survival benefit for more intensive surveillance, meta-analyses examining intensive versus less intensive surveillance found a significant absolute risk reduction in all-cause mortality favoring intensive posttreatment surveillance. Surveillance tests evaluated in these studies included history and physical examination, serum assay for CEA,",
"    <span class=\"nowrap\">",
"     abdominal/chest",
"    </span>",
"    imaging, proctosigmoidoscopy, and colonoscopy. These data are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=see_link&amp;anchor=H4#H4\">",
"     \"Surveillance after colorectal cancer resection\", section on 'Intensive versus less intense surveillance strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Taken together, this evidence supports intensive surveillance among CRC survivors. However, the emerging consensus is that more follow-up tests are generally appropriate for those with resected stage II or III disease (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ). Because of very favorable outcomes (over 93 percent are cured by surgery alone), recommended posttreatment surveillance for individuals with resected stage I (",
"    <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"     table 1",
"    </a>",
"    ) CRC is limited to periodic colonoscopy and physician visits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=see_link&amp;anchor=H7#H7\">",
"     \"Surveillance after colorectal cancer resection\", section on 'Surveillance for treated stage I disease'",
"    </a>",
"    .) The optimal combination and frequency of surveillance tests is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=see_link&amp;anchor=H4#H4\">",
"     \"Surveillance after colorectal cancer resection\", section on 'Intensive versus less intense surveillance strategies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=see_link&amp;anchor=H9#H9\">",
"     \"Surveillance after colorectal cancer resection\", section on 'Effectiveness of individual tests'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15754630\">",
"    <span class=\"h3\">",
"     Guidelines from expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple professional organizations have developed guidelines for CRC surveillance based upon their interpretation of the available evidence, including the American Society of Clinical Oncology (ASCO) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/19\">",
"     19",
"    </a>",
"    ] and the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/20\">",
"     20",
"    </a>",
"    ]. Their recommendations, which differ slightly, are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"     table 3",
"    </a>",
"    ). Routine CEA monitoring and periodic CT scanning are not recommended beyond five years by either organization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/20\">",
"     20",
"    </a>",
"    ]. The NCCN recommendation for a surveillance colonoscopy one year after CRC surgery is also recommended in guidelines from the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine CEA monitoring and CT scanning are not recommended beyond five years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551617884\">",
"    <span class=\"h2\">",
"     Surveillance for late effects of treatment on QOL and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with CRC, physical health-related quality of life (QOL) is reduced early after treatment but generally returns to normal levels at approximately one year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/22\">",
"     22",
"    </a>",
"    ] Most research indicates that overall QOL in long-term CRC survivors five or more years after diagnosis is comparable to that of the general population, although specific impairments may persist for years in the following domains: psychological (distress and depression), social (employment), and physical (bowel problems and fatigue) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/23-30\">",
"     23-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, long-term complications of surgery, late toxicities from chemotherapy and radiation therapy (RT), and comorbidities with advancing age can all be associated with lower QOL among CRC survivors at &ge;5 years after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/25,29,30\">",
"     25,29,30",
"    </a>",
"    ]. In one study of patients with rectal cancer, a lower QOL was associated with receiving chemoradiotherapy in addition to surgery, having a permanent stoma, or a primary tumor in the lower-third of the rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617978421\">",
"    <span class=\"h3\">",
"     Psychosocial issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539332700\">",
"    <span class=\"h4\">",
"     Psychological distress and depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of active anti-cancer therapies, cancer survivors generally report more psychological distress (including fear of recurrence and death, adjustment to physical changes, alterations in customary social support, social reintegration, and employment and insurance problems) when compared to individuals without a prior history of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/31\">",
"     31",
"    </a>",
"    ]. Psychological distress can be debilitating and may interfere with long-term health behaviors. Distress levels tend to be highest early in the survivorship phase. For CRC patients specifically, a prospective survey (n&gt;1800) revealed that 7 percent experienced clinically significant psychological distress at 12 months post-diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/32\">",
"     32",
"    </a>",
"    ]. The presence of other comorbidities and the lack of social support were independently associated with increased distress.",
"   </p>",
"   <p>",
"    Depression is common immediately after starting treatment for CRC. In one study, 18 percent of CRC survivors screened positive for depression within four to six weeks of starting treatment; after a year of follow-up, the prevalence of depression decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/33\">",
"     33",
"    </a>",
"    ]. Female patients, African Americans, people with two or more comorbid conditions, and those with either poor physical or social functioning exhibited worse depressive symptoms.",
"   </p>",
"   <p>",
"    Over the long-term, patients who survive at least five years after a CRC diagnosis continue to experience higher rates of depression when compared to age-matched controls (14 versus 10 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/23\">",
"     23",
"    </a>",
"    ]). Moreover, in another study, 26 to 44 percent of long-term CRC survivors continued to worry about cancer recurrence, diagnostic tests, or another cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies suggest that regular psychological distress screening should be performed during the cancer survivorship phase of care to identify CRC survivors who may need specialized psychological interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H539332739\">",
"    <span class=\"h4\">",
"     Social relationships and employment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of reintegrating into social relationships can be difficult for many survivors; this frequently affects a wide spectrum of social domains, including interactions with spouses and partners, friends, and peers at school or work. While data specific to CRC are sparse, one study showed that CRC survivors were at higher risk for unemployment when compared to age- and gender-matched healthy adults (59 versus 53 percent for colon, and 54 versus 43 percent for rectal cancer, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/35\">",
"     35",
"    </a>",
"    ]. In another prospective cohort study of survivors of CRC or lung cancer, employment declined from 39 percent to 31 percent over the first 15 months after cancer diagnosis, and approximately 17 percent of those who were employed at baseline left the workforce as a result of their cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/36\">",
"     36",
"    </a>",
"    ]. Lower socioeconomic status and advanced age among CRC survivors were associated with significantly higher rates of labor force departure, highlighting the need for attention to these specific subsets of the population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15755702\">",
"    <span class=\"h4\">",
"     Issues related to an ostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant number of CRC patients require diversion of the fecal stream in the form of either a permanent or temporary ostomy as a component of their cancer management. An ostomy has pervasive effects on everyday life (wearing an ostomy bag underneath one&rsquo;s clothing, the possibility of repeated skin irritations and other complications, difficulties with diet selection and bowel control, as well as reduced social, emotional, sexual, and occupational functioning) that combine to reduce overall functioning and QOL [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. An individual patient&rsquo;s response and subsequent adjustment to intestinal diversion surgery can be highly variable, thus making management and follow-up care challenging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=see_link\">",
"     \"Management of patients with a colostomy or ileostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because ostomies typically result in the loss of control of intestinal contents, including both stool and gas, survivors who are living with ostomies are more likely to experience significant issues with their self-image, comfort with travel and other physical activities, and interpersonal relationships. These issues may contribute to higher rates of depression and decreased overall QOL [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/27,37-41\">",
"     27,37-41",
"    </a>",
"    ]. &nbsp;Therefore, they warrant particular attention during the survivorship phase of cancer care.",
"   </p>",
"   <p>",
"    Sexual activity is an area of special concern. Ostomy surgery does not typically affect sexual desire or organic sexual function, although injury to pelvic nerves related to rectal dissection or radiation therapy may occur. (See",
"    <a class=\"local\" href=\"#H25842894\">",
"     'Sexual dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients frequently express concerns regarding the psychological aspects of sexual activity, including the partner&rsquo;s response to intimacy. Thus, appropriate counseling in this area is important to the rehabilitation and support of ostomy patients. In general, survivors are advised to empty their pouch and ensure that the pouch is sealed appropriately before engaging in sexual activity. In addition, many patients and partners find it helpful to use special lingerie or cummerbunds to conceal and secure the pouch.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14373701\">",
"    <span class=\"h4\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the potential for significant psychosocial sequelae, clinical practice guidelines advise regularly scheduled visits with a health care provider during the first five years of survivorship and that cancer patients be routinely screened for distress at all stages of disease to facilitate appropriate supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/19,20,42\">",
"     19,20,42",
"    </a>",
"    ]. In addition to providing opportunities to screen for psychosocial problems, these visits allow health care providers to offer appropriate referrals to mental health, rehabilitation, and social services to facilitate reintegration. Survivors may also benefit from a referral to a patient support group in order to share their concerns with others who have successfully navigated through the cancer survivorship process and receive advice and encouragement about how best to cope with psychological and emotional stressors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/43\">",
"     43",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617978428\">",
"    <span class=\"h3\">",
"     Medical symptoms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617978435\">",
"    <span class=\"h4\">",
"     Bowel and anorectal problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic persistent diarrhea is one of the most common long-term sequelae of treatment for CRC, affecting 49 percent of survivors in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/23\">",
"     23",
"    </a>",
"    ]. Chronic diarrhea limits activities and can negatively affect QOL. Specifically asking about this issue is important because survivors may assume that abnormal bowel symptoms are an inevitable consequence of treatment and not volunteer information about persistent diarrhea at follow-up appointments.",
"   </p>",
"   <p>",
"    Among patients who undergo low anterior resection (LAR) for rectal cancer, progressively lower surgical anastomoses are associated with a corresponding progressive decline in anorectal function, including increased stool frequency, more incontinence and perianal irritation, decreased stool and flatus discrimination, more incomplete evacuations, and decreased rectal compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/44\">",
"     44",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38137?source=see_link\">",
"     \"Overview of surgical procedures for resectable primary rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients treated for rectal cancer, rates of bowel and anorectal problems are also higher in irradiated patients, whether RT is administered preoperatively or postoperatively, and they are high in patients receiving chemoradiotherapy as compared to conventional fractionation RT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/45\">",
"     45",
"    </a>",
"    ]. The contribution of RT delivered for treatment of rectal cancer can be illustrated by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized Dutch trial compared preoperative short-course RT (an approach that is infrequently used in the US because of higher rates of late GI toxicity) versus surgery alone in 597 patients with rectal cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/46\">",
"       46",
"      </a>",
"      ]. At a median five years of follow-up, the irradiated group had significantly higher rates of fecal incontinence overall (62 versus 38 percent, p&lt;0.001), daily incontinence (14 versus 5 percent) and pad wearing as a result of incontinence (56 versus 33 percent, p&lt;0.001) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/46\">",
"       46",
"      </a>",
"      ]. Among the 362 patients who did not have a stoma, mean bowel frequency during the day was significantly higher in the irradiated patients (3.69 versus 3.02).",
"      <br/>",
"      <br/>",
"      At least in the US, the more common approach is preoperative standard fractionation RT with concomitant radiosensitizing doses of a fluoropyrimidine. One of the advantages of neoadjuvant as compared to adjuvant chemoradiotherapy is a lower rate of long-term GI toxicity, particularly anastomotic stricture.",
"     </li>",
"     <li>",
"      In a matched comparison of patients who did (41 patients) and did not (59 patients) receive chemoradiotherapy after an LAR for rectal cancer, the group that had chemoradiotherapy had more bowel movements per day (median 7 versus 2); more nighttime movements (46 versus 14 percent), more fecal incontinence (occasional 39 versus 7 percent or frequent 17 versus 0 percent), wore a pad more often (41 versus 10 percent), and were less often unable to defer defecation for more than 15 minutes (78 versus 19 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anti-diarrheal medications are common first-line treatment for chronic diarrhea after radiation therapy. Dietary adjustments, especially elimination of raw vegetables, may be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/48\">",
"     48",
"    </a>",
"    ]. Low-fat diets, probiotic supplementation, and elemental diets also may be beneficial among patients treated with pelvic radiation, but the evidence is stronger in preventing acute than chronic diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Available options for treatment of fecal incontinence include medical therapy to reduce stool frequency and improve stool consistency, biofeedback therapy to improve control of the pelvic floor and abdominal wall musculature, and surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=see_link&amp;anchor=H27#H27\">",
"     \"Fecal incontinence in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617978442\">",
"    <span class=\"h4\">",
"     Urinary dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of long-term urinary dysfunction in patients undergoing surgery for rectal cancer depends on the specific operation (rates are higher with abdominoperineal resection [APR] as compared to LAR) and the extent of pelvic dissection (rates are lowest in patients undergoing total mesorectal excision (TME) with autonomic nerve preservation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=see_link&amp;anchor=H98515613#H98515613\">",
"     \"Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery\", section on 'Urinary dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rates of long-term urinary incontinence do not seem to be higher in patients who undergo RT in addition to surgery. This was illustrated in a report from the Dutch trial described above in which rates of difficulty with bladder emptying were not significantly different in the groups that did versus did not receive preoperative RT (27 versus 34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25842894\">",
"    <span class=\"h4\">",
"     Sexual dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of sexual dysfunctions are experienced by CRC survivors that may impact their QOL. Among men, these include decreased libido, erectile dysfunction (ED), and ejaculatory disorders, including retrograde ejaculations and low or alterations in ejaculation. Among women, specific sexual dysfunctions include decreased libido or sexual desire, dyspareunia, changes in genital arousal and lubrication, and altered orgasms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevalence rates for specific sexual dysfunction are difficult to define, in part because of variable methods of data collection and lack of baseline data on sexual activity. A systematic review of sexual function after treatment for rectal cancer concluded that there is a wide range of sexual dysfunction rates in published studies (23 to 69 percent in men, and 19 to 62 percent in women) but that, on average, 30 to 40 percent of previously sexually active patients reported sexual inactivity following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/53\">",
"     53",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In general, sexual dysfunction is more common in patients treated for rectal than colon cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/54\">",
"     54",
"    </a>",
"    ], and in contrast to urinary dysfunction, RT is a major risk factor, as illustrated by the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a questionnaire study of 241 patients treated with surgery with or without preoperative RT for locally advanced rectal cancer, a median of 4.5 years after surgery, irradiated patients had significantly poorer scores for erectile function, orgasmic function, intercourse satisfaction, and overall satisfaction with sex life compared to those treated without RT [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/55\">",
"       55",
"      </a>",
"      ]. Erectile dysfunction was associated with low serum testosterone levels.",
"     </li>",
"     <li>",
"      In a study of 990 Dutch patients who underwent TME with or without preoperative radiation therapy, among male patients who were sexually active preoperatively, an increase in general sexual dysfunction, erectile dysfunction, and ejaculatory problems was reported by 76, 80, and 72 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/56\">",
"       56",
"      </a>",
"      ]. Ejaculatory and erectile dysfunction deteriorated over time. Among female patients who were sexually active preoperatively, general sexual dysfunction, dyspareunia, and vaginal dryness were reported by 62, 59, and 57 percent, respectively. Risk factors for increased sexual dysfunction in both men and women included preoperative RT and the presence of a stoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies show that posttreatment sexual dysfunction is often not addressed either at the time of treatment for CRC or during follow-up care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Specifically asking about this issue is important because of its impact on QOL and the availability of specific treatments, particularly for men.",
"   </p>",
"   <p>",
"    A number of therapies are available to address sexual dysfunction in men. Testosterone replacement therapy may be effective in increasing sexual desire and may improve erectile function in men with low levels of serum testosterone. Oral therapy with a phosphodiesterase-5 inhibitor is considered a first-line approach to treatment of erectile dysfunction. In one study, 79 percent of patients with erectile dysfunction who had undergone rectal excision for rectal cancer and inflammatory bowel disease had a satisfactory response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/60\">",
"     60",
"    </a>",
"    ]. On the other hand, others report better efficacy for intracavernous pharmacologic therapy than for sildenafil in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=see_link\">",
"     \"Overview of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Available treatment options for sexual dysfunction in women are more limited, and none have been systematically evaluated in CRC survivors. Water or silicone-based lubricants during intercourse and vaginal moisturizers can be useful for women with vaginal dryness and dyspareunia. If these are insufficient to alleviate dyspareunia, low-dose vaginal estrogen preparations may be considered. Pelvic floor muscle training and vaginal dilators may be recommended after pelvic RT to prevent vaginal stenosis, but there are few data to support the efficacy of these approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/62\">",
"     62",
"    </a>",
"    ]. There are limited efficacy and safety data for pharmacologic therapy. Management of sexual dysfunction in women is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15755829\">",
"    <span class=\"h4\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer-related fatigue is a common, distressing, and potentially treatable condition. In one study of CRC survivors, 23 percent reported fatigue four years after diagnosis; however, this level of fatigue was not substantially different than the general population and was actually less than that of patients with other noncancer chronic conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/63\">",
"     63",
"    </a>",
"    ]. The most important contributory factors are treatment with cytotoxic chemotherapy or radiation therapy, anemia, pain (and its treatment), emotional distress, sleep disturbance, poor nutrition, and other comorbidities. Although most common during active cancer therapy, cancer-related fatigue may affect patients after cancer treatment has been completed. Screening, assessment and management of fatigue in patients with cancer are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link\">",
"     \"Cancer-related fatigue: Prevalence, screening and clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=see_link\">",
"     \"Cancer-related fatigue: Treatment\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551618114\">",
"    <span class=\"h4\">",
"     Side effects related to chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following curative resection, CRC patients who are considered to be at high risk for disease recurrence are frequently offered adjuvant chemotherapy in order to decrease their chance of relapse. Despite the potential survival benefits, chemotherapy also carries the risk for significant toxicities. Chemotherapies that are commonly used in the setting of CRC can be associated with mucositis, emesis, diarrhea, febrile neutropenia, fatigue, hand-foot syndrome, and cardiotoxicity. Fortunately, most of these symptoms are reversible with cessation of the chemotherapy, and late and long-term effects from CRC-specific cytotoxic agents are relatively infrequent with the exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -related peripheral neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link&amp;anchor=H3#H3\">",
"     \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\", section on 'Fluorouracil'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=see_link&amp;anchor=H23#H23\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Acral erythema (hand-foot skin reaction)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H551618121\">",
"    <span class=\"h5\">",
"     Oxaliplatin-induced peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    is associated with a cumulative, dose-limiting, late onset symmetric distal (stocking-glove pattern) axonal neuropathy, typically without motor involvement. Up to 90 percent of patients receiving a six month course of an oxaliplatin-containing adjuvant chemotherapy regimen develop a neuropathy during treatment , but neuropathy is generally reversible. Approximately 12 percent of patients have mild persistent neuropathy four years posttreatment, and only approximately 1 percent have severe neuropathy. Symptoms may include numbness, tingling and cold-induced pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link\">",
"     \"Neurologic complications of platinum-based chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients do not require specific treatment. For patients with a persisting painful neuropathy, treatment with opioid or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/64\">",
"     64",
"    </a>",
"    ] may be beneficial. Other anticonvulsants and antidepressants have been effective in other types of neuropathic pain, but have not yet proven effective for treating chemotherapy-induced peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/65\">",
"     65",
"    </a>",
"    ]. If neuropathy is disabling, referral for occupational and physical therapy is appropriate. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H18#H18\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Drugs used for neuropathic pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2946556\">",
"    <span class=\"h4\">",
"     Complications due to radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications from RT include chronic radiation proctitis, pelvic fractures, and second malignancies. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617978477\">",
"    <span class=\"h5\">",
"     Chronic radiation proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with pelvic radiation therapy (RT) for rectal cancer may develop chronic radiation proctitis, a delayed response to RT that is caused by atrophy and fibrosis of the irradiated intestinal epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Symptoms usually develop about one year after radiation exposure, and may include diarrhea, rectal urgency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pain, obstruction, and bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link&amp;anchor=H11872693#H11872693\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CRC survivors should be educated about symptoms of proctitis and the need to seek appropriate medical attention if symptoms develop. If radiation proctitis is suspected, referral to a gastroenterologist is appropriate. Although mucosal biopsies are not diagnostic, they can help to exclude other causes of proctitis such as infection or inflammatory bowel disease.",
"   </p>",
"   <p>",
"    Empiric evidence for the optimal management of these patients is sparse. Typically, management is tailored to the specific pattern of symptoms and its intensity. Specific therapy may not be necessary in those who have only mild symptoms, such as occasional hematochezia or mild tenesmus. Stool softeners are a conservative first-line treatment for relieving mild obstructive symptoms that are due to radiation-induced strictures.",
"   </p>",
"   <p>",
"    Diagnosis and management of chronic radiation proctitis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of radiation proctitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617978484\">",
"    <span class=\"h5\">",
"     Pelvic fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic RT may predispose to bone loss and a heightened risk of bone fracture. Most of the data are in men receiving RT for prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H25#H25\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'Insufficiency fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are some data in patients treated for rectal cancer. A large, retrospective cohort study of older women undergoing treatment for rectal, anal, or cervical cancer showed that survivors of rectal cancer were significantly more likely to have a pelvic fracture if they received RT as a component of therapy than if they did not (cumulative five-year fracture rate, 11.2 versus 8.7 percent); 90 percent of the fractures were hip fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/68\">",
"     68",
"    </a>",
"    ]. The use of combined modality therapy may increase the effect of RT on bone density; the use of other medications and estrogen deficiency may further contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6553?source=see_link\">",
"     \"Epidemiology and etiology of premenopausal osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32473?source=see_link\">",
"     \"Epidemiology and etiology of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CRC survivors who have received pelvic RT should undergo long-term monitoring of bone density, appropriate medical treatment for osteopenia and osteoporosis, and careful evaluation if symptoms suggesting fractures develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2946578\">",
"    <span class=\"h5\">",
"     Second malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced secondary malignancies are a known but infrequent complication of pelvic irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. There are no data specifically addressing the magnitude of the risk after treatment for rectal cancer; most of the data are in men treated for prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H26#H26\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'Second malignancies'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15755606\">",
"    <span class=\"h1\">",
"     GENETIC ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most CRCs are sporadic, specific genetic disorders have been identified, mostly autosomal dominant, that are associated with a very high risk of developing the disease. Familial adenomatous polyposis (FAP) and Lynch syndrome (hereditary nonpolyposis colorectal cancer (HNPCC)) are the most common of the familial CRC syndromes, but together these two conditions account for only about 5 percent of CRC cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link&amp;anchor=H90629953#H90629953\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Hereditary CRC syndromes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lynch syndrome is more common than FAP and accounts for approximately 3 to 5 percent of all colonic adenocarcinomas. The term Lynch syndrome is now commonly used for families who have been genetically determined to have a disease-causing defect in one of the mismatch repair (MMR) genes. The biologic footprint of a defect in MMR capacity is microsatellite instability (MSI). MSI testing of CRCs is routinely used to help establish the diagnosis of Lynch syndrome. Some institutions perform MSI testing or immunohistochemistry (IHC) testing for MMR proteins in CRCs in young patients (diagnosed prior to age 50 years) or in those who meet the Bethesda criteria (",
"    <a class=\"graphic graphic_table graphicRef72965 \" href=\"UTD.htm?41/48/42763\">",
"     table 4",
"    </a>",
"    ). At other institutions, universal testing of all CRCs for MSI is practiced. Although over 90 percent of Lynch syndrome related CRCs will demonstrate MSI, 15 percent of sporadic CRCs have MSI. Thus, the finding of MSI in a CRC does not indicate Lynch syndrome, but instead identifies those patients who should be referred for germline MMR testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extracolonic cancers are very common in Lynch syndrome, particularly endometrial carcinomas, which may occur in up to 60 percent of female mutation carriers in some families. Other sites at increased risk of neoplasm formation include the ovary, stomach, small bowel, hepatobiliary system, brain and renal pelvis or ureter.",
"   </p>",
"   <p>",
"    The development of one or more of these cancers in a family member of a CRC survivor may prompt consideration for genetic testing. Family history is seldom updated regularly during follow-up. However, regularly updating a three-generation family history pedigree from cancer survivors can be valuable to help determine the potential risk for cancer in family members, as well as for the survivor&rsquo;s own risk of subsequent cancers that may be associated with a previously unrecognized hereditary syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617978491\">",
"    <span class=\"h1\">",
"     LIFESTYLE MODIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of lifestyle modification (eg, diet, exercise, smoking cessation) and the use of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"      aspirin",
"     </a>",
"     /NSAIDs",
"    </span>",
"    in preventing a cancer recurrence is often a topic of interest to cancer survivors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2947555\">",
"    <span class=\"h2\">",
"     Diet and exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous epidemiologic studies indicate an association between lifestyle factors (obesity, physical activity, diet) and the risk of a first diagnosis of CRC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link&amp;anchor=H15#H15\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Protective factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the role of diet, physical activity, and weight in colorectal cancer survivors has been the subject of multiple studies. However, further work is required to determine what impact these factors have on survival outcomes following a diagnosis of CRC. Furthermore, whether dietary interventions, increased physical activity, or purposeful weight loss improve disease outcomes is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43321?source=see_link\">",
"     \"The roles of diet, physical activity, and body weight in cancer survivorship\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2948438\">",
"    <span class=\"h2\">",
"     Aspirin and other NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies suggest that use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other NSAIDs may improve survival among patients receiving treatment for early colon cancer. However, prospective confirmation of the benefit of aspirin in a randomized trial is needed before routine use of aspirin can be recommended to CRC survivors, given the potential for harm (eg, gastrointestinal bleeding). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=see_link&amp;anchor=H39#H39\">",
"     \"Adjuvant therapy for resected stage III (node-positive) colon cancer\", section on 'Adjunctive therapy: Diet, exercise, and NSAIDs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15755837\">",
"    <span class=\"h2\">",
"     Alcohol and tobacco use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excess alcohol intake has been linked to an elevated risk for CRC. Furthermore, cigarette smoking has been associated with an increased risk of and mortality from CRC [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. In one study of CRC survivors, disease-specific and all-cause mortality rates were significantly higher for smokers as compared to never smokers (hazard ratio [HR] 1.30, 95% CI 1.24-1.83) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/73\">",
"     73",
"    </a>",
"    ]. Survivors should be encouraged to quit smoking and use alcohol in moderation, if they drink. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link&amp;anchor=H12#H12\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Alcohol'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link&amp;anchor=H14#H14\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Other risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H617978533\">",
"    <span class=\"h1\">",
"     COORDINATION OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about whether follow-up care is best provided by specialists or generalists as CRC survivors transition from active treatment to survivorship. Only one prospective trial addressed the utility of generalist versus specialist care in CRC survivors. In an Australian trial that randomly assigned 203 patients with colon cancer to follow-up by general practitioners or surgeons, there were no differences between the groups in disease recurrence, time to detection, and all-cause mortality, quality of life (QOL), anxiety, depression, or patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/74\">",
"     74",
"    </a>",
"    ]. In a later analysis, patients&rsquo; ability to choose the setting of follow-up also had no influence on health-related QOL compared with random allocation to general practitioner or surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/22\">",
"     22",
"    </a>",
"    ]. With regards to patterns of surveillance care, general practitioners ordered more fecal occult blood tests than surgeons, whereas more colonoscopies were performed in the surgeon-led group.",
"   </p>",
"   <p>",
"    In general, CRC survivors who are followed by primary care physicians tend to receive more preventive care and appropriate care for comorbid conditions than do patients who are seen by oncologists alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/75\">",
"     75",
"    </a>",
"    ]. Furthermore, because many cancer survivors are elderly, primary care providers may be better equipped to address recommended chronic disease care that is often not addressed among cancer survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/76\">",
"     76",
"    </a>",
"    ]. Yet, most primary care providers encounter few such patients in their practices; they may be unaware of or unprepared to handle potential long-term complications of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/77,78\">",
"     77,78",
"    </a>",
"    ] or be unaware of recommendations for posttreatment surveillance from organizations such as ASCO. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=see_link&amp;anchor=H418030689#H418030689\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\", section on 'Coordination of care'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    A shared care model that involves coordinated care between primary care and specialists may optimize adherence to guidelines for recommended follow-up care in cancer survivors, although there is low quality evidence to support benefit from such a model of care for patients with chronic diseases. A variety of care models have been proposed to coordinate follow-up between specialists and PCPs and the concept of shared care is supported by the Institute of Medicine (IOM) and ASCO [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. The roles and responsibilities for survivorship care should be well delineated for both patients and their providers. Communication between the primary care provider and subspecialist is vital given that uncertainties about physician roles and responsibilities can lead to deficiencies in care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/34/28202/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=see_link&amp;anchor=H418030697#H418030697\">",
"     \"Overview of cancer survivorship care for primary care and oncology providers\", section on 'Shared care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15755859\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colorectal cancer (CRC) survivors are considered here to be individuals who have completed active treatment and have no evidence of disease. Care for CRC survivors includes surveillance for recurrent or second cancers, encouragement of healthy lifestyles that minimize cancer risk, treatment of psychosocial and medical consequences of cancer and its therapy, management of comorbid disease in this generally older population, and coordination of care between specialists and primary care providers. (See",
"      <a class=\"local\" href=\"#H2563742\">",
"       'Approach to cancer survivorship'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Treatment for CRC depends on stage and tumor location (",
"      <a class=\"graphic graphic_table graphicRef72913 \" href=\"UTD.htm?23/26/23982\">",
"       table 1",
"      </a>",
"      ). For patients with local or locoregional (node-positive) colon or rectal cancer, surgical resection is a prerequisite for cure. Adjuvant chemotherapy following curative intent surgery is a standard approach for patients with stage III (node-positive) colon cancer and may be recommended to patients with higher-risk stage II disease. Postoperative (or preoperative) chemotherapy and chemoradiotherapy is a standard approach following resection for T3N0 or node-positive rectal cancer. (See",
"      <a class=\"local\" href=\"#H15754038\">",
"       'Colon cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15754045\">",
"       'Rectal cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of CRC recurrences occur within the first five years after diagnosis. (See",
"      <a class=\"local\" href=\"#H15750451\">",
"       'Prognosis and natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines for posttreatment disease surveillance during the first five years posttreatment from the American Society of Clinical Oncology and the National Comprehensive Cancer Network are outlined in the table (",
"      <a class=\"graphic graphic_table graphicRef58912 \" href=\"UTD.htm?20/53/21341\">",
"       table 3",
"      </a>",
"      ). Patients with stage I disease have a favorable prognosis (five-year survival of 93 percent) and surveillance recommendations are limited to periodic colonoscopy and physician visits. (See",
"      <a class=\"local\" href=\"#H15754630\">",
"       'Guidelines from expert groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CRC survivors should be regularly screened for psychosocial distress, including depression and employment issues, often associated with survivorship. Other common symptoms in CRC survivors include bowel problems and fatigue. Urinary incontinence and sexual dysfunction are more common in survivors of rectal cancer. (See",
"      <a class=\"local\" href=\"#H617978421\">",
"       'Psychosocial issues'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H617978428\">",
"       'Medical symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemotherapies that are commonly used in the setting of nonmetastatic CRC include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      . The most common long-term effect of chemotherapy is oxaliplatin-induced peripheral neuropathy; the 1 percent of patients with chronic severe painful neuropathy may require treatment with opioids, antidepressants, or anticonvulsants. Complications of radiation therapy include radiation proctitis and increased risk for pelvic fracture. (See",
"      <a class=\"local\" href=\"#H2946556\">",
"       'Complications due to radiation therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H551618114\">",
"       'Side effects related to chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All CRC cancer survivors should be encouraged to pursue a healthy lifestyle that includes following a prudent diet and avoiding weight gain, pursuing an active exercise program, minimizing alcohol intake, and refraining from smoking. Observational studies suggest that use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and other NSAIDs may improve survival among patients receiving treatment for early colon cancer. However, prospective confirmation of the benefit of aspirin in a randomized trial is needed before routine use of aspirin can be recommended to CRC survivors, given the potential for harm (eg, gastrointestinal bleeding). (See",
"      <a class=\"local\" href=\"#H617978491\">",
"       'Lifestyle modification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of physicians may follow patients after the primary therapy of CRC, provided they are experienced in the surveillance of these patients and the complications that may arise from treatment. A shared care model that integrates both specialists and primary care providers in ongoing follow-up care may provide the best adherence to guidelines for recommended preventive and chronic disease care. (See",
"      <a class=\"local\" href=\"#H617978533\">",
"       'Coordination of care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Hewitt, M, Greenfield, S, Stovall, E, et al. From cancer patient to cancer survivor: Lost in transition. (National Academies Press, Washington DC), 2006 file://www.iom.edu/Reports/2005/From-Cancer-Patient-to-Cancer-Survivor-Lost-in-Transition.aspx (Accessed on January 31, 2011).",
"    </li>",
"    <li>",
"     Information about the National Coalition for Cancer survivorship available online at file://www.canceradvocacy.org/about/ (Accessed on February 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/3\">",
"      Mullan F. Seasons of survival: reflections of a physician with cancer. N Engl J Med 1985; 313:270.",
"     </a>",
"    </li>",
"    <li>",
"     file://seer.cancer.gov/csr/1975_2008/ (Accessed on August 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/5\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/6\">",
"      Rim SH, Seeff L, Ahmed F, et al. Colorectal cancer incidence in the United States, 1999-2004 : an updated analysis of data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/7\">",
"      Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/8\">",
"      Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175.",
"     </a>",
"    </li>",
"    <li>",
"     file://cancercontrol.cancer.gov/ocs/prevalence/prevalence.html#survivor (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Cancer survivors--United States, 2007. MMWR Morb Mortal Wkly Rep 2011; 60:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/11\">",
"      Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci 2003; 58:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/12\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/13\">",
"      Meyerhardt JA, Mayer RJ. Follow-up strategies after curative resection of colorectal cancer. Semin Oncol 2003; 30:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/14\">",
"      Abulafi AM, Williams NS. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg 1994; 81:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/15\">",
"      O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96:1420.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th edition, Edge, SB, Byrd, DR, Compton, CC, et al (Eds) (Eds), Springer, New York 2010. p.143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/17\">",
"      Kjeldsen BJ, Kronborg O, Fenger C, J&oslash;rgensen OD. The pattern of recurrent colorectal cancer in a prospective randomised study and the characteristics of diagnostic tests. Int J Colorectal Dis 1997; 12:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/18\">",
"      Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/19\">",
"      Desch CE, Benson AB 3rd, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005; 23:8512.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Distress Management. file://www.nccn.org/professionals/physician_gls/pdf/distress.pdf (Accessed on August 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/21\">",
"      Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006; 130:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/22\">",
"      Gall CA, Weller D, Esterman A, et al. Patient satisfaction and health-related quality of life after treatment for colon cancer. Dis Colon Rectum 2007; 50:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/23\">",
"      Ramsey SD, Berry K, Moinpour C, et al. Quality of life in long term survivors of colorectal cancer. Am J Gastroenterol 2002; 97:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/24\">",
"      Schag CA, Ganz PA, Wing DS, et al. Quality of life in adult survivors of lung, colon and prostate cancer. Qual Life Res 1994; 3:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/25\">",
"      Caravati-Jouvenceaux A, Launoy G, Klein D, et al. Health-related quality of life among long-term survivors of colorectal cancer: a population-based study. Oncologist 2011; 16:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/26\">",
"      Jansen L, Koch L, Brenner H, Arndt V. Quality of life among long-term (&ge;5 years) colorectal cancer survivors--systematic review. Eur J Cancer 2010; 46:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/27\">",
"      Pucciarelli S, Del Bianco P, Toppan P, et al. Health-related quality of life outcomes in disease-free survivors of mid-low rectal cancer after curative surgery. Ann Surg Oncol 2008; 15:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/28\">",
"      Trentham-Dietz A, Remington PL, Moinpour CM, et al. Health-related quality of life in female long-term colorectal cancer survivors. Oncologist 2003; 8:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/29\">",
"      Hoerske C, Weber K, Goehl J, et al. Long-term outcomes and quality of life after rectal carcinoma surgery. Br J Surg 2010; 97:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/30\">",
"      Hornbrook MC, Wendel CS, Coons SJ, et al. Complications among colorectal cancer survivors: SF-6D preference-weighted quality of life scores. Med Care 2011; 49:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/31\">",
"      Welch-McCaffrey D, Hoffman B, Leigh SA, et al. Surviving adult cancers. Part 2: Psychosocial implications. Ann Intern Med 1989; 111:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/32\">",
"      Lynch BM, Steginga SK, Hawkes AL, et al. Describing and predicting psychological distress after colorectal cancer. Cancer 2008; 112:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/33\">",
"      Kurtz ME, Kurtz JC, Stommel M, et al. Predictors of depressive symptomatology of geriatric patients with colorectal cancer: a longitudinal view. Support Care Cancer 2002; 10:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/34\">",
"      Deimling GT, Wagner LJ, Bowman KF, et al. Coping among older-adult, long-term cancer survivors. Psychooncology 2006; 15:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/35\">",
"      Taskila-Brandt T, Martikainen R, Virtanen SV, et al. The impact of education and occupation on the employment status of cancer survivors. Eur J Cancer 2004; 40:2488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/36\">",
"      Earle CC, Chretien Y, Morris C, et al. Employment among survivors of lung cancer and colorectal cancer. J Clin Oncol 2010; 28:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/37\">",
"      Liu L, Herrinton LJ, Hornbrook MC, et al. Early and late complications among long-term colorectal cancer survivors with ostomy or anastomosis. Dis Colon Rectum 2010; 53:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/38\">",
"      McMullen CK, Hornbrook MC, Grant M, et al. The greatest challenges reported by long-term colorectal cancer survivors with stomas. J Support Oncol 2008; 6:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/39\">",
"      Krouse R, Grant M, Ferrell B, et al. Quality of life outcomes in 599 cancer and non-cancer patients with colostomies. J Surg Res 2007; 138:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/40\">",
"      Fucini C, Gattai R, Urena C, et al. Quality of life among five-year survivors after treatment for very low rectal cancer with or without a permanent abdominal stoma. Ann Surg Oncol 2008; 15:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/41\">",
"      Krouse RS, Herrinton LJ, Grant M, et al. Health-related quality of life among long-term rectal cancer survivors with an ostomy: manifestations by sex. J Clin Oncol 2009; 27:4664.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Colon Cancer. file://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf (Accessed on August 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/43\">",
"      Kramish Campbell M, Meier A, Carr C, et al. Health behavior changes after colon cancer: a comparison of findings from face-to-face and on-line focus groups. Fam Community Health 2001; 24:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/44\">",
"      Guren MG, Eriksen MT, Wiig JN, et al. Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer. Eur J Surg Oncol 2005; 31:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/45\">",
"      Br&aelig;ndengen M, Tveit KM, Bruheim K, et al. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study. Int J Radiat Oncol Biol Phys 2011; 81:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/46\">",
"      Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol 2005; 23:6199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/47\">",
"      Kollmorgen CF, Meagher AP, Wolff BG, et al. The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg 1994; 220:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/48\">",
"      Gami B, Harrington K, Blake P, et al. How patients manage gastrointestinal symptoms after pelvic radiotherapy. Aliment Pharmacol Ther 2003; 18:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/49\">",
"      McGough C, Baldwin C, Frost G, Andreyev HJ. Role of nutritional intervention in patients treated with radiotherapy for pelvic malignancy. Br J Cancer 2004; 90:2278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/50\">",
"      Lange MM, Maas CP, Marijnen CA, et al. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg 2008; 95:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/51\">",
"      Donovan KA, Thompson LM, Hoffe SE. Sexual function in colorectal cancer survivors. Cancer Control 2010; 17:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/52\">",
"      Hendren SK, O'Connor BI, Liu M, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005; 242:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/53\">",
"      Ho VP, Lee Y, Stein SL, Temple LK. Sexual function after treatment for rectal cancer: a review. Dis Colon Rectum 2011; 54:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/54\">",
"      Di Fabio F, Koller M, Nascimbeni R, et al. Long-term outcome after colorectal cancer resection. Patients' self-reported quality of life, sexual dysfunction and surgeons' awareness of patients' needs. Tumori 2008; 94:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/55\">",
"      Bruheim K, Guren MG, Dahl AA, et al. Sexual function in males after radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2010; 76:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/56\">",
"      Lange MM, Marijnen CA, Maas CP, et al. Risk factors for sexual dysfunction after rectal cancer treatment. Eur J Cancer 2009; 45:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/57\">",
"      Dowswell G, Ismail T, Greenfield S, et al. Men's experience of erectile dysfunction after treatment for colorectal cancer: qualitative interview study. BMJ 2011; 343:d5824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/58\">",
"      Park ER, Bober SL, Campbell EG, et al. General internist communication about sexual function with cancer survivors. J Gen Intern Med 2009; 24 Suppl 2:S407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/59\">",
"      White ID, Allan H, Faithfull S. Assessment of treatment-induced female sexual morbidity in oncology: is this a part of routine medical follow-up after radical pelvic radiotherapy? Br J Cancer 2011; 105:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/60\">",
"      Lindsey I, George B, Kettlewell M, Mortensen N. Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. Dis Colon Rectum 2002; 45:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/61\">",
"      Sterk P, Shekarriz B, G&uuml;nter S, et al. Voiding and sexual dysfunction after deep rectal resection and total mesorectal excision: prospective study on 52 patients. Int J Colorectal Dis 2005; 20:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/62\">",
"      Denton AS, Maher EJ. Interventions for the physical aspects of sexual dysfunction in women following pelvic radiotherapy. Cochrane Database Syst Rev 2003; :CD003750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/63\">",
"      Schneider EC, Malin JL, Kahn KL, et al. Surviving colorectal cancer : patient-reported symptoms 4 years after diagnosis. Cancer 2007; 110:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/64\">",
"      Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004; 22:2909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/65\">",
"      Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 2009; 145:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/66\">",
"      Babb RR. Radiation proctitis: a review. Am J Gastroenterol 1996; 91:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/67\">",
"      Haddock MG, Sloan JA, Bollinger JW, et al. Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial. J Clin Oncol 2007; 25:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/68\">",
"      Baxter NN, Habermann EB, Tepper JE, et al. Risk of pelvic fractures in older women following pelvic irradiation. JAMA 2005; 294:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/69\">",
"      Small W Jr, Kachnic L. Postradiotherapy pelvic fractures: cause for concern or opportunity for future research? JAMA 2005; 294:2635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/70\">",
"      Wright JD, St Clair CM, Deutsch I, et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer 2010; 116:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/71\">",
"      Baxter NN, Tepper JE, Durham SB, et al. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 2005; 128:819.",
"     </a>",
"    </li>",
"    <li>",
"     Jackson NA, Fuchs CS, Niedzwicki D, et al. TRhe impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from Intergroup trial CALGB 89803 (abstract 4039). J Clin Oncol 2008; 26:187s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=55&amp;abstractID=33374 (Accessed on October 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/73\">",
"      Phipps AI, Baron J, Newcomb PA. Prediagnostic smoking history, alcohol consumption, and colorectal cancer survival: the Seattle Colon Cancer Family Registry. Cancer 2011; 117:4948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/74\">",
"      Wattchow DA, Weller DP, Esterman A, et al. General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer 2006; 94:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/75\">",
"      Snyder CF, Earle CC, Herbert RJ, et al. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol 2008; 26:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/76\">",
"      Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer 2004; 101:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/77\">",
"      Nekhlyudov L. \"Doc, should I see you or my oncologist?\": a primary care perspective on opportunities and challenges in providing comprehensive care for cancer survivors. J Clin Oncol 2009; 27:2424.",
"     </a>",
"    </li>",
"    <li>",
"     Nekhlyudov L, Aziz N, Lerro KS. Oncologists' and primary care providers' awareness of late effects of cancer treatment: Implications for survivorship care. J Clin Oncol 30, 2012 (suppl; abstr 6008). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=96601 (Accessed on July 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/79\">",
"      McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol 2013; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council, and National Cancer Policy Board. Cancer Patient to Cancer survivor: Lost in Transition, Hewitt M, Greenfield S, Stovall E (Eds), National Academies Press, Washington, DC 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/34/28202/abstract/81\">",
"      Cheung WY, Neville BA, Cameron DB, et al. Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol 2009; 27:2489.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14230 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28202=[""].join("\n");
var outline_f27_34_28202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15755859\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H617978399\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2563742\">",
"      APPROACH TO CANCER SURVIVORSHIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H889430\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H617978414\">",
"      EPIDEMIOLOGY OF CRC SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17400954\">",
"      TREATMENT, PROGNOSIS, AND NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15753839\">",
"      Overview of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15754038\">",
"      - Colon cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15754045\">",
"      - Rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15750451\">",
"      - Prognosis and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15754422\">",
"      POSTTREATMENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H976608196\">",
"      Surveillance for disease recurrence and second primaries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15754623\">",
"      - Rationale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15754630\">",
"      - Guidelines from expert groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H551617884\">",
"      Surveillance for late effects of treatment on QOL and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H617978421\">",
"      - Psychosocial issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H539332700\">",
"      Psychological distress and depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H539332739\">",
"      Social relationships and employment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15755702\">",
"      Issues related to an ostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14373701\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H617978428\">",
"      - Medical symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H617978435\">",
"      Bowel and anorectal problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H617978442\">",
"      Urinary dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H25842894\">",
"      Sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15755829\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H551618114\">",
"      Side effects related to chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H551618121\">",
"      - Oxaliplatin-induced peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2946556\">",
"      Complications due to radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H617978477\">",
"      - Chronic radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H617978484\">",
"      - Pelvic fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H2946578\">",
"      - Second malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15755606\">",
"      GENETIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H617978491\">",
"      LIFESTYLE MODIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2947555\">",
"      Diet and exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2948438\">",
"      Aspirin and other NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15755837\">",
"      Alcohol and tobacco use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H617978533\">",
"      COORDINATION OF CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15755859\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/14230\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14230|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/63/1009\" title=\"figure 1\">",
"      SEER surv adeno rectum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14230|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23982\" title=\"table 1\">",
"      2010 TNM staging colorectal CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/60/24524\" title=\"table 2\">",
"      Hepatic resection for metastatic colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/53/21341\" title=\"table 3\">",
"      Postop surv ASCO NCCN rec",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/48/42763\" title=\"table 4\">",
"      Revised Bethesda criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30586?source=related_link\">",
"      Adjuvant chemotherapy for resected stage II colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/51/11066?source=related_link\">",
"      Adjuvant therapy for resected colon cancer in elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34506?source=related_link\">",
"      Adjuvant therapy for resected stage III (node-positive) colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25049?source=related_link\">",
"      Clinical features, diagnosis, and treatment of radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32473?source=related_link\">",
"      Epidemiology and etiology of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6553?source=related_link\">",
"      Epidemiology and etiology of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32533?source=related_link\">",
"      Evaluation of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=related_link\">",
"      External beam radiation therapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22458?source=related_link\">",
"      Fecal incontinence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1946?source=related_link\">",
"      Management of intra-abdominal, pelvic, and genitourinary complications of colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2218?source=related_link\">",
"      Management of patients with a colostomy or ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41850?source=related_link\">",
"      Management of potentially resectable colorectal cancer liver metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/22/42346?source=related_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/6/32873?source=related_link\">",
"      Overview of cancer survivorship care for primary care and oncology providers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42696?source=related_link\">",
"      Overview of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38137?source=related_link\">",
"      Overview of surgical procedures for resectable primary rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=related_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41514?source=related_link\">",
"      Pathology and prognostic determinants of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43321?source=related_link\">",
"      The roles of diet, physical activity, and body weight in cancer survivorship",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_34_28203="Hemodyn pulm thromboend II";
var content_f27_34_28203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hemodynamics after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preoperative",
"       </td>",
"       <td class=\"subtitle1\">",
"        Postoperative",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PA mean pressure (mmHg)",
"       </td>",
"       <td>",
"        48 &plusmn; 12",
"       </td>",
"       <td>",
"        27 &plusmn; 8*",
"       </td>",
"       <td>",
"        24 &plusmn; 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PA systolic pressure (mmHg)",
"       </td>",
"       <td>",
"        80 &plusmn; 21",
"       </td>",
"       <td>",
"        44 &plusmn; 15*",
"       </td>",
"       <td>",
"        39 &plusmn; 17*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac output (L/min)",
"       </td>",
"       <td>",
"        3.7 &plusmn; 1.2",
"       </td>",
"       <td>",
"        6.0 &plusmn; 1.1*",
"       </td>",
"       <td>",
"        4.8 &plusmn; 1.0*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PVR (dynes x sec x cm-5)",
"       </td>",
"       <td>",
"        971 &plusmn; 551",
"       </td>",
"       <td>",
"        232 &plusmn; 111*",
"       </td>",
"       <td>",
"        282 &plusmn; 251",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Immediate and late pulmonary hemodynamic results in 47 of the first 150 patients in whom postoperative values were obtained 48 to 72 hours after admission to the intensive care unit, off all vasoactive drugs, and who returned for follow-up catheterization 6 to 24 months after surgery. After significant improvements in all parameters after surgery, there were highly significant reductions in pulmonary artery (PA) systolic pressure and cardiac output at late follow-up.",
"    <div class=\"footnotes\">",
"     * Statistically significant compared to preoperative values.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28203=[""].join("\n");
var outline_f27_34_28203=null;
var title_f27_34_28204="Response to euthanasia requests";
var content_f27_34_28204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Addressing patients' request for euthanasia or physician-assisted suicide",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Physician action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific interventions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rationale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Inquire about the patient's interest in euthanasia or PAS",
"       </td>",
"       <td>",
"        \"What makes you interested in euthanasia or PAS?\"",
"       </td>",
"       <td>",
"        Allows you to understand what is important to the patient,",
"what he or she fears, and what is motivating his or her decisions.",
"Pain, suffering or dignity are ambiguous and \"catch all\" terms, explore",
"what is the underlying concern.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Are things bad enough that you would want to end your life now?\"",
"       </td>",
"       <td>",
"        Allows you to understand whether the patient's inquiry is exploratory or a real request.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Have you hoarded drugs or made other preparations to end your life?\"",
"       </td>",
"       <td>",
"        Allows you to understand the patient's seriousness and how they are thinking about ending their life.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Evaluate and treat physical and psychological symptoms",
"       </td>",
"       <td>",
"        Evaluate pain and pain control: \"Aside from everyday kinds of",
"pains like, toothaches, how much pain have you had during the past",
"week?\"",
"       </td>",
"       <td>",
"        While pain is not a major factor associated with interest in",
"or requests for euthanasia or PAS, it is an important symptom to treat.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate other symptoms including dyspnea, incontinence, and fatigue",
"       </td>",
"       <td>",
"        While other symptoms have not been consistently associated",
"with interest in or requests for euthanasia or PAS, they are important",
"to treat.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refer the patient to a psychiatrist, psychiatric social worker, psychologist, or counselor",
"       </td>",
"       <td>",
"        Depression and hopelessness are the leading factors",
"associated with interest in euthanasia or PAS and physicians tend to",
"under diagnose these conditions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate and treat care needs",
"       </td>",
"       <td>",
"        Determine how much assistance the patient needs and implement",
"home health care assistance where appropriate: \"How much help do you",
"need with bathing, dressing, or eating?\"",
"       </td>",
"       <td>",
"        Being a burden on family and care needs are factors associated with interest in euthanasia or PAS.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate social relationships and supports",
"       </td>",
"       <td>",
"        Determine whether there is a person that the patient can talk",
"to and get emotional support from: \"Is there someone you can confied in",
"or talk about yourself or your problems?\" \"How often is there someone",
"to have a good time with?\"",
"       </td>",
"       <td>",
"        Feeling appreciated has been associated with less interest in euthanasia or PAS.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28204=[""].join("\n");
var outline_f27_34_28204=null;
var title_f27_34_28205="Kaplan-Meier analysis extranodal NK-T cell lymphoma nasal type";
var content_f27_34_28205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Nasal NK/T-cell lymphoma overall survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 298px; background-image: url(data:image/gif;base64,R0lGODlh3QEqAdUAAP///wAAAP+ZM//lzP+yZe7u7mZmZoiIiDMzMyIiIkRERN3d3REREXd3d5mZmczMzLu7u1VVVaqqqv/Mmf/s2f+sWf+/f//Zsv/58v/y5f+fP//FjP+lTP/SpYBNGiATBoWFhVtbWwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADdASoBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uruKAby/wKW+wcTFm8PGycp1CwwQQwoBAQpDB9IIC0rIy9zdagbSzwAHCQUFCQcADwEPABER2t7y82YB4hHp4/AH1AAQDPHoCRzIxZ6QBA6EOEAAwIABIQsCFEiyjaDFi1AMAkCokKFDiBKHSBsZ4MOADBhTqqR4L1+Dff0kAEziQcCElThzaiRnDp06/3bu4NG0mbPoRXAjhUSbVu1atqEcCFAwSrVqk5oCBAywyrUrEZMVtHoda9UXAbFk0+oEcHbrQJJw48qdS7eu3bt48+rdy7ev37+A92Yyi1ZgRbWIDk8i7NYwYkaKJRGuQGCD48e9BrPNKoDAZcyJNVMY0KHzZ9CGIkdCNiBrY2+q6ThIkGZ2kY9DIBjkyLHJuolXPuIeMtxK8S6xH7F2TS958AAPx/WTYltKb+q0iRwfwjthk5dISXp/Ijw6cfPG0SPXPKRtczEGGATIxo9K9SjXo9wXsv1gwvxKMCABNPlIUd5t6lHRnxbONbLNWR1gME+DVRigQAQP1afbNRM1IP9NAu2MBCIA+zWEQAIBJEDfSBmOdABu5VnjgIjtlPjRAwwcEFE23amDgDQNkAgidABIkJ1SBRbxwI8BpOOAfAwkdKB2BkQkjgJVBsCkAUw+wyWK2JiIoooALLBlmVpKw2U4/oyEAHAiDRKBU0JYo+VTSDzInDwVcebnn4BmlYSFET1QHxHorJNNA+M1BI+NCLSTQJBDFLqRdzA+xGWjjgqJII4J7XjppQU4U6YzTxaIDxEKJDlEqelAYAAEZMpUwJTndbpjREFakw6XJmaDgKaRbhSkAtQ04wCv4zRpYhE+EUEhHQe8CQCyP7XzTkBCbKBBYd30Gei4fg5KjYX1LRD/3gGlYtkOAA3Ix5SN0X0EwVK7YVqvpubFKw01kEYJEo//ObDhSA7cV8B8rBboom5E2DmSuvwi2GYBDSTLMMSe4mZbpgBo9JKoHNumrotFTDtHq0KsI50Q/3ArhHt8wqcxthGEyfI48R1AzjP10cvfQwwIle/QSOP288s2MoBAP6J2pxucntY5HZJHcFwnQ1Q2pB5uCsT7DMnDfBxdtV4jLXIEZCtEW87Z7BwnGeZQbZy1EsyHW0R2S1sEzbDZzB9TCAT5ADoORDBR2A0wVMDTVefq9cIDzvgMAi4xtGTF8DoOOb3nPBR1waU+VEAEENyHAKdyEwGrP7MGkNCSaR/n/3GKA7fpdqeP/7rvtdSA2ranhasT7dxgYMyklq5O8fiHEu0dkhBy/S2ABRMKDkC7/sh34gFLOmVmAE4DfCTSadsZzTMzNrnAmMOmXeaP5UeO9PtZEjwqBEwqsEB1OLJb64hAK2mk4wDyqpjtzCO73JWMNvH5F/o+Mj4iDc82/9DS8agXBgReAwFMGlEW0HYomchsM56pmTcaQCk0PKlvR1gQGFQGhYWhA04LiBfXrvCkAa1DW0LJUxEuIIAKTCVwqGnCBpUgwy/Q8Am3gqG6rvCh8dgpTBQpQmtMg8QkFuKJh6gIBcKSwnB5MTVjeNEQWPiGw7SmjNwA4xnlIEcnKP+vbsBygxu5aMY5DqKOTMhbXK62hj3CcRmA9GMbEqkEQZJEhIs0whtVqEhAMFIJBXhR3eJgSD4F5pOgDKUoR0nKUpoyLmWoGwzT0MlKuvIPhyNJC9nQylfaUg/4AlIbJZmVm9zyl3ZQgIo2uUst9hKYyJyDkVQJB8VM4HpHTKY02eAhWRazCM/k4zS3eYZqjmSWVahmAsRxRTwdQTEXICM313kGVa5SPwxYFEB+GJQTDmGS7MynGByggEitDguzmYiRXtY9ewoBn/pMKBfaJ5ELZQEcXGqH9N4ZGYQq9KJXAKE1lIcFWv0PAfCYqEhQeQSLYvSkUihc3k63wyqsCk3/CyjhTIRYUm2i9KZOiE805tQ8KTSATAgsAD23lcWaHhKnSE3C8ziEhdN9iJx0Kiovj5rUqhYhkw1gVzORYFKrenV7EshGASTwznpwVQAc8OVXvwqOZ5TumsYU1Fq/CsIh1FWPSMhANudK1yMloKWFVEJWKsPXqlojbNHoKRpiwxmqFvaiS9VSWcsQG9LY9LEYXYAEDpDVyVJ2Ca3RgGMxm8+NziE5WxQAaVHajAUQE69KwMAWV3tSb+oStkuQK20VatsAgFMNDdLtbhPqzq0yQbjDzSc//cmpKUiMTeU0qBGQm1xuMrQADt1CQIcaxHM2gbrVnaZGJdI4LnDkUDGT/6pgOxPN8Iq3ASvN2RbIgT6+qTcJnHmNe5Op0wDwVAul0hdI4FQ9JgwgLPrdLzAja60RHkmm0jUC4BScTKxqNQulGlDLgEJUmjJhwhRGJgQk8K6HEjK6900CiENsy1j+y7NjoNCKWezKaPxVPr9lpRPOQhka/7KfQjgHYIG7Y874+JbLNMewYBwGCo0GvEc+Y2+vEcknQDnKSZyylqrshKxcAMuudKc5cPvdy4JZwSqzgJnPrJYoHmGKtIRCayqAEjaDxoYXLpMOudyELarVzo/xoJZA+KESE/kJGTiLBQYgIUA/RnnScJpiz0BDIu7J0ZgZ8xac6qxm3SnCSKAAAf++lWBM6/NpcOIuqFUMLlPr04QR60d6PQwFHhPW1fr8KcLkZ19aP+Esg8V1V8Ss6eBwbUa3ik6vQ0bSKIymNBz4srCpsjC55DgKBwiiPSCc4idscbTTvki143JtKOgGaAwQKoe7a4Q6ZkDNFWB0uItCbCYzwU7jrFNUfR2F1JZ63kgFpKhJDXCjcJaF8IUrFWZccIs817cKnwLDGz4QBTBAmD9tro6vMHGK06Nw9GUjmRdeRAKY3OTS9vjHDZA3Lg1541YA9p/+rPIVlgNFEB/5FEYzgJ4PQM0EmMAE/l3zYkwkh5OmtBeyecyicyPbGuakFwYg9LPQ3OnFECf4jPv/BaaDG+u6kBXOk/5ZMHgd7MqIKYrKbVYxdBXtu5AAvhIQ9Ti7nTNXhzsuPFQ0cWQBLvr+dLe5kNq8690WDsgzg/yerXoOvgvPjMrJJ9/ew7cCOMX9O+PRO1PvkoHpgSK65U2xMBbChe1PEJGXlD09z48hAz6P/YFbPfpUlL63qI9CfHjd+gKzQeaXrv0pMM9MLkCM2/xGA/BpL/xSQH2hQsGWqh+fho43HxRaN3QVwid4FCd/DYoWuvjHT/7yT6DO15eE2A0Y8d+T6/1+En36FaH2nPPZDRcwv/7Lz4FxzX8RcicidRdYh7B8+SV7CFh5/4cHfIc6UucI8NdYC8gH/yAQAvZGBpdkB5O3gSenThOoB6ZFR5vwdh84B631WvdnCaFlcpZRgnWAe+1HCam1Zi7YBjCoc5UgW5b1dTWoBpmHg5dAgj3IBj+YgpgghEOYBjdohEEoAKLFgVAYhVI4hVRYhZOXcli3hFhgDU/hfa43ghEYhmI4hmRoeCqnSnSnBTLBMNP3fZaggwgYh3I4h3RYh3boc2pmhh5XN+9DSFSwDnlDH7LWee2GGM+khw3XW34oBe8TVgwjUm5YFYcId7YFSVWAOTDFewTWbGQxiXBXfFgQF4kXE4SYMoZ4PXc4h43GZsBBVlwgKm34hWMBemQYf3aGQAsQDfG0BaLiaf9YFIlUcQFWKIUEx2YgtQ4JwAAJAnPSZH0UVjgzwlkvt1jc5IwKFgEJEA0SUF5AeEvWuF+CRBvx04229I3g2AALkEPad2jTZGvD+I7wGI/yOI/0WI/2OIWykIFkYYC12I/++I8AGZACOZB/ko/cxHOpmJAKuZAM2ZAO+ZAQWYcGmYQWUW9cR5H0MG6nF4MYuQwaaU3k2JHJYJEcKZIjSWxZkItPFXi/KIsm6ZFzkXtMcC8TASyxWIgv6Q0f+U1cEDYENWsumZMnKWZbAA7loInUJ5TFcHAsNIDBcS6st4mAp5Te8HAy+QTHR4qrRpW/YHEYByDOFR3St25byZW7AHL/tCFyVsA/UeWFOGmWyjAsLXdXTAiXv/BT53BbdWmXvHB0WXWRfBkMmkUH+hiYpxCCD2iYghlPKGh3igkMWkiAj3mXGxmSk0kLReiYl7kLy7UkGkeNm8mZI4Fd7MaOoYkL48VRlnmarqBSEiFfq8marNBf/3UF3FcsvmhObymbtcBgF4gEiTMRkHOTpsibt2Bhv3lvGTKIZWmcqfB8XnA69dV6u+mcsZB9XKA40ymVJGGdtbB+nXYFZoInyBeU3ukK9XeVSvAPhkacfnOesRCAH+KUUvBwKyJ4wAifptCAjLeX+mkKiZecTfafmFGYBCoJ/PA0ZNd2B6oKucQUJdmg/6BgDZizWT+yoDEmoalgcXDCPbGpoZpAl0IgopIJoqQwJ36nG6XJjCYqCnlTNC8hH/QJmi1KCg+HoRlao6VgKFm1jiWqo8mQMU2Bn+YJpLwQERDqnshjpMZwKJzXnExqC4cCiUUapbowpVE5UlNppcTgpFqZlFwqpf2gpBwUpr+ApOznlsVpphhhoGxaC276prMQp3IaC3Rap69wp3jaCnq6p6vQp36aCoAaqKcwqIQqDIdKSYmKSIvaR42qDIb6qJCgpu8pqbJApiFjqbPwpGCqqaZApdXpqbOZpdRzSqZ6qqiaqqq6qqzaqq76qr7HB+UZqn/nRLbqBXGaq7e6Hv+4OkO7WhCLgKm62qvEyqvGCqzFiqzHqqzMugWRWgaUuqTO+qvTmqzVuqwMQq3Zqq21aq2WMKzY2q3hGorcSq7eKq7jSkXluhjragXg2qzbmq7u2q5VQKfveq2YcK/xCq/oiq/+uq//2q8Ba67yKqoGe7AIm7AKu7AMWwwZZCq8CLEYNifk85lTsC5doBsWKwW51J9WoD5acDDslwVPMrIjtJJZIKTQIEHhREgq27JDMBsvNgk5Mg6lWCFsogVm0g4esgXFgmwRKzBaMEApi5teYClYEBEDkjc+KgXsabMCSgRIOh08cQ44WgRTWyksOwVZyx/p0AxXOwguQz1NSwX/GpGx56MFaANg6ACWVUC0V7AwZYsFTQQFlrIwukkFhwIAEvux0/FS2VYFe2s1VzC40LCxiHAfaeisHvtQeWsF7TO3UeCTbksF+BK2jZQiatIFiqJd0/BPJMsA7aAsIzQdvbEQgntiiwgFhqsOmCsIijujZtu4hSu59pFuKdsPlQu5QAFQu4gjsjsFWMKL4/QA2Bi1RoAUKBK8T7C3pzuNTWC4rYtthARnkjC2clsQtPu2zOuu2wsFD7qMVPS9WDlTcEsFuvG4emu6iCsFv1G6Q/BSL5G6RTC9rHs192IJNYtAyEG+douJxuc/UNsFuxsF4znATVWz6+C/T+CTW5A3/89wblywJOq5BHtbtUt0v/W7us1LtUdZCQ/LwDnVnVkgsg2UtEuRbwTcvnaUwiLcBAUUnr6LvEggMa+bBEtxw0aApp22FBy8BDz8tSRxw0F8LY/UsEicxEq8xEzcxE78xFAcxVI8xVRcxVZ8xVicxVq8xVzcxV78xWCMa+BQwVOQN9AbxkngSG4iH7YbSFtGBh6iw2H8I907uWcrBqWStmjsBHQsBGy8DkVDPhIwJwISeP5lBAzgV0BhDQ8hs9MgLG7SDj9iAH/laeRDHHe8x03Qx3zLDoBcADOSbofVLOlQmzBzyELgIUGCIg+gG9Qwyk0hjm5CoUbgK5oMBZz8x8WX/KJFcsk4NxLdlTcthIy64RFwARD8NBIAcaEKcQ0NUGK2fMt8HAAapssAwcu8jCKfqaKsorlSQiS5QT4PwMvMXCfh0YUyLM1KkMuevMvuDBAeYi2cVQSJTATtkx0v2g6DzMvWsMzpjKRP0VbqvMnU7MftfM3vXCfysrgra2goUiALgTJLQT8AUM7e1Bt5PNBtYMZai7tdEMca3QZjnMqozAUcHdIondIqvdIs3dIu/dIwHdMyPdM0XdM2fdM4ndM6XYJBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The overall survival from a study of 92 patients with nasal NK/T-cell lymphoma collected from multiple institutions as part of an international retrospective analysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26:4124.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28205=[""].join("\n");
var outline_f27_34_28205=null;
var title_f27_34_28206="Meta analysis ICD v amiodarone";
var content_f27_34_28206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mortality benefit with ICD in survivors of SCD varies with LVEF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 548px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from a meta-analysis of three implantable cardioverter defibrillator (ICD) trials in survivors a sudden cardiac death (SCD) - AVID, CIDS, and CASH.",
"    <br/>",
"    (Top panel) The cumulative risk of death for patients with left ventricular ejection fraction (LVEF) &le;35 percent was 28 percent lower with an ICD compared to amiodarone; this was entirely due to a reduction in sudden death.",
"    <br/>",
"    (Bottom panel) In contrast there is little difference in survival between the ICD and amiodarone in patients with LVEF &gt;35 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Connolly SJ, Hallstrom AP, Cappato R, et al. Eur Heart J 2000; 21:2071.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28206=[""].join("\n");
var outline_f27_34_28206=null;
var title_f27_34_28207="Effect of carbon monoxide on oxygen delivery";
var content_f27_34_28207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Effect of carboxyhemoglobinemia on oxygen content and delivery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 495px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Red curve demonstrates the normal relationship between arterial (A) and venous (V) oxygen content. In general, a difference in arterial and venous oxygen content of 5 mL per 100 mL blood is expected at rest. The green line depicts the effect of a 50 percent decrease in hemoglobin concentration, which decreases arterial (A') and venous (V'1) oxygen content but does not change the partial pressure at which hemoglobin is 50 percent saturated (P",
"    <sub>",
"     50",
"    </sub>",
"    ). The blue curve shows the effect of a 50 percent carboxyhemoglobinemia (COHb), which both decreases oxygen carrying capacity (A') and impairs peripheral unloading of oxygen from hemoglobin under conditions of low oxygen tension (V'2), shifting P",
"    <sub>",
"     50",
"    </sub>",
"    to the left (P'",
"    <sub>",
"     50",
"    </sub>",
"    ). These changes result in a profound reduction in both oxyhemoglobin saturation and delivery of oxygen to peripheral tissues.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_34_28207=[""].join("\n");
var outline_f27_34_28207=null;
